(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 January 2023 (19.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/288028 A3

(51) International Patent Classification:
C07K 7/08 (2006.01) *A61K 38/08* (2019.01)

(21) International Application Number:
PCT/US2022/037221

(22) International Filing Date:
14 July 2022 (14.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/221,806 14 July 2021 (14.07.2021) US

(71) Applicants: **JANSSEN BIOTECH, INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). **PROTAGONIST THERAPEUTICS, INC.** [US/US]; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).

(72) Inventors: **SUN, Chengzao**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **NEELAMKAVIL, Santhosh**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **PATCH, Raymond, J.**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **BARROS, Stephanie, A.**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **SOMANI, Sandeep**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **HENDRICK, Charles**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **ZHANG, Jing**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **BIANCHI, Elisabetta**; Via Pontina Km 30,600, 00071 Pomezia (Rome) (IT). **COSTANTE, Roberto**; Via Pontina Km 30,600, 00071 Pomezia (Rome) (IT). **INGENITO, Raffaele**; Via Pontina Km 30,600, 00071 Pomezia (Rome) (IT). **BRANCA, Danila**; Via Pontina Km 30,600, 00071 Pomezia (Rome) (IT). **BHANDARI, Ashok**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US). **FREDERICK, Brian**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US). **DANIEL, James**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US). **TRAN, Tran Trung**; 7707 Gateway Boulevard, Suite 140, Newark, California 94560 (US).

(74) Agent: **RICIGLIANO, Joseph, W.**; Hoffmann & Baron LLP, 6900 Jericho Turnpike, Syosset, New York 11791 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
23 February 2023 (23.02.2023)

(54) Title: PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR

(57) Abstract: The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL- 23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders. The inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

WO 2023/288028 A3

PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Application No. 63/221,806, filed July 14, 2021 (pending), which is herein incorporated by reference in its entirety, including its respective sequence listing.

PARTIES TO A JOINT RESEARCH AGREEMENT

[0002] The present disclosure was made by, or on behalf of, the below listed parties to a joint research agreement. The joint research agreement was in effect on or before the date the claimed invention was made, and the claimed invention was part of the joint research agreement and made as a result of activities undertaken within the scope of the joint research agreement. The parties to the joint research agreement are JANSSEN BIOTECH, INC. and PROTAGONIST THERAPEUTICS, INC.

INCORPORATION OF SEQUENCE LISTING

[0003] The sequence listing in ST.26 XML format entitled 2948-22_ST26.xml, created on July 13, 2022, comprising 2,769,116 bytes, prepared according to 37 CFR 1.822 to 1.824, submitted concurrently with the filing of this application, is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

[0004] The present invention relates to novel peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof., invention relates to corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

BACKGROUND

[0005] The interleukin-23 (IL-23) cytokine has been implicated as playing a crucial role in the pathogenesis of autoimmune inflammation and related diseases and disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases (IBDs), for example, ulcerative colitis and Crohn's disease. Studies in acute and chronic mouse models of IBD revealed a primary role of interleukin-23 receptor (IL-23R) and downstream effector cytokines in disease pathogenesis. IL-23R is expressed on various adaptive and innate immune cells including Th17 cells, γδ T cells, natural killer (NK) cells, dendritic cells, macrophages, and innate lymphoid cells, which are found abundantly in the intestine. At the intestine mucosal surface, the gene expression and protein levels of IL-23R are found to be elevated in IBD

patients. It is believed that IL-23 mediates this effect by promoting the development of a pathogenic $CD4^+$ T cell population that produces IL-6, IL-17, and tumor necrosis factor (TNF).

[0006] Production of IL-23 is enriched in the intestine, where it is believed to play a key role in regulating the balance between tolerance and immunity through T-cell-dependent and T-cell-independent pathways of intestinal inflammation through effects on T-helper 1 (Th1) and Th17-associated cytokines, as well as restraining regulatory T-cell responses in the gut, favoring inflammation. In addition, polymorphisms in the IL-23 receptor (IL-23R) have been associated with susceptibility to inflammatory bowel diseases (IBDs), further establishing the critical role of the IL-23 pathway in intestinal homeostasis.

[0007] Psoriasis, a chronic skin disease affecting about 2%-3% of the general population has been shown to be mediated by the body's T cell inflammatory response mechanisms. IL-23 has one of several interleukins implicated as a key player in the pathogenesis of psoriasis, purportedly by maintaining chronic autoimmune inflammation via the induction of interleukin-17, regulation of T memory cells, and activation of macrophages. Expression of IL-23 and IL-23R has been shown to be increased in tissues of patients with psoriasis, and antibodies that neutralize IL-23 showed IL-23-dependent inhibition of psoriasis development in animal models of psoriasis.

[0008] IL-23 is a heterodimer composed of a unique p19 subunit and the p40 subunit shared with IL-12, which is a cytokine involved in the development of interferon-γ (IFN-γ)-producing T helper 1 (T_H1) cells. Although IL-23 and IL-12 both contain the p40 subunit, they have different phenotypic properties. For example, animals deficient in IL-12 are susceptible to inflammatory autoimmune diseases, whereas IL-23 deficient animals are resistant, presumably due to a reduced number of $CD4^+$ T cells producing IL-6, IL-17, and TNF in the CNS of IL-23-deficient animals. IL-23 binds to IL-23R, which is a heterodimeric receptor composed of IL-12Rβ1 and IL-23R subunits. Binding of IL-23 to IL-23R activates the Jak-Stat signaling molecules, Jak2, Tyk2, and Stat1, Stat 3, Stat 4, and Stat 5, although Stat4 activation is substantially weaker and different DNA-binding Stat complexes form in response to IL-23 as compared with IL-12. IL-23R associates constitutively with Jak2 and in a ligand-dependent manner with Stat3. In contrast to IL-12, which acts mainly on naive CD4(+) T cells, IL-23 preferentially acts on memory CD4(+) T cells.

[0009] Therapeutic moieties that inhibit the IL-23 pathway have been developed for use in treating IL-23-related diseases and disorders. A number of antibodies that bind to IL-23 or IL-23R have been identified, including ustekinumab, which has been approved for the treatment of

moderate to severe plaque psoriasis (PSO), active psoriatic arthritis (PSA), moderately to severely active Crohn's disease (CD) and moderately to severely active ulcerative colitis (UC). Examples of such identified antibodies, include: Tildrakizumab, an anti-IL23 antibody approved for treatment of plaque psoriasis, Guselkumab, an anti-IL23 antibody approved for treatment of psoriatic arthritis and Risankizumab, an anti-IL23 antibody approved for the treatment of plaque psoriasis in the US, and generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in Japan.

[00010] Although targeted IL-23 antibody therapeutics are used clinically, there are no small-molecule therapeutics that selectively inhibit IL-23 signaling. There are some identified polypeptide inhibitors that bind to IL-23R and inhibit binding of IL-23 to IL-23R (see, e.g., US Patent Application Publication No. US2013/0029907).Thus, there remains a significant need in the art for effective small-molecule and/or polypeptide therapeutic agents to treat and/or prevent IL-23-associated and/or IL23R-associated diseases and disorders, which include, but are not limited to psoriasis (PsO), psoriatic arthritis (PsA), inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

[00011] In particular:

- compounds and methods for specific targeting of IL-23R from the luminal side of the gut may provide therapeutic benefit to IBD patients suffering from local inflammation of the intestinal tissue; and/or

- orally bioavailable small molecule and/or polypeptide inhibitors of IL-23 may provide both a non-steroidal treatment option for patients with mild to moderate psoriasis and treatment for moderate to severe psoriasis that does not require delivery by infusion.

[00012] Compounds and methods for specific targeting of the IL-23R from the luminal side of the gut may provide therapeutic benefit to IBD patients suffering from local inflammation of the intestinal tissue. In addition, orally bioavailable small molecule and/or polypeptide inhibitors of IL-23 may provide both a non-steroidal treatment option for patients with mild to moderate psoriasis and treatment for moderate to severe psoriasis that does not require delivery by infusion.

[00013] The present invention is directed to addressing these needs by providing peptide inhibitors or pharmaceutically acceptable salts, solvates and/or other forms thereof, that bind IL-23R to inhibit IL-23 binding and signaling, via different suitable routes of administration, which may include but is not limited to oral administration.

BRIEF SUMMARY

[00014] In general, the present invention relates to novel peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salts, solvates and/or other forms thereof., corresponding pharmaceutical compositions, methods and/or uses of the IL-23R inhibitors for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

[00015] In particular, the present invention relates to a compound of Formulas (I'), (I) to (III)), or pharmaceutically acceptable salts, solvates and/or other forms thereof. corresponding pharmaceutical compositions, methods and/or uses for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

[00016] The peptide inhibitor(s) of the IL-23R of the present invention is represented by linear form structure of Formula (I'):

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-R2 (I')

The linear form structure of Formula (I') is intended for exemplary and non-limiting purposes, which will be apparent from examples set forth and exemplified throughout the instant specification, i.e., e.g., where each such structure may be longer or shorter than the length of eighteen amino acids and/or other corresponding chemical moieties or functional group substituents as defined herein.

[00017] Specifically in Formula (I') of the present invention:

- X3-X17, respectively and individually, represent individual amino acid (aa) residues or other corresponding chemical moieties or functional group substituents as described below and in the instant invention;
- R1 represents the N-terminal end, which may be, for example a hydrogen or a chemical moiety or functional group substituted on the amino group;
- Similarly, R2 represents the carboxyl end, which may be, for example the OH of the carboxyl or a chemical moiety or functional group attached thereto or substituted for the OH group (e.g., an amino group to give a terminal amide e.g., $-C(O)HN_2$);
- Any of the residues as shown in the linear form structure may be present or absent, i.e., e.g., X3 and/or X16-X18 may be absent;
- In certain aspects, the peptide inhibitors may have:

- a bond between positions X4 and X9 (e.g., a pair of Pen residues or Abu and Cys residues) forming a disulfide bond or thioether bond resulting in formation of a first ring structure; and/or
- however the bond forming the first ring structure may, be located between other amino acids or chemical moieties besides X4 and X9.; andIn other aspects, the peptide inhibitors may have:
- a bond forming a second ring structure resulting in a ring that bridges the first ring structure or a separate ring structure connected by an intervening portion of the molecule.

[00018] The present invention relates to compounds of Formulas (I'), (I) to (X) or pharmaceutically acceptable salts, solvates, or forms thereof, corresponding pharmaceutical compositionsmethods and/or uses for inflammatory, autoimmune inflammation diseases and/or related disorders.

[00019] In particular, the present invention relates to peptide inhibitor of the IL-23R or a pharmaceutically acceptable salt(s), solvate(s) or other form(s) thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of disease including inflammatory, autoimmune inflammation diseases and/or related disorders s. In particular, an inhibitor of the IL-23R of the present invention is identified:

- Formulas (I'), (I) to (XX)in the instant specification and disclosure; and/ or
- in Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, and Table 1I, respectively, ofthe present specification.

[00020] In an aspect, the present invention relates to compounds which are inhibitors of an IL-23 receptor comprising an amino acid sequence of Formula (I)

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (I)

where:

R1 is hydrogen, $CH_3C(O)$-, EtC(O)-, MeSO2, AzCO, BHCO, FPrpTriazoleMeCO, SMSBCO, Biotin, BiotinPEG2PEG2CO or DAGSuc;

X3 is absent or dR, dK, PEG6, gEPEG6;

X4 is Pen, aMeC, hC, or C;

X5 is A, N, Q, N-MeAsn, L, Asn(4C13_2N15), I or K(PEG2PEG2Biotin);

X6 is T, MeThr, V, K, Dbu, Dpr, or A;

X7 is W7Me, W, W(4F7Me), 7MeW, 7PhW, 7EtW, 7FW, 7ClW, 5BrW or, 7(3NAcPh)W'

X8 is KAc, Q, N-MeGln, A, or Cit;

X9 is Pen, aMeC, hC, or C;

X10 is F4OMe, AEF, F, F4Me, F4Ad, Nal, AEF(Boc), 4PipPhe, AEF(Ac), Y, 4OMeF, 4AmF, D(Pip), Tzl(mPEG3), 3FTyr, Y(OTzl), Y(OTzl(mPEG3)), Tzl, or Tzl(PEG3OH);

X11 is Nal, Quin_3, Coumarin(7OMe), 2Nal, or 3Quin;

X12 is aMeK, THP, Spiral_Pip_Ac, Spiral_Pip, MeK, aMeLeu, aMeL, or aMeK(Boc)

X13 is KAc, K;

X14 is A, N, L, N-MeAsn, MeLeu, Asn(4C13_2N15), or I;

X15 is absent, 3Pya, bAla, Thiozolidine, H, dL, N, A, F, aMePhe, Aib, dK, h, 3MeH, 1MeH, tetraFPhe, bMePhe(SR), 5PyrimidAla, v, dR, homoF, Y, y, F(CF3), Y(CHF2), or THP;

X16 is MeGly, dL, MeLeu, N-MeNle, y, paf, maf, D3Pya, bAla, P, N(3AmBenzyl)Gly, N(4AmBenzyl)Gly, 4(R)HydroxyPro, 4(S)AminoPro, 5(R)diMePro, or absent

R2 is –OH, $-NH_2$, $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl)$_2$, MeNH, or CONHMe; and

where:

the inhibitor of an interleukin-23 receptor is cyclized by forming:a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

[00021] The present invention also relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or other forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation diseases and related disorders.

[00022] The present invention also relates to compounds of Formula II-XVIII, respectively, or pharmaceutically acceptable salts, solvates and/or other forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

[00023] The present invention also relates to compounds set forth in any of Tables 1A-I, respectively or pharmaceutically acceptable salts, solvates and/or other forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

[00024] The present invention also relates to pharmaceutical composition(s), which comprises a peptide inhibitor compound of the present invention or a pharmaceutically acceptable salt, solvate, or form thereof as described herein, and a pharmaceutically acceptable carrier, excipient, or diluent.

[00025] The present invention further relates to use or inclusion of one or more compounds (i.e., e.g., compounds of formulas (I) to (X), Tables 1A to 1I or as defined herein for preparation of pharmaceutical compositions, which may be used for treatment of inflammatory, autoimmune inflammation diseases and/or related disorders as defined herein..

[00026] The pharmaceutical compositions of the present invention also may comprise or may exclude an absorption enhancer depending on the intended route of delivery or use thereof for treatment of specific indications. The absorption enhancer may be a permeation enhancer and/or an intestinal permeation enhancer. In one aspect, the absorption enhancer improves oral bioavailability.

[00027] The present invention relates to method(s) and/or uses(s) for treating inflammatory, autoimmune inflammation diseases and/or related disorders which comprises administering:

- a therapeutically effective amount of one or more herein-described peptide inhibitor compounds of the IL-23R or pharmaceutically acceptable salts, solvates and/or other forms thereof; or
- a corresponding pharmaceutical composition, respectively

to a subject or patient in need thereof.

Such inflammatory, autoimmune inflammation diseases and/or related disorders contemplated for use with or defined inthe present invention, may include, but are not limited to, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PsO), or psoriatic arthritis (PsA) and the like.

The present inventionprovides for the use of one or more herein-described compounds of formulas (I) to (X) or Tables 1A to 1I in the treatment of inflammatory, autoimmune inflammation diseases and/or related disorders as defined herein.

The present invention provides for kits comprising one or more herein-described compounds of formulas (I) to (X) or Tables 1A to 1I and instructions for use in treating a disease, inflammatory, autoimmune inflammation diseases and/or related disordersin a patient or subject in need thereof.

DETAILED DESCRIPTION

I. GENERAL

[00028] The present invention relates to novel peptide inhibitors of the IL-23R or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods

and/or uses for treatment inflammatory, autoimmune inflammation diseases and/or related disorders. The present inventionprovides or relates to peptide inhibitors of an IL-23R. The peptide inhibitors of the present invention may exhibit enhanced properties, such as longer in vivo half-life, compared to the corresponding cyclic peptide inhibitor of an IL-23R without a cyclic structure.

II. DEFINITIONS

[00029] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art.

[00030] "About" when referring to a value includes the stated value +/- 10% of the stated value. For example, about 50% includes a range of from 45% to 55%, while about 20 molar equivalents includes a range of from 18 to 22 molar equivalents. Accordingly, when referring to a range, "about" refers to each of the stated values +/- 10% of the stated value of each end of the range. For instance, a ratio of from about 1 to about 3 (weight/weight) includes a range of from 0.9 to 3.3.

[00031] "Patient" or "subject", which are used interchangably, refer to a living organism, which includes, but is not limited to a human subject suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Further non-limiting examples may include, but is not limited to humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, horse, and other mammalian animals and the like. In some aspects, the patient is human.

[00032] Unless indicated otherwise the names of naturally occurring and non-naturally occurring aminoacyl residues used herein follow the naming conventions suggested by the IUPAC Commission on the Nomenclature of Organic Chemistry and the IUPAC-IUB Commission on Biochemical Nomenclature as set out in "Nomenclature of α-Amino Acids (Recommendations, 1974)" Biochemistry, 14(2), (1975). To the extent that the names and abbreviations of amino acids and aminoacyl residues employed in this specification and appended claims differ from those suggestions, they will be made clear to the reader. In sequences of amino acids that represent IL-23 inhibitors the individual amino acids are separated by a hyphen "-" or brackets e.g, lysine is shown as [K].

[00033] Throughout the present specification, unless naturally occurring amino acids are referred to by their full name (e.g., alanine, arginine, etc.), they are designated by their

conventional three-letter or single-letter abbreviations (e.g., Ala or A for alanine, Arg or R for arginine, etc.). Unless otherwise indicated, three-letter and single-letter abbreviations of amino acids refer to the L-isomeric form of the amino acid in question. The term "L-amino acid," as used herein, refers to the "L" isomeric form of a peptide, and conversely the term "D-amino acid" refers to the "D" isomeric form of a peptide (e.g., (D)Asp or D-Asp; (D)Phe or D-Phe). Amino acid residues in the D isomeric form can be substituted for any L-amino acid residue, as long as the desired function is retained by the peptide. D-amino acids may be indicated as customary in lower case when referred to using single-letter abbreviations. For example, L-arginine can be represented as "Arg" or "R," while D-arginine can be represented as "arg" or "r." Similarly, L-lysine can be represented as "Lys" or "K," while D-lysine can be represented as "lys" or "k." Alternatively, a lower case "d" in front of an amino acid can be used to indicate that it is of the D isomeric form, for example D-lysine can be represented by dK.

[00034] In the case of less common or non-naturally occurring amino acids, unless they are referred to by their full name (e.g. sarcosine, ornithine, etc.), frequently employed three- or four-character codes are employed for residues thereof, including, Sar or Sarc (sarcosine, i.e. N-methylglycine), Aib (α-aminoisobutyric acid), Dab (2,4-diaminobutanoic acid), Dapa (2,3-diaminopropanoic acid), γ-Glu (γ-glutamic acid), Gaba (γ-aminobutanoic acid), β-Pro (pyrrolidine-3-carboxylic acid), and Abu (2-amino butyric acid).

[00035] Amino acids of the D-isomeric form may be located at any of the positions in the IL-23R inhibitors set forth herein (any of X1-X18 appearing in the molecule). In an aspects, amino acids of the D-isomeric form may be located only at any one or more of X3, X5, X6, X8, X13, and optionally one additional position. In other aspects, amino acids of the D-isomeric form may be located only at any one or more of X3, X8, X13, and optionally one additional position. In other aspects, amino acids of the D-isomeric form may be located only at any one or more of X8, X13 (e.g., X8 is dK(Ac) and X13 is dE), and optionally one additional position. In other aspects, amino acids of the D-isomeric form may be located only at X3, and optionally one additional position. In other aspects, amino acids of the D-isomeric form may be located only at X3, and optionally two or three additional positions. In other aspects, amino acids of the D-isomeric form may be located at only one or two of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein. In other aspects, amino acids of the D-isomeric form may be located at only three or four of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein. For example an IL-23R inhibitors set forth herein having only positions X3 to X15 present may have amino acids of the D-form present in 3 or four of those positions. In other aspects, amino acids of the

D-isomeric form may be located at only five or six of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein.

[00036] As is clear to the skilled artisan, the peptide sequences disclosed herein are shown proceeding from left to right, with the left end of the sequence being the N-terminus of the peptide and the right end of the sequence being the C-terminus of the peptide. Among sequences disclosed herein are sequences incorporating either an "-OH" moiety or an "-NH_2" moiety at the carboxy terminus (C-terminus) of the sequence. In such cases, and unless otherwise indicated, an "-OH" or an "–NH_2" moiety at the C-terminus of the sequence indicates a hydroxy group or an amino group, corresponding to the presence of a carboxylic acid (COOH) or an amido ($CONH_2$) group at the C-terminus, respectively. In each sequence of the invention, a C-terminal "–OH" moiety may be substituted for a C-terminal "–NH_2" moiety, and vice-versa.

[00037] One of skill in the art will appreciate that certain amino acids and other chemical moieties are modified when bound to another molecule. For example, an amino acid side chain may be modified when it forms an intramolecular bridge with another amino acid side chain, *e.g.*, one or more hydrogen may be removed or replaced by the bond.

[00038] A "compound of the invention" , an "inhibitor of the present disclosure", an "IL-23R inhibitor of the present disclosure", a "compound described herein", and a "herein-described compound" may include, but are not limited to novel compounds disclosed herein, for example the compounds of any of the Examples, i.e., e.g., which may include compounds of Formula (I) to (X).i.e., e.g., such as those found in Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, or Table 1I.

[00039] "Pharmaceutically effective amount" refers to an amount of a compound of the invention in a composition or combination thereof that provides the desired therapeutic or pharmaceutical result.

[00040] By "pharmaceutically acceptable" it is meant the carrier(s), diluent(s), salt(s), solvate(s) or excipient(s) must be compatible with the other components or ingredients of the compositions of the present invention, i.e., that which is useful, safe, non-toxic acceptable for pharmaceutical use. In accordance with the present invention pharmaceutically acceptable means approved or approvable as is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.

[00041] "Pharmaceutically acceptable excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent,

or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[00042] "Absorption enhancer" refers to a component that improves or facilitates the mucosal absorption of a drug in the gastrointestinal tract, such as a permeation enhancer or intestinal permeation enhancer. As conventionally understood in the art, permeation enhancers (PEs) are agents aimed to improve oral delivery of therapeutic drugs with poor bioavailability. PEs are capable of increasing the paracellular and/or transcellular passage of drugs.

[00043] Pharmaceutical excipients that can increase permeation have been termed "absorption modifying excipients" (AMEs). AMEs may be used in oral compositions, for example, as wetting agents (sodium dodecyl sulfate), antioxidants (e.g. EDTA), and emulsifiers (e.g. macrogol glycerides), and may be specifically included in compositions as PEs to improve bioavailability. PEs can be categorized as to how they alter barrier integrity via paracellular or transcellular routes.

[00044] "Intestinal permeation enhancer (IPE)" refers to a component that improves the bioavailability of a component. Suitable representative IPEs for use in the present invention, include, but are not limited to, various surfactants, fatty acids, medium chain glycerides, steroidal detergents, acyl carnitine and alkanoylcholines, *N*-acetylated alpha-amino acids and *N*-acetylated non-alpha-amino acids, and chitosans, other mucoadhesive polymers and the like. For example, a suitable IPE for use in the present invention may be sodium caprate.

[00045] "Composition" or "Pharmaceutical Composition" as used herein is intended to encompass an invention or product comprising the specified active product ingredient (API), which may include pharmaceutically acceptable excipients, carriers or diluents as described herein, such as in specified amounts defined throughout the disclosure. Compositions or Pharmaceutical Compositions result from combination of specific components, such as specified ingredients in the specified amounts as described herein.

[00046] Compositions or pharmaceutical compositions of the present invention may be in different pharmaceutically acceptable forms, which may include, but are not limited to a liquid composition, a tablet or matrix composition, a capsule composition, etc. and the like. When the composition is a tablet composition, the tablet may include, but is not limited to different layers two or more different phases, including an internal phase and an external phase that can comprise a core. The tablet composition can also include, but is not limited to one or more coatings.

[00047] "Solvate" as used herein, means a physical association of the compound of the present invention with one or more solvent molecules. This physical association involves varying degrees bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation. The term "solvate" is intended to encompass both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include hydrates.

[00048] Provided are also pharmaceutically acceptable salts and tautomeric forms of the compounds described herein. "Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.

[00049] The IL-23R inhibitors of the present invention, pharmaceutically acceptable salts, solvates and/or other forms thereof may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (*R*)- or (*S*)- or, as (D)- or (L)- for amino acids. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms of the IL-23R inhibitors of the present disclosure. Optically active (+) and (-), (*R*)- and (*S*)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. Where compounds are represented in their chiral form, it is understood that the aspect encompasses, but is not limited to, the specific diastereomerically or enantiomerically enriched form. Where chirality is not specified but is present, it is understood that the aspect is directed to either the specific diastereomerically or enantiomerically enriched form; or a racemic or scalemic mixture of such compound(s). As used herein, "scalemic mixture" is a mixture of stereoisomers enantiomers at a ratio other than 1:1.

[00050] "Racemates" refers to a mixture of enantiomers. The mixture can include equal or unequal amounts of each enantiomer.

[00051] "Stereoisomer" and "stereoisomers" refer to compounds that differ in the chirality of one or more stereo centers. Stereoisomers include enantiomers and diastereomers. The compounds may exist in stereoisomeric form if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see, e.g., Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).

[00052] "Tautomer" refers to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring -NH- and a ring =N- such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

[00053] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly or conventionally understood by one of ordinary skill in the art. In the chemical arts a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. A dashed line indicates an optional bond. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or the point at which it is attached to the remainder of the molecule. For instance, the group "-SO_2CH_2-" is equivalent to "-CH_2SO_2-" and both may be connected in either direction. Similarly, an "arylalkyl" group, for example, may be attached to the remainder of the molecule at either an aryl or an alkyl portion of the group. A prefix such as "C_{u-v}" or (C_u-C_v) indicates that the following group has from u to v carbon atoms. For example, "C_{1-6}alkyl" and "C_1-C_6 alkyl" both indicate that the alkyl group has from 1 to 6 carbon atoms.

[00054] "Treatment" or "treat" or "treating" as used herein refers to an approach for obtaining beneficial or desired results. For purposes of the present invention, beneficial or desired results include, but are not limited to, alleviation of a symptom and/or diminishment of the extent of a symptom and/or preventing a worsening of a symptom associated with a disease or condition. In one aspect, "treatment" or "treating" includes one or more of the following: (a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); (b) slowing or arresting the development of one or more symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, delaying the worsening or progression of the disease or condition); and

(c) relieving the disease or condition, e.g., causing the regression of clinical symptoms, ameliorating the disease state, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.

[00055] "Therapeutically effective amount" or "effective amount" as used herein refers to an amount that is effective to elicit the desired biological or medical response, including the amount of a compound that, when administered to a subject for treating a disease is sufficient to effect such treatment for the disease. The effective amount will vary depending on the compound, the disease, and its severity and the age, weight, etc., of the subject to be treated. The effective amount can include a range of amounts. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any co-administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.

[00056] "Co-administration" as used herein refers to administration of unit dosages of the compounds disclosed herein before or after administration of unit dosages of one or more additional therapeutic agents, for example, administration of the compound disclosed herein within seconds, minutes, or hours of the administration of one or more additional therapeutic agents. For example, in some aspects, a unit dose of a compound of the invention is administered first, followed within seconds or minutes by administration of a unit dose of one or more additional therapeutic agents. Alternatively, in other aspects, a unit dose of one or more additional therapeutic agents is administered first, followed by administration of a unit dose of a compound of the invention within seconds or minutes. In some aspects, a unit dose of a compound of the invention is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one or more additional therapeutic agents. In other aspects, a unit dose of one or more additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound of the invention. Co-administration of a compound disclosed herein with one or more additional therapeutic agents generally refers to simultaneous or sequential administration of a compound disclosed herein and one or more additional therapeutic agents, such that therapeutically effective amounts of each agent are present in the body of the patient.

[00057] Abbreviation, "(V/V)" refers to the phrase "volume for volume", i.e., the proportion of a particular substance within a mixture, as measured by volume or a volume amount of a

component of the composition disclosed herein relative to the total volume amount of the composition. Accordingly, the quantity is unit less and represents a volume percentage amount of a component relative to the total volume of the composition. For example, a 2% (V/V) solvent mixture can indicate 2 mL of one solvent is present in 100 mL of the solvent mixture.

[00058] Abbreviation, "(w/w)" refers to the phrase "weight for weight", i.e., the proportion of a particular substance within a mixture, as measured by weight or mass or a weight amount of a component of the composition disclosed herein relative to the total weight amount of the composition. Accordingly, the quantity is unit less and represents a weight percentage amount of a component relative to the total weight of the composition. For example, a 2% (w/w) solution can indicate 2 grams of solute is dissolved in 100 grams of solution.

[00059] Systemic routes of administration as conventionally understood in the medicinal or pharmaceutical arts, refer to or are defined as a route of administration of drug, a pharmaceutical composition or formulation, or other substance into the circulatory system so that various body tissues and organs are exposed to the drug, formulation or other substance. As conventionally understood in the art, administration can take place orally (where drug or oral preparations are taken by mouth, and absorbed via the gastrointestinal tract), via enteral administration (absorption of the drug also occurs through the gastrointestinal tract) or parenteral administration (generally injection, infusion, or implantation, etc.

[00060] "Systemically active" peptide drug therapy as it relates to the present invention generally refers to treatment by means of a pharmaceutical composition comprising a peptide active ingredient, wherein said peptide resists immediate metabolism and/or excretion resulting in its exposure in various body tissues and organs, such as the cardiovascular, respiratory, gastrointestinal, nervous or immune systems.

[00061] Systemic drug activity in the present invention also refers to treatment using substances that travel through the bloodstream, reaching and affecting cells in various body tissues and organs. Systemic active drugs are transported to their site of action and work throughout the body to attack the physiological processes that cause inflammatory diseases.

[00062] "Bioavailability" refers to the extent and rate at which the active moiety (drug or metabolite) enters systemic circulation, thereby accessing the site of action. Bioavailability of a drug is impacted by the properties of the dosage form, which depend partly on its design and manufacture.

[00063] "Digestive tract tissue" as used herein refers to all the tissues that comprise the organs of the alimentary canal. For example only, and without limitation, "digestive tract tissue"

includes tissues of the mouth, esophagus, stomach, small intestine, large intestine, duodenum, and anus.

III. COMPOUNDS

[00064] The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof.

[00065] In particular, the present invention relates to a cyclic peptide inhibitorsof the interleukin-23 receptor (IL-23R) or a pharmaceutically acceptable salt thereof, including those for which a structure is as identified in Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, or Table 1I of the present specification.

[00066] In one aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound, or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1A.

[00067] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1B.

[00068] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1C.

[00069] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1D.

[00070] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1E.

[00071] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1F.

[00072] In another aspect, a cyclic peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1G

[00073] In another aspect, a peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound, or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1H.



[00074] In another aspect, a peptide inhibitor compound of the interleukin-23 receptor (IL-23R) compound, or a pharmaceutically acceptable salt thereof, has a structure of a compound in Table 1I.




Table 1A. Compounds



Cmpd.	Structure
101	MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-A-2Nal-THP-E-N-3Pya-Sar-CONH2
102	MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-A-THP-E-N-3Pya-Sar-CONH2
103	MeCO--Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-Dap(Ac)-N-3Pya-Sar--CONH2
104	MeCO-Pen(3)-N-T-7MeW-AIB-Pen(3)-AEF-2Nal-THP-AIB-N-3Pya-Sar-CONH2



Table 1B. Compounds



Cmpd.	Structure



148	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
149	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 


150	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 
151	Ac-[Pen]-A-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLys]-A-A-[3Pal]-[Sarc]-NH2 
152	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLys]-A-A-[3Pal]-[Sarc]-NH2 



153	Ac-[Pen]-A-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLys]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 
154	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLys]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 


155	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[Acvc]-E-N-[THP]-NH2 
156	Ac-[(D)arg]-C-N-T-[W(7-Me)]-[Lys(Ac)]-[aMeCys]-[Phe(4-(2-aminoethoxy))]-[Nal]-[Acvc]-E-N-[THP]-NH2 


157	Ac-[(D)arg]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-(Ac)aminoethoxy))]-[Nal]-[Acvc]-E-N-[THP]-NH2 
158	Ac-[(D)arg]-[Pen]-N-T-[W(7-Me)]-[Phe(4-NHAc)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[Acvc]-E-N-[THP]-NH2 


159	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[aMeGlu]-N-H-NH2 
160	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-OMe)]-[Nal]-[THP]-E-N-[bAla]-NH2 



161	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[bAla]-NH2 



162	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[Acvc]-E-N-[bAla]-NH2 
163	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N 



164	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[bAla]-NH2 



165	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-(Ac)aminoethoxy))]-[Nal]-[THP]-E-N-[bAla]-NH2 

166	Ac-[(D)arg]-[Abu]-Q-T-W-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[aMeGlu]-N-[bAla]-NH2 

167	Ac-[(D)arg]-[Pen]-Q-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[aMeGlu]-N-[bAla]-NH2 
168	Ac-[(D)arg]-[Pen]-Q-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[Lys(Ac)]-N-[bAla]-NH2 

169	[Propionic_acid]-[(D)arg]-[Pen]-Q-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-N-NH2 
170	Ac-[(D)arg]-[Pen]-Q-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[bAla]-NH2 

171	Ac-[Abu]-Q-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[Lys(Ac)]-N-N-NH2 
172	Ac-[(D)arg]-[Abu]-Q-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[Lys(Ac)]-N-N-NH2 

173	Ac-[Abu]-Q-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-N-NH2 
174	Ac-[(D)arg]-[Abu]-Q-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-N-NH2 













175	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[NH(2-(pyridin-3-yl)ethyl)] 



Table 1C. Compounds



Cmpd.	Structure
176	Ac-[Lys(Ac_Morph)]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[NH(2-(pyridin-3-yl)ethyl)] 
177	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[NH(2-(pyridin-3-yl)ethyl)] 


178	Ac-[Lys(Ac_Morph)]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[NH(2-(pyridin-3-yl)ethyl)] 
179	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
180	[Ac_Morph]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



181	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
182	Ac-[Lys(Ac_Morph)]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
183	Ac-[Lys(Ac_Morph)]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



184	[Ac_Morph]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
185	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
186	[Ac_Morph]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



187	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac_Morph)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
188	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[Spiral_Pip_Ac]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 


189	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
190	Ac-[Pen]-N-T-[W(4-F-7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 

191	Ac-[Pen]-N-T-[W(4-F-7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 

192	Ac-[Pen]-[N-MeAsn]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 
193	Ac-[Lys(Ac_Morph)]-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 

194	Ac-[Lys(Ac_Morph)]-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
195	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[Spiral_Pip]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 

196	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Me)]-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 
197	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Me)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 

198	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Hcy]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 















199	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Hcy]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 
200	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 



Table 1D. Compounds



Cmpd.	Structure
201	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
202	Ac-[Pen]-L-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 
203	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-L-[3Pal]-[Sarc]-NH2 


204	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 
205	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-E-L-[3Pal]-[Sarc]-NH2 
206	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



207	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 
208	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 
209	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



210	Ac-[Pen]-L-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 
211	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-E-L-[3Pal]-[Sarc]-NH2 
212	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 




213	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 
214	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(IsoButyl_Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 

215	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Butyl_Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 
216	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Benzyl_Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 

217	Ac-[Pen]-N-[MeThr]-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 

218	Ac-[Pen]-N-T-[W(7-Me)]-[N-MeGln]-[Pen]-F-[Nal]-[THP]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 
219	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[MeLys]-[Lys(Ac)]-N-[3Pal]-[Sarc]-NH2 

220	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[THP]-[Lys(Ac)]-[N-MeAsn]-[3Pal]-[Sarc]-NH2 
221	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[THP]-[Lys(Ac)]-[MeLeu]-[3Pal]-[Sarc]-NH2 

222	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[Spiral_Pip]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 
223	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[Spiral_Pip]-L-L-[3Pal]-[Sarc]-NH2 
224	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[Spiral_Pip]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 










225	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 




Table 1E. Compounds




Cmpd.	Structure
226	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-L-[3Pal]-[Sarc]-NH2 
227	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 



228	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 
229	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 


230	Ac-[Pen]-L-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
231	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 


232	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 
233	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 


234	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Nal]-[Nal]-[aMeLys]-E-L-[3Pal]-[Sarc]-NH2 
235	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Nal]-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 
236	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Nal]-[Nal]-[aMeLys]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 


237	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Nal]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 
238	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLys]-L-L-[3Pal]-[Sarc]-NH2 
239	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLys]-E-L-[3Pal]-[Sarc]-NH2 


240	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 
241	Ac-[Hcy]-N-T-[W(7-Me)]-Q-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 



242	Ac-[Abu]-Q-T-[W(7-Me)]-[Cit]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 

243	Ac-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 

244	Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 

245	Ac-[Hcy]-N-T-[W(7-Me)]-Q-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 

246	Ac-[Abu]-Q-T-[W(7-Me)]-[Cit]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 

247	Ac-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 
248	Ac-[Abu]-Q-T-[W(7-Me)]-Q-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-[Lys(Ac)]-A-[3Pal]-[Sarc]-NH2 









249	Ac-[Pen]-[Asn(4C13_2N15)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLys]-[Lys(Ac)]-[Asn(4C13_2N15)]-[(D)Leu]-NH2 
250	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(IsoButyl_Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[THP]-L-L-[3Pal]-[Sarc]-NH2 


Table 1F. Compounds


Cmpd.	Structure
251	Ac-[Pen]-I-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-I-[3Pal]-[MeLeu]-NH2 
252	Ac-[Pen]-I-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-I-[3Pal]-[(D)Leu]-NH2 
253	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-I-[3Pal]-[(D)Leu]-NH2 


254	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-L-[3Pal]-[N-MeNle]-NH2 



255	Ac-[Abu]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 




256	Ac-[Pen]-T-[W(7-Me)]-[Lys(Ac)]-C-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 




257	Ac-[Pen]-T-[W(7-Me)]-[Lys(Ac)]-[Hcy]-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 



258	Ac-C-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 


259	Ac-[Pen]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 


260	Ac-[Hcy]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
261	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-L-N-[3Pal]-[Sarc]-NH2 



262	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-OMe)]-[Nal]-[aMeLeu]-E-L-[3Pal]-[Sarc]-NH2 
263	Ac-[Pen]-[nLeu]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-[nLeu]-N-[3Pal]-[Sarc]-NH2 
264	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Spiral_Pip]-[Nal]-[aMeLeu]-E-N-[3Pal]-[Sarc]-NH2 

265	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Me)]-[Nal]-[aMeLys]-E-L-[3Pal]-[Sarc]-NH2 
266	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[aMeLeu]-E-L-[3Pal]-[Sarc]-NH2 
267	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Me)]-[Nal]-[aMeLys]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 

268	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-F-[Nal]-[aMeLys]-[Lys(Ac)]-L-[3Pal]-[Sarc]-NH2 
269	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-Ad)]-[Nal]-[THP]-[Lys(Ac)]-I-[3Pal]-[MeLeu]-NH2 

270	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-L-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 

271	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-L-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 

272	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-L-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
273	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CN)]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 













274	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-CN)]-[Nal]-[THP]-L-N-[3Pal]-[Sarc]-NH2 
275	Ac-[Pen]-N-L-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-L-[3Pal]-[Sarc]-NH2 




Table 1G. Compounds.




Cmpd.	Structure
276	Ac-[(D)Pen]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
277	Ac-C-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 




278	Ac-[(D)Cys]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-[3Pal]-[Sarc]-NH2 
279	Ac-[(D)arg]-[Abu]-N-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-S-H-[Sarc]-NH2 



280	Ac-[Abu]-N-T-[W(7-Me)]-Q-C-[Phe(4-(2-aminoethoxy))]-[Nal]-[THP]-E-N-H-[Sarc]-NH2 
281	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLys]-[Lys(Ac)]-N-[Thiozolidine]-NH2 
282	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLys]-[Lys(Ac)]-N-H-[MeNH] 




283	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Quin_3]-[aMeLys]-[Lys(Ac)]-N-H-[MeNH] 
284	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[Phe(4-(2-aminoethoxy))]-[Coumarin(7-OMe)]-[aMeLys]-[Lys(Ac)]-N-[(D)Leu]-NH2 
285	Ac-[Pen]-N-V-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 

286	Ac-[Pen]-N-K-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 
287	Ac-[Pen]-N-[Dab]-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 
288	Ac-[Pen]-N-[Dap]-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 

289	Ac-[Pen]-A-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 
290	Ac-[Pen]-N-A-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 
291	Ac-[Pen]-N-T-W-A-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 

292	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-A-N-N-NH2 
293	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-A-N-NH2 
294	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-A-NH2 

295	Ac-[Pen]-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-N-NH2 
296	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-N-NH2 

297	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-NH2 
298	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-NH2 
299	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-N-N-NH2 










300	Ac-[Pen]-N-T-W-Q-[Pen]-[Phe(4-(2-aminoethoxy))]-[Nal]-[aMeLeu]-[Lys(Ac)]-N-NH2 



Table 1H. Compounds



SEQ ID	Structure Harmonized Sequences txt	Smiles
158	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
159	 EtCO-r-C(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](CSSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O



160	 EtCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)C1=O)=O)=O
161	 EtCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COtBu)-N-F-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCCCNC(C)(C)C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)C1=O)=O)=O



162	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-Achx-aMeE-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
163	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-Achx-aMeE-N-F-AIB-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(NC(C)(C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



164	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-Achx-aMeE-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
165	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-Q-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



166	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-aMeW-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2c[nH]c3c2cccc3)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
167	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-1Nal-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cccc3ccccc23)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




168	 EtCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(CO2allyl)-N-F-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCCCNC(OCC=C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O
169	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-4AmPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)ccc2C(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




170	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-2Nal-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
171	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-aMeFPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc(cc2)ccc2F)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



172	 MeCO-r-C(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-Achx-aMeE-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
173	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-"L"Y02-2Nal-THP-aMeE-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@](C)(Cc(cc2)cc(OC)c2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




174	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-F-AIB-aMeK-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(NC(C)(C)C(N[C@@](C)(CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
175	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-AIB-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(NC(C)(C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



176	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-Achx-aMeE-N-F-AIB-aMeK-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(NC(C)(C)C(N[C@@](C)(CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
177	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-3,4diFPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)cc(F)c2F)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




178	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-Achx-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(NC2(CCCCC2)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
179	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COMe)-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
180	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COEt)-N-F-CONH2	CCC(NCCCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ccccc1)C(N)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@H]1CCC(N)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O



181	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COcPr)-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C2CC2)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
182	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COPr)-N-F-CONH2	CCCC(NCCCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ccccc1)C(N)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@H]1CCC(N)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O
183	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COPent)-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C(F)(F)F)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




184	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COCF3)-N-F-CONH2	CC(C)C(NCCCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ccccc1)C(N)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@H]1CCC(N)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O
185	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-K(COiPr)-N-F-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@](C)(Cc(cc2)cc(OC)c2OC)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




186	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-"D"Y02-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]c(cc3)c2cc3F)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
187	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-5FW-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
188	 MeCO-Pen(3)-Q-T-W-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](CCSC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O



189	 EtCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@](C)(CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
190	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-aMeE-N-H-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C/C=C\C[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O



191	 EtCO-r-aG(4)-Q-T-W-Q-aG(4)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
192	 MeCO-Pen(3)-N-T-7MeW-Q-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
193	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



194	 MeCO-r-Pen(3)-N-T-7MeW-Q-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
195	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




196	 MeCO-r-Pen(3)-N-T-7MeW-Q-Pen(3)-AEF-2Nal-Acpx-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
197	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-aMePhe-CONH2	C[C@@H]([C@@H](C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@H]1[C@@H](C)O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)c1c[nH]c2c1cccc2
198	 MeCO-r-Pen(3)-N-T-bMeW(2S3R)-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



199	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
200	 MeCO-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N[C@H](Cc(cc2)ccc2O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
201	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-y-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



202	 MeCO-r-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-aMePhe-CONH2	CC(C)C[C@@](C)(C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCNC(N)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O
203	 MeCO-Pen(3)-N-T-7MeW-Cit-Pen(3)-AEF-2Nal-aMeL-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



204	 MeCO-r-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@H]1[C@@H](C)O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)c1c[nH]c2c1cccc2
205	 MeCO-r-Pen(3)-N-T-bMeW(2S3S)-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(NCc2ccccc2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



206	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NBzl)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(NC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
207	 MeCO-r-Dap(2)-Q-T-W-Q-D(2)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(NCCOc1ccc(C[C@@H](C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)N2)cc1)=O)C2=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](CN)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)=O)O



208	 MeCO-r-Dap-Q-T-W-Q-D(2)-AEF(2)-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N[C@H](Cc2ccc(CN)cc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
209	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-paf-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N[C@H](Cc2cc(CN)ccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
210	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-maf-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N[C@H](Cc(cc2)ccc2O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



211	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-E-N-H-y-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N[C@H](Cc2cnccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
212	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-D3Pya-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N[C@H](Cc(cc2)ccc2O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




213	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-y-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCNC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(NC(C)(C)C(NCCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
214	 MeCO-Pen(3)-N-T-7MeW-Cit-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-Aib-bAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



215	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-3Quin-aMeK-K(Ac)-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](CCCCN)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
216	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-3Quin-THP-E-N-dK-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@H](CCCCN)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



217	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-3Quin-aMeK-K(Ac)-N-dK-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
218	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-3Quin-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



219	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-3Quin-aMeK-K(Ac)-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
220	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-N-aMePhe-CONH2	CC(C)C[C@H](C(N(C)CC(N)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2nc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O



221	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-3Quin-THP-E-N-dL-Sar-CONH2	CCc1cccc2c1[nH]cc2C[C@@H](C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@H]1[C@@H](C)O)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)NC1=O
222	 MeCO-Pen(3)-N-T-7EtW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-Sar-CONH2	CCc1cccc2c1[nH]cc2C[C@@H](C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@H]1[C@@H](C)O)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O



223	 MeCO-Pen(3)-N-T-7EtW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
224	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(CN)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
225	 MeCO-Pen(3)-N-T-7MeW-K(Gly)-Pen(3)-AEF-2Nal-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



226	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc2ccccc2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
227	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NPh)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc(cccc2)c2N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



228	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NoAn)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(NC2CCNCC2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
229	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NPip)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(NC2CNCC2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



230	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NPyr)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc(cc2)ccc2N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
231	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NpAn)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc2cc(N)ccc2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



232	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NmAn)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc2c[nH]nc2)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
233	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(N4Pyz)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(Nc(cc2)cc3c2[nH]cc3)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



234	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(N5In)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
235	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3nc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



236	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-3Quin-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
237	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




238	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(NCCC(N)=O)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
239	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NPrAm)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C(F)(F)F)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



240	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(COCF3)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)(C)C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
241	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(COtBu)-N-aMePhe-CONH2	CC(C)C[C@@](C)(C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc1cnc[nH]1)C(N)=O)=O)=O)=O)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCNC(N)=O)=O)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O




242	 PentCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
243	 MeCO-Pen(3)-N-T-7MeW-Cit-Pen(3)-AEF-2Nal-aMeL-K(Ac)-N-h-CONH2	CC(C)C[C@@](C)(C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCNC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O



244	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-h-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
245	 MeCO-r-Pen(3)-N-T-7MeW-Cit-Pen(3)-AEF-2Nal-aMeL-E-N-aMePhe-CONH2	CCC(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)C1=O)=O



246	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-h-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc1ccccc1)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O
247	 EtCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NS(C)(=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



248	 EtCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CN=[N+]=[N-])=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
249	 MeSO2-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CN=[N+]=[N-])=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
250	 AzCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NS(C)(=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



251	 AzCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N[C@H](Cc(cc2)ccc2O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
252	 MeSO2-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N(CCC2)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



253	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-y-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N(CCC2)[C@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
254	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-P-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(NCCN)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
255	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-p-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2F)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




256	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-N-D(NEtNH2)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2F)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
257	 MeCO-Pen(3)-N-T-7FW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc(c1ccc2)c[nH]c1c2Cl)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




258	 MeCO-r-Pen(3)-N-T-7FW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc(c1ccc2)c[nH]c1c2Cl)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
259	 MeCO-Pen(3)-N-T-7ClW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c(cc2)c1cc2Br)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



260	 MeCO-r-Pen(3)-N-T-7ClW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c(cc2)c1cc2Br)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
261	 MeCO-Pen(3)-N-T-5BrW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



262	 MeCO-r-Pen(3)-N-T-5BrW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
263	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-3MeH-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@]](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cn(C)cn2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



264	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3MeH-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cn(C)cn2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
265	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-1MeH-CONH2	C[C@H]([C@@H](C(N[C@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)N)C(N[C@@H](Cc(cc2)ccc2OCCNC(OC(C)(C)C)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCNC(OC(C)(C)C)=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



266	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-1MeH-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)N)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(OC(C)(C)C)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
267	 NH2-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(Boc)-2Nal-aMeK(Boc)-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCc(cc2)cc(I)c2O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
268	 NH2-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(Boc)-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CCc(cc2)cc(I)c2O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




269	 BHCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2ccc(CN)cc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
270	 BHCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
271	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-dPaf-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(NC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




272	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(NC)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
273	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-CONHMe	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




274	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-E-N-H-CONHMe	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
275	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




276	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
277	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(NC2(CCOCC2)C(N(CCC2)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



278	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(NC2(CCOCC2)C(N(CCC2)[C@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
279	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-THP-P-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(NCCC(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




280	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-THP-p-CONH2	CC(C)[C@H](C(N(C)CC(N)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O
281	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-bAla-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](CCCNC(N)=N)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
282	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-v-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCc2ccccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



283	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-r-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccc(CN)cc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
284	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-hF-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccc(CN)cc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
285	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-PAF-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



286	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-PAF-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2cnc[nH]2)C(N[C@H](Cc2ccc(CN)cc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
287	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-F-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(Cn2nnc(CCCF)c2)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
288	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-H-paf-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(Cn2nnc(CCCF)c2)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



289	 FPrpTriazoleMeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc2ccc(C3CCNCC3)cc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
290	 FPrpTriazoleMeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc2ccc(C3CCNCC3)cc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
291	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4PipPhe-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(c(F)c(cc2F)F)c2F)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




292	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4PipPhe-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(c(F)c(cc2F)F)c2F)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
293	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-tetraFPhe-CONH2	C[C@@H]([C@@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)c1ccccc1




294	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-tetraFPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncnc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
295	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-bMePhe(SR)-CONH2	C[C@@H]([C@@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O)c1ccccc1
296	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-5PyrimidAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncnc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




297	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-bMePhe(SR)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(CCc(cc2)cc(I)c2O)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
298	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-5PyrimidAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(c2ccc(CNS(C)(=O)=O)cc2)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




299	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(BH)-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
300	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(SMSB)-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(C)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




301	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(NC2(CCOCC2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
302	 MeCO-Pen(3)-N-T-7PhW-K(Ac)-Pen(3)-AEF(Ac)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	CC(C)C[C@H](C(N(C)CC(N)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O




303	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-THP-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N[C@H](Cc(cc2)ccc2C(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
304	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-l-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N[C@H](Cc(cc2)ccc2C(C)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
305	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-H-4AmDPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



306	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-H-4AcDPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(NCCC(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
307	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-3Pya-Sar-CONH2	CC(C)[C@H](C(N(C)CC(N)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O
308	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-bAla-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@H](CCCNC(N)=N)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




309	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-v-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCc2ccccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
310	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-r-Sar-CONH2	C[C@H]([C@@H](C(N[C@@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)ccc2O)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
311	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-homoF-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc(cc2)ccc2O)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



312	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-Y-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
313	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-y-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
314	 MeCO-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CCCCCN(/C(/C2(C)C)=C\C=C\C(C3(C)C)=[N+](C)c(cc4)c3cc4S(O)(=O)=O)c(cc3)c2cc3S(O)(=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



315	 MeCO-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CCOCCOCCNC(CCCCCN(/C(/C2(C)C)=C\C=C\C(C3(C)C)=[N+](C)c(cc4)c3cc4S(O)(=O)=O)c(cc3)c2cc3S(O)(=O)=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
316	 (SulfoCy3)-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CCOCCOCCOCCNC(CCCCCN(/C(/C2(C)C)=C\C=C\C(C3(C)C)=[N+](C)c(cc4)c3cc4S(O)(=O)=O)c(cc3)c2cc3S(O)(=O)=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
317	 (SulfoCy3dPEG2)-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(c2ccc(CNS(C)(=O)=O)cc2)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



318	 (SulfoCy3dPEG3)-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cc(O)ccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
319	 SMSBCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(c2ccc(CNS(C)(=O)=O)cc2)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
320	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3OHPhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccncc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



321	 SMSBCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccc(C(F)(F)F)cc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
322	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-4PyridinAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)ccc2OC(F)F)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



323	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-F(CF3)-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(NC2(CCOCC2)C(N(CCC2)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
324	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-Y(CHF2)-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
325	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-THP-P-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccncc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




326	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c(CN)cccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
327	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-4Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(CC(C2)(F)F)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



328	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-oAMPhe-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(CCC2)[C@]2(C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
329	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-4diFPro-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(NC(C)(C)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



330	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-aMeP-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
331	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-AIB-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



332	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-3MeH-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cc(C)cc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@](C)(Cc2ccccc2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
333	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3MeH-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



334	 MeCO-r-Pen(3)-N-T-5MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-aMePhe-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
335	 MeCO-r-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3MeH-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](Cc2cnccc2)C(NC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



336	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-D3Pya-Sar-CONH2	CC(C)([C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](Cc1cnccc1)C(N[C@@H](CC(N)=O)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1cnccc1)NC([C@H](C[C@H](C1)O)N1C([C@H](CC(N)=O)NC1=O)=O)=O)=O)=O)SSC(C)(C)[C@@H]1NC([C@@H](CCCNC(N)=N)NC(Cn1nnc(CCCF)c1)=O)=O
337	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-CONHMe	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)N)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
338	 FPrpTriazoleMeCO-r-Pen(3)-N-Hyp-3Pya-K(Ac)-Pen(3)-AEF-2Nal-THP-E-3Pya-N-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



339	 NH2-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	CCC(NCCOc1ccc(C[C@@H](C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc2c[nH]c3c2cccc3C)C(N[C@H]2CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CC)=O)=O)NC2=O)=O)cc1)=O
340	 MeCO-r-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(CCc(cc2)cc(I)c2O)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



341	 EtCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(EtCO)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CN=[N+]=[N-])=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
342	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(BH)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(Cn2nnc(CCCF)c2)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



343	 AzCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncc(C)c2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
344	 FPrpTriazoleMeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncc(C(N)=O)c2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



345	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-5MePyridinAla-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncn2C)C(NC)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
346	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-5AmPyridinAla-Sar-CONH2	CC(C)([C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](Cc1cnccc1)C(N[C@@H](CC(N)=O)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1cnccc1)NC([C@H](C[C@H](C1)O)N1C([C@H](CC(N)=O)NC1=O)=O)=O)=O)=O)SSC(C)(C)[C@@H]1NC([C@@H](CCCNC(N)=N)NC(CN=[N+]=[N-])=O)=O



347	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3MeH-CONHMe	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cc3ccccc3nc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
348	 AzCO-r-Pen(3)-N-Hyp-3Pya-K(Ac)-Pen(3)-AEF-2Nal-THP-E-3Pya-N-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]nn2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



349	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3QuinolAla-Sar-CONH2	C[C@H]([C@@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O)=O)c1ccccc1
350	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-4TriazolAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(CC2CCCCC2)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



351	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-bMePhe(2S3S)-CONH2	CC(C)CN(CC(N)=O)C([C@H](Cc1cncc c1)NC([C@H](CC(N)=O)NC([C@H](C CC(O)=O)NC(C1(CCOCC1)NC([C@H] (Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)c cc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CC CCNC(C)=O)=O)=O)=O)=O)NC([C@@ H](CCCNC(N)=N)NC(C)=O)=O)NC1= O)=O)=O)=O)=O)=O)=O)=O
352	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-N(Cyclohexyl)Gly-CONH2	CC(C)(C(N[C@@H](CC(N)=O)C(N(CC [C@H]1O)[C@@H]1C(N[C@@H](Cc1 c[nH]c2c1cccc2C)C(N[C@@H](CCCC NC(C)=O)C(N[C@@H](CCC/C=C\CC C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@ H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)= O)=O)=O)=O)NC([C@@H](CCCNC(N) =N)NC(C)=O)=O



353	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-N(Isobutyl)Gly-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CSSC[C@@](C)(C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
354	 MeCO-r-AIB-N-3OHPro-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



355	 MeCO-r-aMeC(3)-N-T-7MeW-K(Ac)-C(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CSSC[C@@](C)(C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
356	 MeCO-Pen(3)-N-T-W-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](C)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



357	 MeCO-aMeC(3)-N-T-7MeW-K(Ac)-C(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
358	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-A-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](C)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




359	 MeCO-r-Pen(3)-N-T-A-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(CCc(cc2)cc(I)c2O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(C)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
360	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-A-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)cc(C(N)=O)c2O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



361	 BHCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(Ac)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc(cc2)cnc2O)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
362	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-2AmTyr-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)N)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(C)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




363	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-6OH3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
364	 NH2-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(Ac)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(CC(N)=O)Cc2cc(C(N)=O)ccc2)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




365	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-A-Sar-CONH2	C[C@@H]([C@@H](C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)c(cc1)ccc1OCCN
366	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-N(3AmBenzyl)Gly-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)c(cc1)ccc1OCCN




367	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-bMeAEF(2S3R*)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)S)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(CC(N)=O)Cc(cc1)ccc1C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(N)=O)NC([C@H](C(C)(C)S)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)=O)O
368	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-bMeAEF(2S3S*)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O


369	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-N(4AmBenzyl)Gly-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
370	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG4Biotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
371	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6gEBiotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccncc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



372	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Biotin)-N-3Pya-Sar-CONH2	C[C@@H]([C@@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)NC1=O)=O)=O)=O)=O)=O)c1cnc[nH]1
373	 MeCO-r-Pen(3)-N-T-7PyrTrp-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



374	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-bMeH(2S3S*)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
375	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6Biotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
376	 MeCO-k(PEG6Biotin)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6Biotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



377	 Biotin-PEG6-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6Biotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
378	 Biotin-gEPEG6-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6gEBiotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]c(C)n2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
379	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CCCC[C@@H]([C@H]2N3)SC[C@@H]2NC3=O)=O)=O)=O)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



380	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-5MeH-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(COCCOCCNC(COCCOCCNC(CCCC[C@@H]([C@H]2N3)SC[C@@H]2NC3=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
381	 MeCO-k(PEG2PEG2Biotin)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCOCCOCCOCCOCCOCCOCCNC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCC[C@H]([C@@H]2N3)SC[C@H]2NC3=O)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
382	 BiotinPEG2PEG2CO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



383	 Biotin-PEG6-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6gEBiotin)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc(c1ccc2)c[nH]c1c2Br)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
384	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-Dap(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCCCNC(COCCOCCNC(COCCOCCNC(CCCC[C@@H]([C@H]2N3)SC[C@@H]2NC3=O)=O)=O)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



385	 MeCO-Pen(3)-N-T-7BrW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(NCCOCCOCCOCCOCCOCCOCCCC(NCCCC[C@H](C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)NC(C)=O)=O)=O
386	 MeCO-Pen(3)-K(PEG2PEG2Biotin)-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCCC(NCCCC[C@H](C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](C)O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)NC(C)=O)=O)=O)C(O)=O)=O


387	 MeCO-k(dPEG12AcVitE)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc(c1ccc2)c[nH]c1c2-c(cccc1)c1Cl)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
388	 MeCO-k(gGdPEG12AcVitE)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccc(C(F)(F)F)cc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



389	 MeCO-Pen(3)-N-T-7(2ClPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(N)=O)NC([C@H](C)NC(C)=O)=O)=O)O
390	 MeCO-Pen(3)-N-T-7(4CF3Ph)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc2nnc(C(F)(F)F)n2cc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




391	 MeCO-A-N-T-7MeW-K(Ac)-A-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)ccc1NC(C)=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
392	 MeCO-Pen(3)-N-T-7(3CF3TAZP)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



393	 MeCO-Pen(3)-N-T-7(4NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)ccc1OC(F)(F)F)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
394	 MeCO-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)ccc1OC)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



395	 MeCO-Pen(3)-N-T-7(4OCF3Ph)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)C(O)=O)=O
396	 MeCO-Pen(3)-N-T-7(4OMePh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCC(N[C@H]([C@H]([C@H]2O)O)O[C@@H](CO)[C@H]2O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



397	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(PEG6gEVitE)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCCNC(CCC(N[C@@H]([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)=O)=O)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



398	 DAGSuc-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCCNC(CCC(N[C@@H]([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)=O)=O)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
399	 MeCO-k(DAGSuc)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(CCC(N[C@@H]([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)=O)=O)NC(C)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



400	 MeCO-k(DAGSuc)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(CCC(N[C@@H]([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
401	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(DAGSuc)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1c[nH]nc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
402	 DAGSuc-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc2nccn2cc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



403	 MeCO-Pen(3)-N-T-7(4Paz)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1c(C)cc(cnn2C)c2c1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
404	 MeCO-Pen(3)-N-T-7(7Imzpy)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)cc(N2)c1NC2=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



405	 MeCO-Pen(3)-N-T-7(6((1)7dMeNDAZ))W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pyr-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cnc2N(C)CCc2c1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
406	 MeCO-Pen(3)-N-T-7(3UrPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1ccc(C2(CC2)C#N)cc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



407	 MeCO-Pen(3)-N-T-7(5(Ina7Pyr))W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)cc(C=CN2)c1C2=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
408	 MeCO-Pen(3)-N-T-7(4(CpCNPh))W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(N(CCC2)C2=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



409	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-4(R)HydroxyPro-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1C)cc(CC2)c1NC2=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
410	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-4(S)AminoPro-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c(cc1)cnc1-c(cc1)ccc1OC)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



411	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-5(R)diMePro-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(-n2nccc2)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
412	 MeCO-Pen(3)-N-T-7(6(2MeNDAZ))W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C[C@@H](C2)O)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



413	 MeCO-Pen(3)-N-T-7MeW-AIB-Pen(3)-AEF-2Nal-THP-AIB-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C[C@@H](C2)N)[C@@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
414	 MeCO-Pen(3)-N-L-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N2C(C)(C)CC[C@H]2C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




415	 MeCO-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-L-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc2nn(C)cc2cc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
416	 MeCO-Aib-E(2)-T-7MeW-K(Ac)-Aib-AEF(2)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(NC(C)(C)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(NC(C)(C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



417	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-F-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O
418	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Y-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O



419	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(NC(C)(C)C(N[C@@H](Cc(cc1)ccc1OCCNC(CC[C@@H]1NC(C(C)(C)NC(C)=O)=O)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
420	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4AmF-2Nal-THP-E(2)-N-3Pya-dK(2)-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc2ccccc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



421	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4AmF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
422	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-L-L-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



423	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2C(N)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
424	 MeCO-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-L-L-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CC(C)C)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O



425	 2Benzyl(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O
426	 2Benzyl(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-THP-A-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CC(C)C)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O
427	 MeCO-Pen(3)-N-T-BT-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc(cccc1)c1C(N[C@H]1CC(N)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



428	 MeCO-Pen(3)-L-T-7MeW-K(Morph)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc(cccc1)c1C(N[C@H]1CC(N)=O)=O)C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
429	 MorphCO-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1csc2c1cccc2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O


430	 MeCO-Pen(3)-N-T-7MeW-K(Morph)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CN2CCOCC2)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O
431	 MeCO-K(Morph)-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(CN2CCOCC2)=O)NC1=O)=O)=O)=O)=O


432	 MeCO-K(Morph)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CN2CCOCC2)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O
433	 MeCO-Pen(3)-L-T-7MeW-K(mPEG4)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CN2CCOCC2)=O)NC(C)=O)=O)NC1=O)=O)=O)=O)=O


434	 MeCO-Pen(3)-N-T-7MeW-K(mPEG4)-Pen(3)-F-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CN2CCOCC2)=O)NC(C)=O)=O)NC1=O)=O)=O)=O)=O
435	 MeCO-K(Morph)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc1ccccc1)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CCOCCOCCOCCOC)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O



436	 MeCO-K(Morph)-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CN2CCOCC2)=O)NC(C)=O)=O)NC1=O)=O)=O)=O)=O
437	 MorphCO-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CN2CCOCC2)=O)NC(C)=O)=O)NC1=O)=O)=O)=O)=O



438	 MeCO-Pen(3)-L-T-7MeW-K(Morph)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(CN2CCOCC2)=O)NC1=O)=O)=O)=O
439	 MeCO-K(mPEG12)-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CN2CCOCC2)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O



440	 MeCO-K(mPEG12)-Pen(3)-L-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)NC(C)=O)=O)NC1=O)=O)=O)=O



441	 MeCO-Pen(3)-N-T-7MeW-K(mPEG12)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)NC(C)=O)=O)NC1=O)=O)=O)=O



442	 MeCO-Pen(3)-L-T-7MeW-K(mPEG12)-Pen(3)-4OMeF-2Nal-aMeL-L-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O



443	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-D(Pip)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CC(C)C)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@H]1CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O
444	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Tzl(mPEG3)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](CC(N2CCCCC2)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



445	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-3FTyr-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc2cn(CCOCCOCCOC)nn2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
446	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Y(OTzl)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)cc(F)c2O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



447	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Y(OTzl(mPEG3))-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCc2c[nH]nn2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
448	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Tzl-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCc2cn(CCOCCOCCOC)nn2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



449	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-Tzl(PEG3OH)-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc2c[nH]nn2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
450	 MeCO-Abu(1)-N-T-W-Q-C(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc2cn(CCOCCOCCO)nn2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



451	 5Ava(2)-Ala-N-T-W-Q-AIB-AEF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
452	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Quin-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(NC(C)(C)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(NCCCCC(N[C@@H](C)C(N[C@H]1CC(N)=O)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




453	 MeCO-r-Ala-E(2)-T-7MeW-K(Ac)-AIB-AEF(2)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc(ccc2n3)cc2ccc3O)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
454	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(NC(C)(C)C(N[C@@H](Cc(cc1)ccc1OCCNC(CC[C@@H]1NC([C@H](C)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)=O)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



455	 MeCO-Abu(1)-N-T-7MeW-K(Ac)-C(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
456	 MeCO-Abu(1)-N-T-7MeW-K(Ac)-Pen(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



457	 MeCO-r-Abu(1)-N-T-7MeW-K(Ac)-C(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCC[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
458	 MeCO-r-Abu(1)-N-T-7MeW-K(Ac)-Pen(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




459	 MeCO-r-4RAminoPro(2)-N-T-7MeW-K(Ac)-Asp(2)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCC[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
460	 MeCO-r-4SAminoPro(2)-N-T-7MeW-K(Ac)-Asp(2)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N[C@H](C[C@H]1C(N[C@H]2CC(N)=O)=O)CN1C([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc3ccccc3cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC2=O)O




461	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-E-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N[C@@H](C[C@H]1C(N[C@H]2CC(N)=O)=O)CN1C([C@@H](CCCNC(N)=N)NC(C)=O)=O)=O)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc3ccccc3cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC2=O)O
462	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-aMeK-K(Ac)-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O



463	 MeCO-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnc[nH]2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
464	 MeCO-Pen(pXyl)(1)-N-T-7MeW-K(Ac)-Pen(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
465	 MeCO-Pen(oXyl)(1)-N-T-7MeW-K(Ac)-Pen(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc1ccc(CSC(C)(C)[C@@H](C(N[C@H]2CC(N)=O)=O)NC(C)=O)cc1)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc3ccccc3cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC2=O)O

477	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF(G)-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc1c(CSC(C)(C)[C@@H](C(N[C@H]2CC(N)=O)=O)NC(C)=O)cccc1)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc3ccccc3cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC2=O)O
466	 MeCO-Pen(mXyl)(1)-N-T-7MeW-K(Ac)-Pen(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc1cccc(CSC(C)(C)[C@@H](C(N[C@H]2CC(N)=O)=O)NC(C)=O)c1)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc3ccccc3cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC2=O)O

478	 MeCO-r-Abu(1)-N-T-W-K(Ac)-aMeC(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
467	 MeCO-r-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@@H]([C@H](C(N[C@H](Cc1c[nH]c2c1cccc2C)C(N[C@H](CCCCNC(C)=O)C(N[C@H](C(C)(C)SSC(C)(C)[C@H](C(N[C@@H]1CC(N)=O)=O)NC(C)=O)C(N[C@H](Cc(cc2)ccc2O)C(N[C@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@H](CCC(O)=O)C(N[C@H](CC(N)=O)C(N[C@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O

468	 MeCO-pen(3)-n-t-D7MeW-k(ac)-pen(3)-y-2nal-THP-e-n-3pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](Cc(cc1)ccc1O)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1c[nH]cn1)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(N)=O)NC([C@H](C)NC(C)=O)=O)=O)O
469	 MeCO-A-N-T-W-Q-A-Y-W-A-E-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2c[nH]c3c2cccc3)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
470	 MeCO-r-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-W-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2O)C(N[C@@H](Cc2c[nH]c3c2cccc3)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O

471	 MeCO-r-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-Y-W-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CS)C(N[C@@H](Cc(cc1)ccc1O)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1c[nH]cn1)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CC(N)=O)NC([C@H](CS)NC(C)=O)=O)=O)O
472	 MeCO-C-N-T-W-Q-C-Y-W-A-E-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
473	 MeCO-r-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-H-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2c[nH]cn2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O

474	 MeCO-r-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-Acpx-E-N-H-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2ccccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
475	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-F-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2-c1cc(NC(C)=O)ccc1)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cncc(C)c2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O













476	 MeCO-r-Pen(3)-N-T-7(3NAcPh)W-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-5MePyridinAla-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCNC(N)=N)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O





Table 1I. Compounds





SEQ ID	Structure Amino Acid Sequence	Smiles
476	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-Pyr#-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(Nc1cn(CC(N)=O)c(C(N)=O)c1)=O)=O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O





477	 MeCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-THP-E-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
478	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-N-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
479	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O





480	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-THP-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(NC2(CCOCC2)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
481	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-bAla-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(NCCC(N)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
482	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-N-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O





483	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-E-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
484	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-THP-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
485	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
486	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(O)=O)=O)=O)=O)=O)=O)NC1=O)O





487	 EtCO-r-Pen(3)-Q-T-W-Q-Pen(3)-AEF-2Nal-COOH	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(O)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O
488	 MeCO-r-Abu(1)-Q-T-W-Q-C(1)-COOH	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CCC(N)=O)C(N[C@@H](CSCC[C@@H](C(N[C@H]1CCC(N)=O)=O)NC([C@@H](CCCNC(N)=N)NC(C)=O)=O)C(O)=O)=O)=O)=O)NC1=O)O
489	 EtCO-r-Abu(1)-Q-T-W-Q-C(1)-AEF-2Nal-CONH2	CCC(N[C@H](CCCNC(N)=N)C(N[C@@H](CCSC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(N)=O)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](Cc1c[nH]c2c1cccc2)NC([C@H]([C@@H](C)O)NC([C@H](CCC(N)=O)N1)=O)=O)=O)=O)C1=O)=O)=O
490	 MeCO-AIB-7MeW-S5H(4)-AIB-AEF-2Nal-S5H(4)-K(Ac)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)NC([C@H](Cc1cccc2ccccc12)NC([C@H](Cc(cc1)ccc1OCCN)NC(C(C)(C)N1)=O)=O)=O)C1=O)=O)=O)NC(C)=O





491	 MeCO-3OHPro-7MeW-K(Ac)-S5H(4)-AEF-2Nal-aMeK-S5H(4)-N-3Pya-Sar-CONH2	C[C@](CCCCN)(C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@H]1Cc2cccc3ccccc23)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC([C@H]([C@@H](CC2)O)N2C(C)=O)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)NC1=O
492	 MeCO-AIB-7MeW-K(Ac)-S5H(4)-AEF-2Nal-aMeK-S5H(4)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cccc2ccccc12)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)=O)=O)NC(C)=O
493	 MeCO-3OHPro-7MeW-S5H(4)-AIB-AEF-2Nal-S5H(4)-K(Ac)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cccc2ccccc12)C(N[C@@H](CCC/C=C\CCC[C@@H]1NC([C@H](Cc2c[nH]c3c2cccc3C)NC([C@H]([C@@H](CC2)O)N2C(C)=O)=O)=O)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O
494	 7Ahp(2)-2Nal-THP-hE(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCCC(NCCCCCCC(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC1=O)=O)=O)=O




495	 6Ahx(2)-AEF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCC(NCCCCCC(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)=O)=O)NC1=O)=O)=O)=O
496	 MeCO-T-7MeW-K(Ac)-S5Me(4)-AEF-2Nal-THP-S5Me(4)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@](C)(CCC/C=C\CCC[C@@](C)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)=O)=O)NC(C)=O)O
497	 MeCO-T-7MeW-S5Me(1)-AIB-AEF-2Nal-S5Me(1)-K(Ac)-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@](C)(CCC/C=C\CCC[C@@](C)(C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC(C(C)(C)N1)=O)=O)=O)C1=O)=O)=O)NC(C)=O)O
498	 MeCO-S5H(4)-AEF-2Nal-aMeK-S5H(4)-N-3Pya-Sar-CONH2	C[C@](CCCCN)(C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@H]1Cc2cc3ccccc3cc2)=O)=O)NC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)NC1=O





499	 MeCO-Lys(2)-AEF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CC(N[C@@H](CCCCNC(CC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)=O)C1=O)=O
500	 MeCO-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-Sar-CONH2	CC(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O
501	 MeCO-AEF(2)-2Nal-THP-E-hE(2)-3Pya-Sar-CONH2	CC(N[C@@H](Cc(cc1)ccc1OCCNC(CCC[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)N1)=O)=O)=O)=O)C1=O)=O
502	 MeCO-S5Me(4)-AEF-2Nal-THP-S5Me(4)-N-3Pya-Sar-CONH2	C[C@](CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC(C)=O)(C(N[C@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)NC1=O





503	 MeCO-K(Ac)-S5H(4)-AEF-2Nal-aMeK-S5H(4)-N-3Pya-Sar-CONH2	C[C@](CCCCN)(C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@H]1Cc2cc3ccccc3cc2)=O)=O)NC([C@H](CCCCNC(C)=O)NC(C)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)NC1=O
504	 MeCO-K(Ac)-S5H-AEF-2Nal-aMeK-S5H-N-3Pya-Sar-CONH2	C[C@](CCCCN)(C(N[C@@H](CCCC=C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](CCCC=C)NC([C@H](CCCCNC(C)=O)NC(C)=O)=O)=O)=O)=O
505	 MeCO-S5H(4)-2Nal-THP-E-S5H(4)-3Pya-Sar-CONH2	CC(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CCC(O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)N1)=O)=O)=O)C1=O)=O
506	 MeCO-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)NC(C)=O)=O




507	 MeCO-AIB-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)NC(C)=O
508	 MeCO-S5Me-AEF-2Nal-THP-S5Me-N-3Pya-Sar-CONH2	C[C@](CCCC=C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@](C)(CCCC=C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)NC(C)=O
509	 MeCO-hLys(2)-2Nal-THP-Q-D(2)-3Pya-Sar-CONH2	CC(N[C@@H](CCCCCNC(C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@H](CCC(N)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)N1)=O)=O)=O)=O)C1=O)=O
510	 8Aoc(2)-2Nal-THP-hE(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCCC(NCCCCCCCC(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC1=O)=O)=O)=O





511	 MeCO-T-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-N(iBu)Gly-CONH2	CC(C)CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCC/C=C/CCC[C@@H](C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC([C@H]([C@@H](C)O)NC(C)=O)=O)=O)=O)NC1=O)=O)=O)=O
512	 MeCO-3OHPro-7MeW-K(Ac)-Lys-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCCCN)C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1ncccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](CC1)O)N1C(C)=O)=O)=O)=O
513	 MeCO-3OHPro-7MeW-K(Ac)-Lys(2)-AEF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCCCNC(CC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC([C@H]([C@@H](CC1)O)N1C(C)=O)=O)=O)=O
514	 7Ahp(2)-2Nal-THP-Q-D(2)-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(NCCCCCCC(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(N[C@H]1CCC(N)=O)=O)=O)=O)=O)=O)=O)NC1=O)=O)=O



515	 6Ahx(2)-AEF-2Nal-THP-E(2)-N-N-Sar-CONH2	CN(CC(N)=O)C([C@H](CC(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(NCCCCCC(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)=O)=O)NC1=O)=O)=O)=O
516	 MeCO-AIB-7MeW-K(Ac)-S5Me(4)-AEF-2Nal-THP-S5Me(4)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@](C)(CCC/C=C\CCC[C@@](C)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)=O)=O)NC(C)=O
517	 MeCO-T-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-N(Cyclohexyl)Gly-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CCC/C=C/CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(CC1CCCCC1)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)=O)=O)NC(C)=O)O
518	 5Ava(2)-2Nal-THP-hE(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCCC(NCCCCC(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC1=O)=O)=O)=O




519	 bAla(2)-AEF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCC(NCCC(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)=O)NC1=O)=O)=O)=O
520	 6Ahx(2)-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CN(CC(N)=O)C([C@H](Cc1cnccc1)NC([C@H](CC(N)=O)NC([C@H](CCC(NCCCCC(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC1=O)=O)=O)=O
521	 MeCO-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-N(3AmBenzyl)Gly-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(CC(N)=O)Cc1cc(C(N)=O)ccc1)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
522	 MeCO-T-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-N(3AmBenzyl)Gly-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(CC(N)=O)Cc1cc(C(N)=O)ccc1)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)=O)=O)NC(C)=O)O





523	 MeCO-7MeW-K(Ac)-S5H(4)-AEF-2Nal-THP-S5H(4)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCC/C=C\CCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
524	 MeCO-Pen(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-K(Ac)-N-CON(Me)2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
525	 2Benzyl(3)-N-T-7MeW-K(Ac)-Pen(3)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc(cccc1)c1C(N[C@H]1CC(N)=O)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O
526	 2Benzyl(3)-N-T-7MeW-K(Ac)-Pen(3)-4OMeF-2Nal-THP-A-N-3Pya-Sar-CONH2	C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c1cccc2C)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SCc(cccc1)c1C(N[C@H]1CC(N)=O)=O)C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC2(CCOCC2)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O




527	 MeCO-7MeW-K(Ac)-aMeS5H(4)-AEF-2Nal-THP-aMeS5H(4)-N-3Pya-Sar-CONH2	C[C@](CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC(C)=O)=O)=O)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)NC1=O
528	 MeCO-7MeW-K(Ac)-aMeK(2)-4OMeF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	C[C@](CCCCNC(CC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)N1)=O)=O)=O)=O)(C1=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
529	 MeCO-7MeW-K(Ac)-E(2)-4OMeF-2Nal-THP-K(2)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCC(NCCCC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)N1)=O)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O



530	 MeCO-7MeW-K(Ac)-K(2)-4OMeF-2Nal-THP-E(2)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCCCNC(CC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)N1)=O)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
531	 MeCO-7MeW-K(Ac)-aMeS5H(4)-4OMeF-2Nal-THP-aMeS5H(4)-N-3Pya-Sar-CONH2	C[C@](CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OC)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC(C)=O)=O)=O)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)NC1=O
532	 MeCO-7MeW-K(Ac)-aMeS5H(4)-AEF-2Nal-THP-aMeS5H(4)-N-3Pya-CONH2	C[C@](CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC(C)=O)=O)=O)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N)=O)=O)=O)=O)NC1=O
533	 MeCO-7MeW-K(Ac)-Abu(1)-4OMeF-2Nal-THP-C(1)-N-3Pya-Sar-CONH2	CC(NCCCC[C@@H](C(N[C@@H](CCSC[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OC)N1)=O)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O

534	 MeCO-7MeW-K(Ac)-aMeS5H(4)-AEF-2Nal-Aib-aMeS5H(4)-N-3Pya-Sar-CONH2	CC(C)(C(N[C@@](C)(CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@H]1Cc2cc3ccccc3cc2)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC(C)=O)=O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N(C)CC(N)=O)=O)=O)=O)=O)NC1=O
535	 MeCO-7MeW-K(Ac)-Aib-AEF-2Nal-THP-Aib-N-3Pya-CONH2	CC(C)(C(N[C@@H](Cc(cc1)ccc1OCCN)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(NC(C)(C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1ccc2C)NC(C)=O)=O)=O

536	 MeCO-7MeW-K(Ac)-Aib-4MeF-2Nal-THP-Aib-N-3Pya-CONH2	CC(C)(C(N[C@@H](Cc1ccc(C)cc1)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC1(CCOCC1)C(NC(C)(C)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
537	 MeCO-7MeW-K(Ac)-K(2)-AEF-2Nal-THP-E(2)-N-CONae3Pya	CC(NCCCC[C@@H](C(N[C@@H](CCCCNC(CC[C@@H](C(N[C@@H](CC(N)=O)C(NCCc1cnccc1)=O)=O)NC(C1(CCOCC1)NC([C@H](Cc1cc2ccccc2cc1)NC([C@H](Cc(cc1)ccc1OCCN)N1)=O)=O)=O)=O)C1=O)=O)NC([C@H](Cc1c[nH]c2c1cccc2C)NC(C)=O)=O)=O
538	 MeCO-7MeW-K(Ac)-aMeS5H(4)-4OMeF-N2al-THP-aMeS5H(4)-N-3Pya-CONH2	C[C@](CCC/C=C\CCC[C@@](C)(C(N[C@@H](Cc(cc1)ccc1OC)C(N[C@@H](Cc1cc2ccccc2cc1)C(NC12CCOCC2)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc2c[nH]c3c2cccc3C)NC(C)=O)=O)=O)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc2cnccc2)C(N)=O)=O)=O)NC1=O

539	 MeCO-7MeW-K(Ac)-aMePra(4)-F-2Nal-aMeL-aMeK(N3)(4)-N-3Pya-Sar-CONH2	CC(C)C[C@@](C)(C(N[C@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc2ccccc2)C(N[C@H]2Cc3cc4ccccc4cc3)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC2=O
540	 MeCO-7MeW-K(Ac)-aMePra(4)-4OMeF-2Nal-aMeL-aMeK(N3)(4)-N-3Pya-Sar-CONH2	CC(C)C[C@@](C)(C(N[C@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@H]2Cc3cc4ccccc4cc3)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)=O)NC2=O
541	 MeCO-7MeW-K(Ac)-aMePra(4)-F-2Nal-aMeL-aMeK(N3)(4)-L-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc2ccccc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@]2(C)CC(C)C)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)NC2=O)=O
542	 MeCO-7MeW-K(Ac)-aMePra(4)-4OMeF-2Nal-aMeL-aMeK(N3)(4)-L-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(N[C@@]2(C)CC(C)C)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)NC2=O)=O

543	 MeCO-7MeW-K(Ac)-aMePra(4)-F-2Nal-THP-aMeK(N3)(4)-L-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc2ccccc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC23CCOCC3)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)NC2=O)=O
544	 MeCO-7MeW-K(Ac)-aMePra(4)-4OMeF-2Nal-THP-aMeK(N3)(4)-L-3Pya-Sar-CONH2	CC(C)C[C@@H](C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)NC([C@@](C)(CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC23CCOCC3)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)NC2=O)=O
545	 MeCO-7MeW-K(Ac)-aMePra(4)-F-2Nal-THP-aMeK(N3)(4)-N-3Pya-Sar-CONH2	C[C@@](CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc2ccccc2)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC23CCOCC3)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC2=O

546	 MeCO-7MeW-K(Ac)-aMePra(4)-AEF-2Nal-THP-aMeK(N3)(4)-N-3Pya-Sar-CONH2	C[C@@](CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC23CCOCC3)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC2=O
547	 MeCO-7MeW-K(Ac)-aMePra(4)-4OMeF-2Nal-THP-aMeK(N3)(4)-N-3Pya-Sar-CONH2	C[C@@](CCCCn1nnc(C[C@](C)(C(N[C@@H](Cc(cc2)ccc2OC)C(N[C@@H](Cc2cc3ccccc3cc2)C(NC23CCOCC3)=O)=O)=O)NC([C@H](CCCCNC(C)=O)NC([C@H](Cc3c[nH]c4c3cccc4C)NC(C)=O)=O)=O)c1)(C(N[C@@H](CC(N)=O)C(N[C@@H](Cc1cnccc1)C(N(C)CC(N)=O)=O)=O)=O)NC2=O

SYNTHESIS

[00075] The compounds described herein may be synthesized by many techniques that are known to those skilled in the art. In certain aspects, monomer subunits are synthesized and purified using the techniques described in the accompanying Examples. In some aspects, the present invention provides a method of producing a compound (or monomer subunit thereof) of the invention, comprising chemically synthesizing a peptide having an amino acid sequence described herein, including but not limited to any of the amino acid sequences set forth in the compounds of Formula (I) to Formula (X), Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, and Table 1I herein. In some aspects, a portion of the peptide is recombinantly synthesized, instead of being chemically synthesized. In some aspects, methods of producing a compound further include cyclizing the compound precursor after the constituent

subunits have been attached. In particular aspects, cyclization is accomplished via any of the various methods described herein.

[00076] Substituted tryptophans may be prepared by any suitable route. Preparation of certain substituted tryptophans including those substituted at the 7 position, such as 7-ethyl-L-tryptophans, are described in, for example WO 2021/146441 Al.

[00077] The present invention further describes synthesis of compounds described herein, such as the compounds of Formulas (I) to (XX) and the compounds of Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, and Table 1I. In some aspects, one or more of the amino acid residues or amino acid monomers are lipidated and then covalently attached to one another to form a compound of the invention. In some aspects, one or more of the amino acid residues or amino acid monomers are covalently attached to one another and lipidated at an intermediate oligomer stage before attaching additional amino acids and cyclization to form a compound of the invention. In some aspects, a cyclic peptide is synthesized and then lipidated to form a compound of the invention. Illustrative synthetic methods are described in the Examples.

[00078] The present invention further describes synthesis of compounds described herein, such as the compounds of Formulas (I) to Formula (X), and the compounds of Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table G, Table 1H, and Table 1I. Illustrative synthetic methods are described in the Examples.

IV. PHARMACEUTICAL COMPOSITIONS

[00079] The present invention relates to pharmaceutical composition which comprise an IL-23R inhibitor of the present invention. The present invention includes pharmaceutical compositions comprising one or more inhibitors of the present invention and a pharmaceutically acceptable carrier, diluent or excipient. The pharmaceutically acceptable carrier, diluent or excipient may be a solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like.

[00080] The pharmaceutical compositions may be administered orally, parenterally, intracisternally, intravaginally, intraperitoneally, intrarectally, topically (as by powders, ointments, drops, suppository, or transdermal patch), by inhalation (such as intranasal spray), ocularly (such as intraocularly) or buccally. The term “parenteral” as used herein refers to modes

of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intradermal and intraarticular injection and infusion. Accordingly, in certain embodiments, the compositions are formulated for delivery by any of these routes of administration. A pharmaceutical composition may be formulated for and administered orally. A pharmaceutical composition may be formulated for and administered parenterally.

[00081] In a particular aspect, an IL-23R inhibitor of the present invention, is suspended in a sustained-release matrix. A sustained-release matrix, as used herein, is a matrix made of materials, usually polymers, which are degradable by enzymatic or acid-base hydrolysis or by dissolution. Once inserted into the body, the matrix is acted upon by enzymes and body fluids. A sustained-release matrix desirably is chosen from biocompatible materials such as liposomes, polylactides (polylactic acid), polyglycolide (polymer of glycolic acid), polylactide co-glycolide (copolymers of lactic acid and glycolic acid) polyanhydrides, poly(ortho)esters, polypeptides, hyaluronic acid, collagen, chondroitin sulfate, carboxylic acids, fatty acids, phospholipids, polysaccharides, nucleic acids, polyamino acids, amino acids such as phenylalanine, tyrosine, isoleucine, polynucleotides, polyvinyl propylene, polyvinylpyrrolidone and silicone. One embodiment of a biodegradable matrix is a matrix of one of either polylactide, polyglycolide, or polylactide co-glycolide (co-polymers of lactic acid and glycolic acid).

[00082] The IL-23R inhibitors of the present invention may be prepared and/or formulated as pharmaceutically acceptable salts, solvates and/or other forms thereof or when appropriate in neutral form. Pharmaceutically acceptable salts are non-toxic salts of a neutral form of a compound that possess the desired pharmacological activity of the neutral form. These salts may be derived from inorganic or organic acids or bases. For example, a compound that contains a basic nitrogen may be prepared as a pharmaceutically acceptable salt by contacting the compound with an inorganic or organic acid. Non-limiting examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, and mandelates.

Lists of other suitable pharmaceutically acceptable salts are found in Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Wiliams and Wilkins, Philadelphia, Pa., 2006.

[00083] Examples of "pharmaceutically acceptable salts" of the compounds disclosed herein also include salts derived from an appropriate base, such as an alkali metal (for example, sodium, potassium), an alkaline earth metal (for example, magnesium), ammonium and NX_4^+ (wherein X is C_1–C_4 alkyl). Also included are base addition salts, such as sodium or potassium salts.

[00084] The pesent invention relates to pharmaceutical compositions comprising an IL-23R inhibitor of the present invention or pharmaceutically acceptable salts, isomers, or a mixture thereof, in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molecule. As known in the art, the deuterium atom is a non-radioactive isotope of the hydrogen atom. Such compounds may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds described herein or pharmaceutically acceptable salts, isomer, or a mixture thereof when administered to a mammal. *See,* e.g., Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.

[00085] Examples of isotopes that can be incorporated into the disclosed compounds also include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C, ^{13}N, ^{15}N, ^{15}O, ^{17}O, ^{18}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F, ^{36}Cl, ^{123}I, and ^{125}I, respectively. Substitution with positron emitting isotopes, such as ^{11}C, ^{18}F, ^{15}O and ^{13}N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds of Formula (I), can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

[00086] In certain aspects, pharmaceutical compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders, for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, β-cyclodextrin, vegetable

oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prolonged absorption of an injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.

[00087] Injectable depot forms include those made by forming microencapsulated matrices of the peptide inhibitor in one or more biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters), poly(anhydrides), and (poly)glycols, such as PEG. Depending upon the ratio of peptide to polymer and the nature of the particular polymer employed, the rate of release of the peptide inhibitor can be controlled. Depot injectable formulations are also prepared by entrapping the peptide inhibitor in liposomes or microemulsions compatible with body tissues.

[00088] The injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

[00089] Topical administration includes administration to the skin or mucosa, including surfaces of the lung and eye. Compositions for topical lung administration, including those for inhalation and intranasal, may involve solutions and suspensions in aqueous and non-aqueous formulations and can be prepared as a dry powder which may be pressurized or non-pressurized. In non-pressurized powder compositions, the active ingredient may be finely divided form may be used in admixture with a larger-sized pharmaceutically acceptable inert carrier comprising particles having a size, for example, of up to 100 micrometers in diameter. Suitable inert carriers include sugars such as lactose.

[00090] Alternatively, a pharmaceutical composition of the present invention may be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition may be such that the active ingredient does not dissolve therein to any substantial extent. The pressurized composition may also contain a surface active agent, such as a liquid or solid non-ionic surface active agent or may be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

[00091] A further form of topical administration is to the eye. A peptide inhibitor of the present invention may be delivered in a pharmaceutically acceptable ophthalmic vehicle, such that the peptide inhibitor is maintained in contact with the ocular surface for a sufficient time period to allow the peptide inhibitor to penetrate the corneal and internal regions of the eye, as for example the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/ciliary, lens, choroid/retina and sclera. The pharmaceutically acceptable ophthalmic vehicle may, for example, be an ointment, vegetable oil or an encapsulating material. Alternatively, the peptide inhibitors of the invention may be injected directly into the vitreous and aqueous humor.

[00092] Compositions for rectal or vaginal administration include suppositories which may be prepared by mixing the peptide inhibitors of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at room temperature but liquid at body temperature and, therefore, melt in the rectum or vaginal cavity and release the active compound.

[00093] Peptide inhibitors of the present invention may also be administered in liposomes or other lipid-based carriers. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a peptide inhibitor of the present invention, stabilizers, preservatives, excipients, and the like. In certain embodiments, the lipids comprise phospholipids, including the phosphatidyl cholines (lecithins) and serines, both natural and synthetic. Methods to form liposomes are known in the art.

[00094] Pharmaceutical compositions suitable for parenteral administration in a method or use described herein may comprise sterile aqueous solutions and/or suspensions of the IL:-23R inhibitors made isotonic with the blood of the recipient, generally using sodium chloride, glycerin, glucose, mannitol, sorbitol, and the like.

[00095] The present invention provides a pharmaceutical composition for oral delivery. Compositions and peptide inhibitors of the present invention may be prepared for oral administration according to any of the methods, techniques, and/or delivery vehicles described herein. Further, one having skill in the art will appreciate that the peptide inhibitors of the instant invention may be modified or integrated into a system or delivery vehicle that is not disclosed herein, yet is well known in the art and compatible for use in oral delivery of peptides.

[00096] Formulations for oral administration may comprise adjuvants (e.g. resorcinols and/or nonionic surfactants such as polyoxyethylene oleyl ether and n- ether) to artificially increase the permeability of the intestinal walls, and/or enzymatic inhibitors (e.g. pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) or trasylol) to inhibit enzymatic degradation. In certain embodiments, the peptide inhibitor of a solid-type dosage form for oral administration can be mixed with at least one additive, such as sucrose, lactose, cellulose, mannitol, trehalose, raffinose, maltitol, dextran, starches, agar, alginates, chitins, chitosans, pectins, gum tragacanth, gum arabic, gelatin, collagen, casein, albumin, synthetic or semisynthetic polymer, or glyceride. These formulations for oral administration can also contain other type(s) of additives, e.g., inactive diluting agent, lubricant such as magnesium stearate, paraben, preserving agent such as sorbic acid, ascorbic acid, alpha-tocopherol, antioxidants such as cysteine, disintegrators, binders, thickeners, buffering agents, pH adjusting agents, sweetening agents, flavoring agents or perfuming agents.

[00097] In particular aspects, oral dosage forms or unit doses compatible for use with the peptide inhibitors of the present invention may include a mixture of peptide inhibitor and nondrug components or excipients, as well as other non-reusable materials that may be considered either as an ingredient or packaging. Oral compositions may include at least one of a liquid, a solid, and a semi-solid dosage forms. In some embodiments, an oral dosage form is provided comprising an effective amount of peptide inhibitor, wherein the dosage form comprises at least one of a pill, a tablet, a capsule, a gel, a paste, a drink, a syrup, ointment, and suppository. In some instances, an oral dosage form is provided that is designed and configured to achieve delayed release of the peptide inhibitor in the subject's small intestine and/or colon.

[00098] Tablets may contain excipients, glidants, fillers, binders and the like. Aqueous compositions are prepared in sterile form, and when intended for delivery by other than oral administration generally will be isotonic. Compositions may optionally contain excipients such as those set forth in the "Handbook of Pharmaceutical Excipients" (1986). Excipients include ascorbic acid and other antioxidants, chelating agents such as EDTA, carbohydrates such as dextran, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH of the compositions ranges from, for example, about 3 to about 11. The pH of the compositions may, for example, range from about 5 to about 7 or from about 7 to about 10.

[00099] An oral pharmaceutical composition of the present invention may comprise an IL-23R inhibitor of the present invention may comprise an enteric coating that is designed to delay release of the IL-23R inhibitor in the small intestine. The invention relates to a pharmaceutical composition that comprises an IL-23R inhibitor of the present invention and a protease inhibitor,

such as aprotinin, in a delayed release pharmaceutical formulation. Pharmaceutical compositions (e.g., oral pharmaceutical compositions) may comprise an enteric coat that is soluble in gastric juice at a pH of about 5.0 or higher. Such enteric coatings may comprise a polymer having dissociable carboxylic groups, such as derivatives of cellulose, including hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and cellulose acetate trimellitate and similar derivatives of cellulose and other carbohydrate polymers.

[000100] An oral pharmaceutical composition comprising an IL-23R inhibitor of the present invention that comprises an IL-23R inhibitor may comprise an enteric coating that is designed to protect and release the pharmaceutical composition in a controlled manner within the subject's lower gastrointestinal system, and to avoid systemic side effects. In addition to enteric coatings, the peptide inhibitors of the instant invention may be encapsulated, coated, engaged or otherwise associated within any compatible oral drug delivery system or component. For example, in some embodiments an IL-23R inhibitor of the present invention is provided in a lipid carrier system comprising at least one of polymeric hydrogels, nanoparticles, microspheres, micelles, and other lipid systems.

[000101] To overcome peptide degradation of an IL-23R inhibitor of the present invention in the small intestine, the pharmaceutical compositions may comprise a hydrogel polymer carrier system in which a peptide inhibitor of the present invention is contained, whereby the hydrogel polymer protects the IL-23R inhibitor from proteolysis in the small intestine and/or colon. The an IL-23R inhibitor may further be formulated for compatible use with a carrier system that is designed to increase the dissolution kinetics and enhance intestinal absorption of the peptide. These methods include the use of liposomes, micelles and nanoparticles to increase GI tract permeation of peptides.

[000102] Various bioresponsive systems may also be combined with one or more an IL-23R inhibitors of the present invention to provide a pharmaceutical agent for oral delivery. For example, an IL-23R inhibitor of the present invention may be used in combination with a bioresponsive system, such as hydrogels and mucoadhesive polymers with hydrogen bonding groups (e.g., PEG, poly(methacrylic) acid [PMAA], cellulose, Eudragit®, chitosan and alginate) to provide a therapeutic agent for oral administration.

[000103] In certain aspects, pharmaceutical composition and formulations may include an IL-23R inhibitor of the present invention and one or more absorption enhancers, enzyme inhibitors, or mucoso adhesive polymers. In an embodiment, the absorption enhancer may be an intestinal permeation enhancer.

[000104] IL-23R inhibitors of the present invention may be formulated in a formulation vehicle, such as, e.g., emulsions, liposomes, microsphere or nanoparticles.

[000105] The present invention provides for a method for treating a subject with an IL-23R inhibitor of the present invention having an increased half-life. In one aspect, the present invention provides a peptide inhibitor having a half-life of at least several hours to one day in vitro or in vivo (e.g., when administered to a human subject) sufficient for daily (q.d.) or twice daily (b.i.d.) dosing of a therapeutically effective amount. In certain embodiments, the IL-23R inhibitor has a half-life of three days or longer sufficient for weekly (q.w.) dosing of a therapeutically effective amount. In certain embodiments, the IL-23R inhibitor has a half-life of eight days or longer sufficient for bi-weekly (b.i.w.) or monthly dosing of a therapeutically effective amount. In certain embodiments, the IL-23R inhibitor is derivatized or modified such that is has a longer half-life as compared to the underivatized or unmodified peptide inhibitor. In certain embodiments, the IL-23R inhibitor contains one or more chemical modifications to increase serum half-life.

[000106] When used in at least one of the treatments or delivery systems described herein, a peptide inhibitor of the present invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt form.

[000107] The total daily usage of the IL-23R inhibitor and compositions of the present invention can be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including: a) the disorder being treated and the severity of the disorder; b) activity of the specific compound employed; c) the specific composition employed, the age, body weight, general health, sex and diet of the patient; d) the time of administration, route of administration, and rate of excretion of the specific peptide inhibitor employed; e) the duration of the treatment; f) drugs used in combination or coincidental with the specific peptide inhibitor employed, and like factors well known in the medical arts.

[000108] In particular embodiments, the total daily dose of a IL-23R inhibitor of the present invention to be administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.0001 to 300 mg/kg body weight daily or 1 to 300 mg/kg body weight daily.

[000109] The compositions may conveniently be presented in unit dosage form and can be prepared by any of the methods well known in the art of pharmacy. Techniques and compositions generally are found in Remington's Pharmaceutical Sciences (Mack Publishing

Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[000110] Compositions suitable for oral administration can be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste. The active ingredient may also be administered as a buccal or sublingual formulation. Buccal or sublingual formulations may comprise an active ingredient in a matrix that releases the active ingredient for transport across the buccal and/or sublingual membranes. The buccal or sublingual formulation may further include a rate controlling matrix that releases the active compounds at a predetermined rate for transport across the buccal and/or sublingual membranes. The buccal or sublingual formulation may further include one or more compounds selected from the group consisting of (i) taste masking agents, (ii) enhancers, (iii) complexing agents, and mixtures thereof; and (iv) other pharmaceutically acceptable carriers and/or excipients. The enhancer may be a permeation enhancer.

[000111] A tablet is made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent. The tablets can optionally be coated or scored and optionally are formulated so as to provide slow or controlled release of the active ingredient therefrom.

V. NON-INVASIVE DETECTION OF INTESTINAL INFLAMMATION

[000112] The IL-23R inhibitors of the present invention may be used for detection, assessment and diagnosis of intestinal inflammation by microPET imaging, wherein the peptide inhibitor is labeled with a chelating group or a detectable label, as part of a non-invasive diagnostic procedure. In certain embodiments, an IL-23R inhibitor of the present invention is conjugated with a bifunctional chelator. In certain embodiments, an IL-23R inhibitor of the

present invention is radiolabeled. The labeled an IL-23R inhibitor is then administered to a subject orally or rectally. In certain embodiments, the an IL-23R inhibitor is included in drinking water. Following uptake of the an IL-23R inhibitor, microPET imaging may be used to visualize inflammation throughout the subject's bowels and digestive track.

VI. METHODS OF TREATMENTS AND/OR USES

[000113] The present invention relates to methods for treating a subject afflicted with a condition or indication associated with IL-23 or IL-23R (e.g., activation of the IL-23/IL-23R signaling pathway), wherein the method comprises administering to the subject an IL-23R inhibitor disclosed herein. A In one aspect, the present invention relates to a method for treating a subject afflicted with a condition or indication characterized by inappropriate, deregulated, or increased IL-23 or IL-23R activity or signaling, comprising administering to the individual a peptide inhibitor of the present invention in an amount sufficient to inhibit (partially or fully) binding of IL-23 to an IL-23R in the subject. The inhibition of IL-23 binding to IL-23R may occur in particular organs or tissues of the subject, e.g., the stomach, small intestine, large intestine/colon, intestinal mucosa, lamina propria, Peyer's Patches, mesenteric lymph nodes, or lymphatic ducts.

[000114] The present invention relates to methods comprising providing a peptide inhibitor described herein to a subject in need thereof. The subject in need thereof may be a subject that has been diagnosed with or has been determined to be at risk of developing a disease or disorder associated with IL-23/IL-23R. The subject may be a mammal. The subject may be, in particular, a human.

[000115] The disease or disorder to be treated by treatment with an IL-23R inhibitor of the present invention may be inflammatory, autoimmune inflammation diseases and/or related disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, or psoriasis. In particular, the disease or disorder may be psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, ulcerative colitis, Crohn's disease, Celiac disease (nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous

disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

[000116] The present invention relates to a method or use of an IL-23R inhibitor for treating an inflammatory disease in a subject that includes administering to the subject a therapeutically effective amount of an IL-23R inhibitor of the present invention or pharmaceutically acceptable solvate or salt thereof, or a composition disclosed herein comprising an IL-23 inhibitor of the present invention.

[000117] In some aspects, the present invention provides a method of treating an inflammatory disease or autoimmune inflammation diseases and/or related disorders in a subject that includes administering to the subject a therapeutically effective amount of an IL-23R inhibitor of the present invention or pharmaceutically acceptable solvate or salt thereof, or a composition of the present invention.

[000118] Suitable inflammatory, autoimmune inflammation diseases and/or related disorders for treatment with a compound or pharmaceutically acceptable salt thereof, or a composition of the present invention, may include, but are not limited to inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PsO), or psoriatic arthritis (PsA) and the like. The inflammatory disease to be treated may be inflammatory bowel disease (IBD), Crohn's disease, or ulcerative colitis. The inflammatory disease to be treated may be selected from psoriasis, or psoriatic arthritis. The inflammatory disease to be treated may be psoriasis The inflammatory disease to be treated may be psoriatic arthritis. The inflammatory disease to be treated may be IBD.

[000119] The present invention relates to methods for treating an inflammatory, autoimmune inflammation diseases and/or related disorders in a subject in need thereof, comprising administering to the subject an IL-23R inhibitor disclosed herein (e.g., a peptide inhibitor or the IL-23R of Formula (I) to Formula (X) or any of Tables 1A-1I. The inflammatory disease may be IBD, Crohn's disease, or ulcerative colitis. In aspect, the IBD may be ulcerative colitis. In an aspect, the IBD may be Crohn's disease. In an aspect, the inflammatory disease may be psoriasis (PsO), or psoriatic arthritis (PsA).

[000120] The present invention relates to methods for treating an inflammatory, autoimmune inflammation diseases and/or related disorders in a subject in need thereof,

comprising administering to the subject an IL-23R inhibitor of Formulas I to X) or any of Tables 1A-1I.

[000121] The inflammatory, autoimmune inflammation diseases and/or related disorders may be IBD, Crohn's disease, or ulcerative colitis. In aspect, the IBD may be ulcerative colitis. In an aspect, the IBD may be Crohn's disease. In an aspect, the inflammatory disease may be psoriasis (PsO), or psoriatic arthritis (PsA).

[000122] The present invention relates to methods for treating an inflammatory, autoimmune inflammation diseases and/or related disorders in a subject in need thereof, comprising administering to the subject an IL-23R inhibitor of Formulas I to X) or any of Tables 1A-1I. The inflammatory disease may be IBD, Crohn's disease, or ulcerative colitis. In aspect, the IBD may be ulcerative colitis. In an aspect, the IBD may be Crohn's disease. In an aspect, the inflammatory disease may be psoriasis (PsO), or psoriatic arthritis (PsA).

[000123] The present invention relates to methods of inhibiting IL-23 binding to an IL-23R on a cell, comprising contacting the IL-23R with a peptide inhibitor of the receptor disclosed herein. The cell may be a mammalian cell. The method may be performed in vitro or in vivo. Inhibition of binding may be determined by a variety of routine experimental methods and assays known in the art.

[000124] The present invention relates to a method of selectively inhibiting IL-23 or IL-23R signaling (or the binding of IL-23 to IL-23R) in a subject (e.g., in a subject in need thereof), comprising providing to the subject a peptide inhibitor of the IL-23R described herein. The present invention includes and provides a method of selectively inhibiting IL-23 or IL-23R signaling (or the binding of IL-23 to IL-23R) in the GI tract of a subject (e.g., a subject in need thereof), comprising providing to the subject a peptide inhibitor of the IL-23R of the present invention by oral administration. The exposure of GI tissues (e.g., small intestine or colon) to the administered peptide inhibitor may be at least 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold greater than the exposure (level) in the blood. In particular embodiments, the present invention includes a method of selectively inhibiting IL23 or IL23R signaling (or the binding of IL23 to IL23R) in the GI tract of a subject (e.g., a subject in need thereof), comprising providing to the subject a peptide inhibitor, wherein the peptide inhibitor does not block the interaction between IL-6 and IL-6R or antagonize the IL-12 signaling pathway. In a further related embodiment, the present invention includes a method of inhibiting GI inflammation and/or neutrophil infiltration to the GI, comprising providing to a subject in need thereof a peptide inhibitor of the present invention. In some embodiments, methods of the present invention

comprise providing a peptide inhibitor of the present invention (i.e., a first therapeutic agent) to a subject (e.g., a subject in need thereof) in combination with a second therapeutic agent. In certain embodiments, the second therapeutic agent is provided to the subject before and/or simultaneously with and/or after the peptide inhibitor is administered to the subject. In particular embodiments, the second therapeutic agent is an anti-inflammatory agent. In certain embodiments, the second therapeutic agent is a non-steroidal anti-inflammatory drug, steroid, or immune modulating agent. In certain embodiments, the method comprises administering to the subject a third therapeutic agent. In certain embodiments, the second therapeutic agent is an antibody that binds IL-23 or IL-23R.

[000125] The present invention relates to methods of inhibiting IL-23 signaling by a cell, comprising contacting the IL-23R with a peptide inhibitor described herein. In certain embodiments, the cell is a mammalian cell. In particular embodiments, the method is performed in vitro or in vivo. In particular embodiments, the inhibition of IL-23 signaling may be determined by measuring changes in phospho-STAT3 levels in the cell.

[000126] In any of the foregoing methods, IL-23R inhibitor administration to a subject may be conducted orally, but other routes of administration are not excluded. Other routes of administration include, but are not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, topical, buccal or ocular routes. Dosages of a peptide inhibitor or the IL-23R described herein (e.g., a compound of Formulas I to X or any of Tables 1A-1I), or salt or solvate thereof to be administered to a subject may be determined by a person of skill in the art taking into account the the disease or condition being treated including its severity, and factors including the age weight, sex, and the like. Exemplary dose ranges include, but are not limited to, from about 1 mg to about 1000 mg, or from about 1 mg to about 500 mg, from about 1 mg to about 100 mg, from about 10 mg to about 50 mg, from about 20 mg to about 40 mg, or from about 20 mg to about 30 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be from about 600 mg to about 1000 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be from about 300 mg to about 600 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be from about 5 mg to about 300 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be from about 25 mg to about 150 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be from about 25 mg to about 100 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be present in a dose range of from about 1 mg to about 100 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be present in a dose range

of from about 20 mg to about 40 mg. A dose range of a peptide inhibitor or the IL-23R described herein may be present in a dose range of from about 20 mg to about 30 mg.

ASPECTS OF THE PRESENT INVENTION

[000127] The following aspects illustrate and are not intended to limit scope of the present invention. Instead, these aspects provide guidance to any skilled artisan on how to prepare and use compounds, compositions and methods taught by the present invention, where such skilled artisans will appreciate that modifications may be made without departing from the spirit and scope of the invention.

1. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula I

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2

wherein:

R1 is hydrogen, $CH_3C(O)$-, EtC(O)-, MeSO2, AzCO, BHCO, FPrpTriazoleMeCO, SMSBCO, Biotin, BiotinPEG2PEG2CO, DAGSuc;

X3 is dR, dK, PEG6, gEPEG6, R, K, or absent;

X4 is Pen, aMeC, hC, or C;

X5 is A, N, Q, N-MeAsn, L, Asn(4C13_2N15), I, K(PEG2PEG2Biotin);

X6 is T, MeThr, V, K, Dbu, Dpr, or A;

X7 is W7Me, W, W(4F7Me), 7MeW, 7PhW, 7EtW, 7FW, 7ClW, 5BrW, 7(3NAcPh)W'

X8 is KAc, Q, NMeGln, A, Cit, dK(Ac), dQ, dNMeGln, dA, or dCit;

X9 is Pen, aMeC, hC, or C;

X10 is F4OMe, AEF, F, F4Me, F4Ad, Nal, AEF(Boc), 4PipPhe, AEF(Ac), Y, 4OMeF, 4AmF, D(Pip), Tzl(mPEG3), 3FTyr, Y(OTzl), Y(OTzl(mPEG3)), Tzl, Tzl(PEG3OH);

X11 is Nal, Quin_3, Coumarin(7OMe), 2Nal, 3Quin;

X12 is aMeK, THP, Spiral_Pip_Ac, Spiral_Pip, MeK, aMeLeu, aMeL, aMeK(Boc)

X13 is KAc, K, dK(Ac), or dK ;

X14 is A, N, L, N-MeAsn, MeLeu, Asn(4C13_2N15), I;

X15 is 3Pya, bAla, Thiozolidine, H, dL, N, A, F, aMePhe, Aib, dK, h, 3MeH, 1MeH, tetraFPhe, bMePhe(SR), 5PyrimidAla, v, dR, homoF, Y, y, F(CF3), Y(CHF2), THP, or absent;

X16 is MeGly, dMeGly, dL, MeLeu, dMeLeu, N-MeNle, dN-MeNle, y, paf, maf, d3Pya, bAla, dbAla, P, dP, N(3AmBenzyl)Gly, N(4AmBenzyl)Gly, 4(R)HydroxyPro, 4(S)AminoPro, 5(R)diMePro, or absent;

R2 is –OH, -NH_2, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, MeNH, CONHMe; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

2. The inhibitor of an interleukin-23 receptor of aspect 1, wherein X4 and X9 are Pen or hC residues that are selected independently.

3. The inhibitor of an interleukin-23 receptor of any of aspects 1 to 2, wherein X15 is 3Pya.

4. The inhibitor of an interleukin-23 receptor of any of aspects 1 to 3, wherein X11 is 2Nal or 3Quin.

5. The inhibitor of an interleukin-23 receptor of any of aspects 1 to 4, wherein X7 is 7MeW, or W.

6. The inhibitor of an interleukin-23 receptor of any of aspects 1 to 5, wherein:

R1 is hydrogen or $CH_3C(O)$-; and

R2 is -NH_2, MeNH, or CONHMe.

7. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula II

R1- X3-Abu-X5-T-X7-X8-X9-AEF-X11-X12-X13-X14-X15-X16-X17-R2 (II)

wherein:

R1 is hydrogen, or $CH_3C(O)$-;

X3 is dR, R, or absent;

X4 is Abu;

X5 is Q, N, or T;

X6 is T;

X7 is W or 7MeW;

X8 is Q, K, KAc, dQ, dK, or dK(Ac);

X9 is Pen, C, hC, or aMeC;

X10 is AEF;

X11 is 2Nal, or Nal;

X12 is THP, Acvc, or Achx;

X13 is E, KAc, aMeE, Q, AIB, Achx, aMedE, dE, dK(Ac), or dQ;

X14 is N or S;

X15 is H, bAla, N, 3Pya, F, aMeF, aMeW, 1Nal, 4AmPhe, 2Nal, aMeFPhe, aMePhe, 3,4diFPhe, DY02, 5FW, or absent;

X16 is MeGly, AIB, or absent;

X17 is aMeK or absent;

R2 is –OH, -NH_2, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9.

8. The inhibitor of an interleukin-23 receptor of aspect 7, wherein X9 is aMeC.

9. The inhibitor of an interleukin-23 receptor of any of aspects 7 to 8, wherein X5 is N.

10. The inhibitor of an interleukin-23 receptor of any of aspects 7 to 8, wherein X8 is KAc.

11. The inhibitor of an interleukin-23 receptor of any of aspects 7 to 10, wherein X11 is Nal.

12. The inhibitor of an interleukin-23 receptor of any of aspects 7 to 11, wherein X15 is 3Pya.

13. The inhibitor of an interleukin-23 receptor of any of aspects 1 to 12, wherein:

R1 is $CH_3C(O)$-; and

R2 is -NH_2.

14. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula III

R1- X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (III)

wherein:

R1 is hydrogen, $CH_3C(O)$-, FPrpTriazoleMeCO, NH2, EtCO, AzCO, or BHCO;

X3 is dR, R, K, or dK;

X4 is Pen, Abu, AIB, aMeC, C, hC, Ala, 4RAminoPro, or 4SAminoPro;

X5 is N, D, or E;

X6 is T, Hyp, or 3OHPro;

X7 is 7MeW, W, 3Pya, A, 7PyrW, or 7(3NAcPh)W;

X8 is KAc, or dKAc;

X9 is Pen, C, S5H, AIB, D, E, hC, aMeC;

X10 is AEF, AEF(EtCO), AEF(BH), AEF(Ac), bMeAEF(2S3R*), bMeAEF(2S3S*), Y, or A;

X11 is 2Nal, A, Nal, or W;

X12 is THP;

X13 is E, KAc, S5H, dE, dKAc, or R5H;

X14 is N, S, 3Pya;

X15 is 3Pya, H, bAla, v, dR, hF, PAF, F, THP, l, 4Pya, oAMPhe, 3MeH, D3Pya, N, 5MePyridinAla, 5AmPyridinAla, 3QuinolAla, 6OH3Pya, A

X16 is MeGly;

R2 is $-NH_2$ $-HN(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl$)_2$ or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9; or

wherein when X4 is 4RAminoPro or 4SAminoPro and X9 is E or D, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X4 and X9;

or

wherein when X5 is D or E, and X10 comprises an AEF residue, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X5 and X10;

or

wherein when X9 and X13 comprise S5H residues the inhibitor of an interleukin-23 receptor is cyclized by an aliphatic linkage between X9 and X13.

15. The inhibitor of an interleukin-23 receptor of aspect 14, wherein:

X4 is and X9 is selected independntly from Pen, C, and aMeC and X9 is Abu and the peptide is cyclized by formation of a thioether linkage; or

X4 and X9 are selected independently from Pen, C, hC, and aMeC, and the inhibitor is cyclized by a disulfide bond between amino acids at positions X4 and X9.

16. The inhibitor of an interleukin-23 receptor of aspect 14, wherein X15 is 5MePyridinAla or 5AmPyridinAla.

17. The inhibitor of an interleukin-23 receptor of any of aspects 14 to 16, wherein X3 is dR and X4 is Pen.

18. The inhibitor of an interleukin-23 receptor of any of aspects 14 to 17, wherein X11 is 2Nal and X12 is THP.

19. The inhibitor of an interleukin-23 receptor of any of aspects 14 to 18, wherein one or both of X5 and X14 are N.

20. The inhibitor of an interleukin-23 receptor of any of aspects 14 to 19, wherein R1 is $CH_3C(O)$-.

21. The inhibitor of an interleukin-23 receptor of any of aspects 14 to 20, wherein R2 is an $-NH_2$.

22. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula IV

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (IV)

wherein:

R1 is hydrogen, $CH_3C(O)$-, Ac_Morph, or MorphCO;

X3 is K(AcMorp), Kmorp, dK(AcMorp), or absent;

X4 is Pen, C, hC, or aMeC;

X5 is L, N, or nLeu;

X6 is T or L;

X7 is W or 7MeW;

X8 is KAc, K(AcMorph), K(IsoButyl_Ac), K(Butyl_Ac), K(Benzyl_Ac), KMorph, K, dKAc, dK(AcMorph), dK(IsoButyl_Ac), dK(Butyl_Ac), dK(Benzyl_Ac), dKMorph, or dK;

X9 is Pen, C, hC, or aMeC;

X10 is F4OMe, F, AEF, F4Ad, L, F4CN, or 4OMeF;

X11 is 2Nal or Nal;

X12 is L, THP, Spiral_Pip, aMeK, or aMeL;

X13 is L, dL, or nL (i.e., norleucine);

X14 is N or L;

X15 is 3Pya or absent;

X16 is MeGly or absent;

R2 is NH(2-(pyridin3-l)ethyl), $-NH_2$, $-HN(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl$)_2$, or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

23. The inhibitor of an interleukin-23 receptor of aspect 22, wherein one or both of X4 and X9 are Pen.

24. The inhibitor of an interleukin-23 receptor of any of aspects 22 to 23, wherein X3 is absent.

25. The inhibitor of an interleukin-23 receptor of any of aspects 23 to 24, wherein X8 is KAc or K .

26. The inhibitor of an interleukin-23 receptor of any of aspects 22 to 25, wherein X11 is 2Nal.

27. The inhibitor of an interleukin-23 receptor of any of aspects 22 to 26, wherein X12 is aMeL or THP.

28. The inhibitor of an interleukin-23 receptor of any of aspects 22 to 27, wherein:

R1 is $CH_3C(O)$-; and

R2 is –OH or -NH_2.

29. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula V

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-THP-X13-X14-X15-R2 (V)

wherein:

R1 is hydrogen, or $CH_3C(O)$, Propionic_acid, EtCO, PentCO, AzCO, MeSO2, NH2, BHCO, FPrpTriazoleMeCO, (SulfoCy3), (SulfoCy3dPEG2), (SulfoCy3dPEG3), or SMSBCO;

X3 is dR, R, or absent;

X4 is Abu, Pen, C, hC, aMeC, aG, or Dpr;

X5 is Q or N;

X6 is T;

X7 is W, W7Me, 7MeW, bMeW(2S3R), bMeW(2S3S), 7FW, 7ClW, 5BrW, or 5MeW;

X8 is Q, K, KAc, Q, dK, or dKAc;

X9 is C, Pen, hC, aMeC, aG, E, or D;

X10 is AEF, F4OMe, F4Ad, Phe(4(2(Ac)aminoethoxy)), ac, LY02, AEF(Boc), 4PipPhe, AEF(BH), or AEF(SMSB);

X11 is 2Nal or Nal;

X12 is THP;

X13 is E, KAc, K, Q, aMeE, AIB, dE, dKAc, dK, dQ, aMedE, or Achx;

X14 is N;

X15 is H, bAla, , N, F, aMePhe, aMeF, aMeW, 1Nal, 4AmPhe, 2Nal, aMeFPhe, 3,4diFPhe, DY02, 5FW, D(NBzl), D(NPh), D(NoAn), D(NPip), D(NPyr), D(NpAn), D(NmAn), D(N4Pyz), D(N5In), D(NPrAm), dH, D(NEtNH2), 3MeH, 1MeH, tetraFPhe, bMePhe(SR), 5PyrimidAla, 3OHPhe, 4PyridinAla, 3Pya, 4TriazolAla, bMePhe(2S3S), 2AmTyr, bMeH(2S3S*), or 5MeH;

R2 is –NH_2, -OH, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, or CONHMe; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9; or

wherein when X4 is Dpr and X9 is E or D, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X4 and X9; or

wherein when X4 and X9 are aG, the inhibitor of an interleukin-23 receptor is cyclized by an aliphatic bond (generated from a Ring Closing Metathesis "RCM" reaction) between X4 and X9.

30. The inhibitor of an interleukin-23 receptor of aspect 29, wherein X4 and X9 are aG, and the inhibitor of an interleukin-23 receptor is cyclized by an aliphatic bond between X4 and X9.

31. The inhibitor of an interleukin-23 receptor of aspect 29, wherein X4 is Dpr and X9 is E or D, and the inhibitor is cyclized by an amide bond between X4 and X9.

32. The inhibitor of an interleukin-23 receptor of aspect 29, wherein the inhibitor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9.

33. The inhibitor of an interleukin-23 receptor of aspect 29, wherein X4 and X9 are selected independntly from Pen, C, hC, and aMeC and the inhibitor is cyclized by a disulfide bond between amino acids at positions X4 and X9.

34. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 33, wherein X3 is absent.

35. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 34, wherein X7 is W or W7Me.

36. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 35, wherein one or both of X10 is AEF.

37. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 36, wherein X15 is F, aMePhe, D(NPh), bMePhe(SR), 3OHPhe, tetraFPhe, or bMePhe(2S3S).

38. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 37, whereinx15 is H, dH, 3MeH, 1MeH, 3MeH, bMeH(2S3S*), or 5MeH.

39. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 38, wherein R1 is $CH_3C(O)$-.

40. The inhibitor of an interleukin-23 receptor of any of aspects 29 to 39, wherein R2 is NH_2.

41. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula VI

R1-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (VI)

wherein:

R1 is hydrogen, or CH3C(O);

X4 is Pen, Abu, C, hC, dPen, dC, or aMeC;

X5 is L, N, Q, T, dN or absent;

X6 is T, L, dT, or absent;

X7 is W7Me, W(4F7Me), 7PhW, 7MeW, 7EtW, W, 7BrW, 7(2ClPh)W, 7(4CF3Ph)W, 7(3CF3TAZP)W, 7(4NAcPh)W, 7(3NAcPh)W, 7(4OCF3Ph)W, 7(4OMePh)W, 7(4Paz)W, 7(7Imzpy)W, 7(6(1)7dMeNDAZ))W, 7(3UrPh)W, 7(5(Ina7Pyr))W, 7(4(CpCNPh))W, 7(6(2MeNDAZ))W, BT, D7MeW;

X8 is KAc, Q, K(Gly), dKAc, dQ, or dK(Gly);

X9 is Pen, C, hC, aMeC, or dPen;

X10 is AEF, F4Ad, F4OMe, F4Me, Nal, F, Spiral_Pip, L, 4AmF, AEF(G), dY, or Y;

X11 is Nal, 3Quin, 2Nal, 2Quin, d2Nal, or W;

X12 is THP, aMeLeu, Acvc, aMeK, or Acpx, A;

X13 is E or dE;

X14 is N, L, or dN;

X15 is 3Pya, THP, N, H, dK, dL, dPaf, PAF, 3MeH, 3pya, or F;

X16 is MeGly, dK, K, or absent; and

R2 is $–NH_2$, -OH, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, or CONHMe; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between a Pen, C, hC, dPen, dC, or aMeC at X4 and a Pen, C, hC, aMeC, or dPen, residue at X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a Pen, C, hC, or aMeC residue at X9.

42. The inhibitor of an interleukin-23 receptor of aspect 41, wherein the inhibitor is cyclized by a disulfide bond between a Pen, Abu, C, hC, dPen, dC, or aMeC at X4 and a Pen, C, hC, aMeC, or dPen X9 the inhibitor is cyclized by a thioether bond between the Abu residue at X4 and a Pen, C, hC, or aMeC residue at X9.

43. The inhibitor of an interleukin-23 receptor of aspect 41, wherein the inhibitor is cyclized by a disulfide bond between a Pen, C, hC, dPen, dC, or aMeC residue at X4 and a Pen, C, hC, aMeC, or dPen residue at X9.

44. The inhibitor of an interleukin-23 receptor of aspect 43, wherein X4 is Pen or dPen.

45. The inhibitor of an interleukin-23 receptor of aspect 43 or aspect 44, wherein X9 is Pen or dPen.

46. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 45, wherein X5 is N or dN.

47. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 46, wherein X6 is T or dT.

48. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 47, wherein X7 is W, 7MeW, or d7MeW.

49. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 48, wherein X8 is KAc or dKAc.

50. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 49, wherein X10 is AEF(G) or dY.

51. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 50, wherein X10 is AEF, F4Ad, F4OMe, F4Me, Nal, F, Spiral_Pip, L, 4AmF, or Y.

52. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 51, wherein X11 is 2Nal or d2Nal.

53. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 52, wherein X12 is THP.

54. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 53, wherein X14 is N or dN.

55. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 54, wherein X15 is 3Pya, or 3pya.

56. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 54, wherein X15 is THP, N, H, dK, dL, dPaf, PAF, 3MeH, or F.

57. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 56, wherein X16 is MeGly.

58. The inhibitor of an interleukin-23 receptor of any of aspects 43 to 56, wherein R2 is NH_2.

59. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula VII

R1-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (VII)

wherein:

R1 is 7Ahp, 6Ahx, 8Aoc, or 5Ava;

X5 is N or absent;

X6 is T or absent;

X7 is 7MeW or absent;

X8 is KAc or absent;

X9 is Pen , Aib, or absent;

X10 is AEF or absent;

X11 is 2Nal;

X12 is THP;

X13 is E, dE, hE, hdE, D, dD, or Q;

X14 is N, D, or E;

X15 is 3Pya or N;

X16 is MeGly; and

R2 is absent, -NH_2 -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$ or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a bond between a residue at R1 and X13, R1 and X14, or between a residue at R1 and X9.

60. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula VIII

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14 (VIII)

wherein:

R1 is hydrogen, $CH_3C(O)$-, FPrpTriazoleMeCO, NH2, EtCO, AzCO, or BHCO;

X3 is dR, R, or absent;

X4 is Pen, Abu, C, or aMeC;

X5 is Q or N;

X6 is T;

X7 is W or 7MeW;

X8 is Q, dQ, KAc, dKAc;

X9 is Pen, Abu, C, or aMeC;

X10 is AEF or absent;

X11 is 2Nal or absent;

X12 is THP or absent;

X13 is E, dE, D, dD, KAc, dKAc, or absent; and

X14 isN, THP, bAla, N, Pyr, or absent;

R2 is absent or -NH2 -HN(C1-C4 alkyl), -N(C1-C4 alkyl)2 or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a dislfide bond between a residue at X4 and a residue at X9.

61. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula IX

R1-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (IX)

wherein:

R1 is hydrogen, $CH_3C(O)$-, NH2, or EtCO;

X6 is absent, 3OHPro, AIB, or T;

X7 is W, 7MeW, or absent;

X8 is KAc, dKAc, AIB, or absent;

X9 is S5H, S5Me, aMeS5H, aMeK, aMeK(N3), E, K, or aMePra;

X10 is AEF, 4OMeF, or F;

X11 is 2Nal;

X12 is THP, aMeK, or aMeL;

X13 is S5H, S5Me, aMeS5H, aMeK, aMeK(N3), E, dE, D, dD, K, dK, or aMePra;

X14 is N or L;

X15 is 3Pya or absent;

X16 is MeGly, N(iBu)Gly, N(Cyclohexyl)Gly, N(3AmBenzyl)Gly, or N(3AmBenzyl)Gly; and

R2 is absent, $-NH_2$ $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl)$_2$ or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a bond between a residue at X9 and a residue at X13.

62. A peptide inhibitor of an interleukin-23 receptor, which comprises an amino acid sequence of Formula X

R1-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (X)

wherein:

R1 is hydrogen, $CH_3C(O)$-, NH2, or EtCO;

X6 is AIB, 3OHPro, T, or absent;

X7 is W, 7MeW, or absent;

X8 is S5H, KAc, or absent;

X9 is AIB, S5H, A, or absent;

X10 is AEF, S5H, hLys, or 4OMeF;

X11 is 2Nal;

X12 is S5H, aMeK, S5Me, or THP;

X13 is KAc, S5H, E, Q, Pen, Abu, C, aMeC, dKAc, dE, dQ, dC, or aMedC;

X14 is N, hE, S5H, D, or N;

X15 is 3Pya;

X16 is MeGly;

R2 is absent, $-NH_2$ $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl)$_2$ or –OH; and


wherein the inhibitor of an interleukin-23 receptor is cyclized by a bond between a residue at X9 and a residue at X12, a bond between a residue at X9 and a residue at X13, a bond between a residue at X10 and a residue at X14, or a bond between a residue at X4 and a residue at X9.

63. An inhibitor of an interleukin-23 receptor provided in any of Tables 1A to Table 1G.


64. An inhibitor of an interleukin-23 receptor provided in Table 1H.

65. An inhibitor of an interleukin-23 receptor provided in Table 1I.


66. An inhibitor of an interleukin-23 receptor selected from compound 345, 469, 477, and 478.




Compound 345 SEQ ID NO:345



Compound 468, SEQ ID NO:468



Compound 477 SEQ ID NO:477



Compound 478, SEQ ID:NO:478

67. The peptide inhibitor of an interleukin-23 receptor of any of aspects 1-66, wherein D amino acids are present or substituted for a corresponding L amino acid only at

(i) one or more of positions X3, X5, X6, X8, X13 and X16, and optionally one of positions X1-X2, X4, X7, X9 to X12, X14-X18 present in the inhibitor; or

(ii) one or more of positions X3, X8 and X13, and optionally at one of positions X1-X2, X4-X7, X9 to X12, X14-X18 present in the inhibitor.

68. The peptide inhibitor of an interleukin-23 receptor of any of aspects 1-66, wherein D amino acids are present are present or substituted for a corresponding L amino acid only at

(i) X3, and optionally at one of positions X1-X2, X4 -X18 present in the inhibitor; or

(ii) one of positions X3, and X8, and optionally one of positions X1-X2, X4-X7, X9-X18 present in the inhibitor.

69. The peptide inhibitor of an interleukin-23 receptor of any of aspects 1-66, wherein the inhibitor comprises amino acids of the D-isomeric form, or substituted with a D amino acid in place of the corresponding L amino acid, at only one or two of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein.

70. The peptide inhibitor of an interleukin-23 receptor of any of aspects 1-66, wherein the inhibitor comprises amino acids of the D-isomeric form, or substituted with a D amino acid

in place of the corresponding L amino acid, at only three or four of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein.

71. The peptide inhibitor of an interleukin-23 receptor of any of aspects 1-66, wherein the inhibitor comprises amino acids of the D-isomeric form, or substituted with a D amino acid in place of the corresponding L amino acid, at only five or six of positions X1 to X18 appearing in the IL-23R inhibitors set forth herein.

72. The peptide inhibitor of an interleukin-23 receptor of any preceding aspect wherein the interleukin-23 receptor is a human interleukin receptor.

73. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to any one of aspects 1-58, and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

74. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to any one of aspects 59-66, and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

75. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 63 or 66: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

76. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 63: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

77. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 64: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

78. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 65: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

79. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 66: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

80. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 67: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

81. A pharmaceutical composition which comprises:
    (i) peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to aspect 68 to 72: and
    (ii) a pharmaceutically acceptable carrier, excipient, or diluent.

82. The use of a peptide inhibitor of an interleukin-23 receptor according to any of aspects 1-73 for the preparation of a medicament.

83. The use of a peptide inhibitor of an interleukin-23 receptor according to any of aspects 1-73, or a pharmaceutical composition according to any of aspects 74-82, for the preparation of a medicament for the treatment of inflammatory, autoimmune inflammation diseases and/or related disorders.

84. The use of a peptide inhibitor of an interleukin-23 receptor according to any of aspects 1-73, or a pharmaceutical composition according to any of aspects 74-82, for the preparation of a medicament for the treatment of inflammatory, autoimmune inflammation diseases and/or related disorders including, but not limited to: multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, Celiac disease (nontropical Sprue), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, enteropathy associated with seronegative arthropathies, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes

mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

85. The use of aspect 84, wherein the diseases or disorders are selected from Inflammatory Bowel Disease (IBD), Ulcerative colitis (UC), Crohn's Disease (CD), psoriasis (PsO) or psoriatic arthritis (PsA).

86. A method for treating a disease or disorder associated with Interleukin 23 (IL-23)/Interleukin 23 Receptor (IL-23R), which comprises administering:

(i) an effective amount of a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt, solvate, or form thereof according to any one of aspects 1-73;

or

(ii) a pharmaceutical composition according to any one of aspects 74 to 82, respectively to a patient in need thereof.

87. The method of aspect 82, wherein the disease or disorder is associated with autoimmune inflammation.

88. The method of aspect 82, wherein the disease or disorder is associated with multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, Celiac disease (nontropical Sprue), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, enteropathy associated with seronegative arthropathies, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

89. The method of aspect 82, wherein the disease or disorder is associated with Ulcerative colitis (UC), Crohn's Disease (CD), psoriasis (PsO), or psoriatic arthritis (PsA).

90. The method of aspect 82, wherein the disease or disorder is Ulcerative colitis (UC).

91. The method of aspect 82, wherein the disease or disorder is Crohn's Disease (CD).

92. The method of aspect 82, wherein the disease or disorder is psoriasis (PsO).

93. The method of aspect 82, wherein the disease or disorder is psoriasis psoriatic arthritis (PsA).

94. A kit which comprises a peptide inhibitor of an interleukin-23 receptor of an of aspects 1-72, or a pharmaceutical composition according to any of aspects 73-82, and instructions for the use of the inhibitor of an interleukin-23 receptor or pharmaceutical composition.

95. The kit of aspect 94, wherein the instructions are directed to the treatment of an inflammatory disease or disorder.

96. The kit of aspect 95, wherein the disease is inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), psoriasis (PsO), and psoriatic arthritis (PsA).





EXAMPLES




[000128] The following examples illustrate the invention. These examples are not intended to limit the scope of the present invention, but rather to provide guidance to the skilled artisan to prepare and use the compounds, compositions, and methods of the present invention. While particular aspects of the present invention are described, the skilled artisan will appreciate that various changes and modifications can be made without departing from the spirit and scope of the invention.




[000129] Some abbreviations useful in describing the invention are defined below in the following Table 2A to Table 2D.



Table 2A. Amino Acid Abbreviations

Abbreviation	Definition	Smiles
dR, arg, or r	D-Arginine	
dK, (D)Lys, (D)-Lys, lys, or k	D-lysine	
5Apa	5AminoPentanoicAcid	


2-Nal or 2Nal	 $C_{13}H_{11}NOR_2$	O=C([C@H](Cc1cc2ccccc2cc1)N[R])[R]
3MeH	3-methyl-L-histidine	Cn1cncc1C[C@H](N[R])C([R])=O
3Pya, 3Pal, 3-(2-pyridyl)-alanine		O=C([C@H](Cc1cnccc1)N[R])[R]
THP, 4-aminotetrahydro-2H-pyran-4-carboxylic acid	 4-amino-4-carboxy-tetrahydropyran	O=C(C1(CCOCC1)N[R])[R]
7PhW, 7PhTrp or W(7-Ph)	 7-phenyl-L-tryptophan	O=C([C@H](Cc1c[nH]c2c1cccc2-c1ccccc1)N[R])[R]


7MeW, 7(MeW), 7MeTrp, 7-methyl-L-tryptophan	 7-methyl-L-tryptophan	Cc1cccc2c1[nH]cc2C[C@@H](C([R])=O)N[R]
Abu	2-aminobutyric acid	C[C@@H](C=O)N
AEF, Phe(4-(2-aminoethoxy)), or F(4-2ae)	 4-(2-aminoethoxy)-L-phenylalanine	NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
Ahp, 7Ahp, 7AHP, or 7AHP(2)	7-aminoheptanoic acid	O=C([R])CCCCCCN[R]
Ahx or 6Ahx, 6Ahx, 6Ahx(2), 6-aminohexanoic acid	6-aminohexanoic acid	O=C(CCCCCN[R])[R]
aMeF, aMePhe, or aMe-Phe	 alpha-methyl L-phenylalanine	C[C@](Cc(cc1)ccc1F)(C([R])=O)N[R]


aMeK, aMeLys, or aMe-Lys	alpha-methyl L-lysine	
Arg or R	L-arginine	
dR, arg, r or (D)Arg	D-arginine	
Asn or N	L-asparagine	
Ava, 5Ava(2), or 5Ava	 5-Aminovaleric Acid	O=C(CCCCN[R])[R]
bAla, b-ALA, beta-Alanine, bA	 beta-alanine	O=C(CCN[R])[R]
Bis-amino-PEG2	1,2-bis(2-aminoethoxy)ethane	
Cys or C	L-cysteine	
Dbu, Dab, (*S*)-2,4-diaminobutanoic acid, or DAB	 L-2,4-diaminobutyric acid	NCC[C@@H](C(O)=O)N

Dap, Dap, DAP, Dpr or (S)-2,3-diaminopropanoic acid	 L-2,3-diaminopropionic acid	NC[C@@H](C([R])=O)N[R]
dDab, D(Dab), dDpr, (R)-2,3-diaminopropanoic acid	D-2,4-diaminobutyric acid	NC[C@H](C([R])=O)N[R]
dDap, D(Dap), dDap, dap, dDbu, (R)-2,3-diaminopropanoic acid	 D-2,3-diaminopropionic acid	NC[C@H](C([R])=O)N[R]
Fmoc-2Nal	2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(naphthalen-2-yl)propanoic acid	
Fmoc-3Pya	(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(pyridin-3-yl)butanoic acid	
Fmoc-7MeW	(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-methyl-1H-indol-3-yl)propanoic acid	
Fmoc-AEF	(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl)propanoic acid	

Fmoc-aMePhe	(((9H-fluoren-9-yl)methoxy)carbonyl)-alphamethyl-L-phenylalanine	
Fmoc-arg or Fmoc-r	N-alpha-(9-fluorenylmethyloxycarbonyl)-N'-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-D-arginine	
Fmoc-Asn or Fmoc-N	N^2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N4-trityl-L-asparagine	
Fmoc-Dap(DDe)	N2-(Fmoc)-N6-(1-(4,4-dimethyl-3,5-dioxocyclohexylidene)ethyl)-L-Dap	
Fmoc-DDe-Lys(Fmoc)-OH	N6-(((9H-fluoren-9-yl)methoxy)carbonyl)-N2-(1-(4,4-dimethyl-3,5-dioxocyclohexylidene)ethyl)-L-lysine	
Fmoc-Glu or Fmoc-E	(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-2-methyl-5-oxopentanoic acid	
Fmoc-Lys(Ac) or Fmoc-K(Ac)	N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-acetyl-L-lysine	
Fmoc-Lys(DDe) or Fmoc-K(DDe)	N2-(Fmoc)-N6-(1-(4,4-dimethyl-3,5-dioxocyclohexylidene)ethyl)-L-lysine	
Fmoc-Lys(NMeAc) or Fmoc-K(NMeAc)	N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-acetyl-N6-methyl-L-lysine	

Fmoc-NMeLys(DDe) or Fmoc-NMeK(DDe)	(9H-fluoren-9-yl)methyl (1-amino-6-((1-(4,4-dimethyl-3,5-dioxocyclohexylidene)ethyl)amino)-1-oxohexan-2-yl)(methyl)carbamate	
Fmoc-Pen-Trt	(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methyl-3-(tritylthio)butanoic acid	
Fmoc-Pro or Fmoc-P	Fmoc-proline-OH	
Fmoc-pro or Fmoc-p	Fmoc-D-proline-OH	
Fmoc-R5H	(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)hept-6-enoic acid	
Fmoc-Sar or Fmoc-Sarc	N-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-methylglycine	
Fmoc-THP	4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)tetrahydro-2H-pyran-4-carboxylic acid	
Fmoc-Thr or Fmoc-T	N-(((9H-fluoren-9-yl)methoxy)carbonyl)-O-(tert-butyl)-L-threonine	
GABA, Gaba, Gaba(2), Gaba2, or 4Abu	 4-aminobutyric acid	O=C(CCCN[R])[R]
Glu or E	L-glutamic acid	
glu or e or D(Glu)	D-glutamic acid	
His or H	L-histidine	

Lys or K	L-lysine	
lys or k or (D)Lys	D-lysine	
hCys, hC	L-Homocysteine	C(CS)[C@@H](C(=O)O)N
KAc, Lys(Ac), K(Ac), K(COMe), or K-Ac	N-ε-acetyl-L-Lysine N6-Acetyl-L-lysine	CC(NCCCC[C@@H](C([R])=O)N[R])=O
MeK, N-MeLys, NMeLys, NMeK, or MeLys	N-methyl-Lysine (2S)-2-amino-6-(methylamino)hexanoic acid	
Pen	 L-penicillamine, 3-Mercapto-L-valine (R)-2-Amino-3-mercapto-3-methylbutanoic acid	CC(C)([C@@H](C(O)=O)N)S

F4CONH2, Phe(4-$CONH_2$) or Phe(4-CONH2) or Phe(Cmd) or Phe_4Ad	4-carbamoyl-L-phenylalanine (S)-2-amino-3-(4-carbamoylphenyl)propanoic acid	N[C@H](C([R])=O)Cc1ccc(C(N[R])=O)cc1
F4OMe, Phe(4-OMe), or Phe_4OMe	4-methoxy-L-phenylalanine	N[C@@H](CC1=CC=C(OC)C=C1)C(O)=O
Quin, 3Quin, 3-Quin, 3QuinolAla, or 3QuinA	 (S)-2-amino-3-(quinolin-3-yl)propanoic acid	O=C([C@H](Cc1cc2ccccc2nc1)N[R])[R]
R5H,	(R)-2-aminopentanoic acid 5-diyl	
R6H, (R,E)-2-amino-8-hydroxyoct-7-enoic acid	(R)-2-aminohexanoic acid 6-diyl	C=CCCCC[C@H](C([R])=O)N[R]



R7H, (R,E)-2-amino-9-hydroxynon-8-enoic acid	(R)-2-aminoheptanoic acid 7-diyl	C=CCCCCC[C@H](C([R])=O)N[R]
S5H	(S)-2-aminopentanoic acid 5-diyl	C=CCCC[C@H](N[R])C([R])=O
meG, Sarc, MeGly, Sar, Sarc, MeGly, Sarcosine, Methylamino-Acetic Acid, N-methylglycine	 sarcosine or N-methylglycine	CN(CC([R])=O)[R]
Thr or T	L-threonine	
nFEtOH, Phe(4-OCH2COOH, or 2-amino-2-[4-(carboxymethoxy)phenyl]acetic acid,	Fc1c(F)c([H])c(F)c(F)c1NC[C@@H](C([R])=O)N[R] (R)-2-amino-2-(4-(carboxymethoxy)phenyl)acetic acid	N[C@@H](C=O)c(cc1)ccc1OCC=O
DappF6 Dap(pF(6))	tetra-fluoro-phenylalanine	Fc1c(F)c([H])c(F)c(F)c1NC[C@@H](C([R])=O)N[R]

Table 2B. Abbreviations for Substituents, Reagents, and Solvents

Abbreviation	Definition	Smiles
Ac or MeCO	acetyl	
ACN	acetonitrile	
Boc	tert-butoxy-carbonyl	
$CONH_2$	carboxamide	
COOH	carboxylic Acid	
DCM	dichloromethane	
Dde	N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl	
DIC	N,N′-diisopropylcarbodiimide	
DMF	N,N-dimethylformamide	
Et_2O	di-ethylether	
FMOC or Fmoc	((9H-fluoren-9-yl)methoxy)carbonyl	
HOAT or HOAt	1-hydroxy-7-azabenzotriazole	
MeOH	methanol	
MTBE	methyl tert-butyl ether	
MW	microwave	
Oxyma	ethyl cyanohydroxyiminoacetate	
PEG2_DiAcid or PEG2DA	 3,3'-(ethane-1,2-diylbis(oxy))dipropanecarbonyl	






















Abbreviation	Definition	Smiles
pF	 2,3,5,6-tetrafluorophen-1,4-diyl linker	Fc1c(F)c([R])c(F)c(F)c1[R]
pFS	 2,3,5,6-tetrafluoro-4-mercaptophenol	Fc(c(S[R])c(c(F)c1[R])F)c1F
RT	room temperature	
TFA	trifluoroacetic acid	
TIPS	triisopropylsilane	








Table 2C. Monomers








#	Symbol/Name	Structure	Smiles
1	bMeW(2S3R) bMeW(2S,3R)	 $C_{12}H_{12}N_2OR_2$	C[C@H](C1=CNC2=C1C=CC=C2)[C@H](N[R])C([R])=O








2	bMeW(2S3S), bMeW(2S,3S)	 $C_{12}H_{12}N_2OR_2$	C[C@@H](C1=CNC2=C1C=CC=C2)[C@H](N[R])C([R])=O
3	6OH2Nal	 (*S*)-2-amino-3-(6-hydroxynaphthalen-2-yl)propanoic acid	[R]C([C@H](CC1=CC=C(C=C(O)C=C2)C2=C1)N[R])=O
4	NMe7MeW	 $C_{13}H_{14}N_2OR_2$	[R]C([C@@H](N[R])CC1=CN(C)C2=C1C=CC=C2C)=O
5	7(4Paz)W	 $C_{14}H_{12}N_4OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CNN=C3)=O
6	7(7(124TAZP))W	 $C_{17}H_{13}N_5OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CC4=NC=NN4C=C3)=O
7	7(3UrPh)W	 $C_{18}H_{14}N_4O_2R_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CC(NC(N4)=O)=C4C=C3)=O







8	7(7Imzpy)W	$C_{18}H_{14}N_4OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CC4=NC=CN4C=C3)=O]
9	7(4OMePh)W	 $C_{18}H_{16}N_2O_2R_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CC=C(OC)C=C3)=O
10	7(3(6AzaInd1Me))W	 $C_{19}H_{16}N_4OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CN(C)C4=C3C=CN=C4)=O
11	7(6(2MeNDAZ))W	 $C_{19}H_{16}N_4OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CC4=NN(C)C=C4C=C3)=O
12	NMebAla	 $C_5H_{11}NO$	CN(C)CCC=O
13	AcMorp, Ethyl-morpholino	 $C_5H_{11}NO$	CN1CCOCC1
14	dOrn, D-Orn D-Ornithine	 $C_5H_{12}N_2O$	NCCC[C@H](C(O)=O)N







15	3Hyp, 3-Hydroxy-L-proline	 $C_5H_9NO_2$	OC1[C@@H](C=O)NCC1
16	aMeE aMeGlu, alpha-methyl glutamic acid	 $C_6H_{11}NO_2$	C[C@](CCC(O)=O)(C([R])=O)N[R] C[C@](CCC(O)=O)(C=O)N
17	hGlu, (S)-2-aminohexanedioic acid	 $C_6H_{11}NO_2$	N[C@@H](CCCC=O)C=O OC(CCC[C@@H](C([R])=O)N[R])=O
18	CON(NMePip)	 $C_6H_{12}N_2O$	CN(CC1)CCN1C=O
19	-CODiFPip, CO(DiFPip)	 $C_6H_9F_2NO$	O=CN(CC1)CCC1(F)F
20	CO(OAZBO)	 $C_8H_{13}NO_2$	CC(N1C2COCC1CC2)=O







21	Me1Pya, (S)-3-(2-amino-2-carboxyethyl)-1-methylpyridin-1-ium	 $C_9H_{13}N_2O^+$	C[n+]1cccc(C[C@@H](C=O)N)c1
22	DappF6, tetra-fluoro-phenylalanine	 $C_9H_8F_4N_2O$	N[C@@H](CNc(c(F)c(c(S)c1F)F)c1F)C=O
23	bMePhe(2S,3R) bMePhe(SR), bMePhe(2S,3R)	 $C_{10}H_{11}NOR_2$	C[C@@H]([C@@H](C([R])=O)N[R])c1ccccc1
24	N4AmBenzylGly, N(4AmBenzyl)Gly	 $C_{10}H_{12}N_2O_2$	NC(c1ccc(CNCC=O)cc1)=O
25	-Dec, 1,10-Decanedioic Acid	 $C_{10}H_{18}O_3$	OC(CCCCCCCCC=O)=O
26	2OH3Pyrimid5Ala	 $C_{11}H_{15}N_3O_2R_2$	CC(C)(C)Oc1ncc(C[C@@H](C([R])=O)N[R])cn1
27	KacMorph, K(AcMorph), KAcMorph, L-Lysine(ac-Morpholino	 $C_{12}H_{23}N_3O_3$	N[C@@H](CCCCNC(CN1CCOCC1)=O)C=O






28	6OH2Nal	 $C_{13}H_{13}NO$	N[C@@H](Cc1cc2ccccc2cc1)C=O N[C@@H](Cc1cc2ccccc2cc1)C=O Oc1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2c1
29	DabNMecarn, Dab(NMecarn)	 $C_{16}H_{31}N_4O_4^+$	CN(CC[C@@H](C=O)N)C(CCC(N[C@H](CC=O)C[N+](C)(C)C)=O)=O CN(CC[C@@H](C=O)N)C(CCC(N[C@H](CC=O)C[N+](C)(C)C)=O)=O CN(CC[C@@H](C=O)N)C(CCC(N[C@H](CC(O)=O)C[N+](C)(C)C)=O)=O
30	DabNMeCarn, Dab(NMeCarn)	 $C_{16}H_{31}N_4O_5^+$	CN(CC[C@@H](C=O)N)C(CCC(N[C@@H](CC(O)=O)C[N+](C)(C)C)=O)=O
31	F(4TzlTMA4)	 $C_{18}H_{26}N_5OR_2^+$	C[N+](C)(C)CCCCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1
32	NMeK(d), NMeKdCar	 $C_{18}H_{33}N_4O_5R_2^+$	CN([C@@H](CCCCNC(CCC(N[C@@H](CC(O)=O)C[N+](C)(C)C)=O)=O)C([R])=O)[R]
33	7(5(Ina7Pyr))W	 $C_{19}H_{18}N_4OR_2$	[R]C([C@@H](N[R])CC1=CNC2=C1C=CC=C2C3=CN=C(N(C)CC4)C4=C3)=O
34	F(4TzlTMA5)	 $C_{19}H_{28}N_5OR_2^+$	C[N+](C)(C)CCCCCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1






35	CF3CO F3CO	 C_2F_3OR	O=C(C(F)(F)F)[R]
36	CF3Propylamide	 $C_3H_2F_3OR$	O=C(CC(F)(F)F)[R]
37	C(1*) (*pure but configuration unknown)	 $C_3H_4NOSR_3$	O=C([C@H](CS[R])N[R])[R]
38	bAla, b-ALA, beta-Alanine, bA	 $C_3H_5NOR_2$	O=C(CCN[R])[R]
39	CON(Me)2	 C_3H_6NOR	CN(C)C([R])=O
40	D(2)	 $C_4H_4NO_2R_3$	O=C(C[C@@H](C([R])=O)N[R])[R]
41	cPrCO	 C_4H_5OR	O=C(C1CC1)[R]






42	hS, hS, , Hse, L-homoserine, homoS, or homoSer	 $C_4H_7NO_2R_2$	OCC[C@@H](C([R])=O)N[R]
43	T, dThr, dT	 $C_4H_7NO_2R_2$	C[C@H]([C@H](C([R])=O)N[R])O
44	4sb, 4SB	 $C_4H_7NO_3SR_2$	O=C([R])CCCS(=O)(N[R])=O
45	Aib, AIB, 2-Aminoisobutyric acid, Alpha-aminoisobutyric acid ,(2-aminoalanine)	 $C_4H_7NOR_2$	CC(C)(C([R])=O)N[R]
46			
47	NMebAla	 $C_4H_7NOR_2$	CN(CCC([R])=O)[R]
48	aMeC	 $C_4H_7NOSR_2$	C[C@](CS)(C([R])=O)N[R] C[C@](CS)(C=O)N







49	hC, hCys, homoC, or homoCys	 $C_4H_7NOSR_2$	O=C([C@H](CCS)N[R])[R]
50	iPrCO	 C_4H_7OR	CC(C)C([R])=O
51	dDab, dab, (R)-2,4-diaminobutanoic acid	 $C_4H_8N_2OR_2$	NCC[C@H](C([R])=O)N[R]
52	homobAla	 $C_4H_8NO_2R$	C[C@@H](CC(O)=O)N[R]
53	Bua, Butanoic acid	 $C_4H_8O_2$	CCCC(O)=O
54	Orn, ORN, Ornithine	 $C_5H_{10}N_2OR_2$	NCCC[C@@H](C([R])=O)N[R]
55			







56	Orn, L-ornithine	 $C_5H_{12}N_2O_2$	NCCC[C@@H](C(O)=O)N
57	4diFPro	 $C_5H_5F_2NOR_2$	O=C([C@H](CC(C1)(F)F)N1[R])[R] O=C[C@H](C1)NCC1(F)F
58	prG, prG, Fmoc-L-propargyl-Gly-OH, Pra	 $C_5H_5NOR_2$	C#CC[C@@H](C([R])=O)N[R]
59	4TriazolAla	 $C_5H_6N_4OR_2$	O=C([C@H](Cc1cnn[nH]1)N[R])[R]
60	Tzl	 $C_5H_6N_4OR_2$	O=C([C@H](Cn1nncc1)N[R])[R]
61	PyE, PyE (S)-5-oxopyrrolidine-2-carboxylic acid	 $C_5H_6NO_2R$	O=C([C@H](CC1)NC1=O)[R] O=C[C@H](CC1)NC1=O






62	E(2)	 $C_5H_6NO_2R_3$	O=C(CC[C@@H](C([R])=O)N[R])[R]
63	Tetrazole	 $C_5H_7N_5OR_2$	O=C([C@H](CCn1nncn1)N[R])[R]N[C@@H](CCn1nncn1)C=O
64	3OHPro	 $C_5H_7NO_2R_2$	OC(CC1)[C@@H](C([R])=O)N1[R]
65	4(R)HydroxyPro	 $C_5H_7NO_2R_2$	O[C@H](C[C@H]1C([R])=O)CN1[R]
66	Hyp	 $C_5H_7NO_2R_2$	OC(C[C@H]1C([R])=O)CN1[R]






67	AllylGly	 $C_5H_7NOR_2$	C=CC[C@@H](C([R])=O)N[R]
68	Dap(Ac)	 $C_5H_8N_2O_2R_2$	CC(NC[C@@H](C([R])=O)N[R])=O
69	N(NMe), NNMe, NMeAsn	 $C_5H_8N_2O_2R_2$	CNC(C[C@@H](C([R])=O)N[R])=O
70	aMeN. aMeAsn	 $C_5H_8N_2O_2R_2$	C[C@](CC(N)=O)(C([R])=O)N[R]
71	4(S)AminoPro	 $C_5H_8N_2OR_2$	N[C@@H](C[C@H]1C([R])=O)CN1[R]






72	CO(Morph)	 $C_5H_8NO_2R$	O=C(N1CCOCC1)[R]
73	-COMorph, CO(Morph)	 $C_5H_9NO_2$	O=CN1CCOCC1
74			
75	Nva	 $C_5H_9NOR_2$	CCC[C@@H](C([R])=O)N[R]
76	dM, dMet, D-Methionine	 $C_5H_9NOSR_2$	CSCC[C@H](C([R])=O)N[R]
77	dPen, pen	 $C_5H_9NOSR_2$	CC(C)([C@H](C([R])=O)N[R])S
78	BuCO	 C_5H_9OR	CCCCC([R])=O






79	iBuCO	 C_5H_9OR	CC(C)CC([R])=O CC[C@H](C)C([R])=O
80	tBuCO	 C_5H_9OR	CC(C)(C)C([R])=O
81	N(N(Me)2), NNMe2	 $C_6H_{10}N_2O_2R_2$	CN(C)C(C[C@@H](C([R])=O)N[R])=O
82	MorphCO, 2-morpholinoacetic acid	 $C_6H_{10}NO_2R$	O=C(CN1CCOCC1)[R]
83	CON(NMePip)	 $C_6H_{11}N_2OR$	CN(CC1)CCN1C([R])=O
84	eK	 $C_6H_{11}N_2OR_3$	O=C(O)[C@@H](N[R])CCCCN[R]







85	Cit, Citrulline	 $C_6H_{11}N_3O_2R_2$	NC(NCCC[C@@H](C([R])=O)N[R])=O N[C@@H](CCCNC(N)=O)C(O)=O
86	D(NEtNH2)	 $C_6H_{11}N_3O_2R_2$	NCCNC(C[C@@H](C([R])=O)N[R])=O
87	Aad, 2-Aminoadipic acid	 $C_6H_{11}NO_4$	N[C@@H](CCCC(O)=O)C(O)=O
88	N(Isobutyl)Gly	 $C_6H_{11}NOR_2$	CC(C)CN(CC([R])=O)[R]
89	PentCO	 $C_6H_{11}OR$	CCCCCC([R])=O
90	NMeQ, NMeGln, N-Methyl-Glutamine	 $C_6H_{12}N_2O_3$	CN[C@@H](CCC(N)=O)C(O)=O







91	SP6	 $C_6H_{13}N_2OR_2^+$	C[N+](C)(CCN[R])CC([R])=O C[N+](C)(CCN)CC=O
92	3IOxa4Ala	 $C_6H_6N_2O_2R_2$	O=C([C@H](Cc1conc1)N[R])[R]
93	3Oxa4Ala	 $C_6H_6N_2O_2R_2$	O=C([C@H](Cc1cocn1)N[R])[R]
94	diFCpx	 $C_6H_7F_2NOR_2$	O=C([C@](CC1)(CC1(F)F)N[R])[R]
95	aMePra	 $C_6H_7NOR_2$	C[C@](CC#C)(C([R])=O)N[R]
96	CO(DiFPip)	 $C_6H_8F_2NOR$	O=C(N(CC1)CCC1(F)F)[R]






97	dab(COCH2(1*)) dab(COCH2)(1*)	 $C_6H_9N_2O_2R_3$	O=C(C[R])NCC[C@@H](C([R])=O)N[R]
98	Tetrazole(NMe)	 $C_6H_9N_5OR_2$	Cn1nnc(CC[C@@H](C([R])=O)N[R])n1
99			
100	dhE	 $C_6H_9NO_3R_2$	OC(CCC[C@H](C([R])=O)N[R])=O
101	Acpx	 $C_6H_9NOR_2$	O=C(C1(CCCC1)N[R])[R] NC1(CCCC1)C=O
102	aMeP, aMePro	 $C_6H_9NOR_2$	C[C@](CCC1)(C([R])=O)N1[R]






103	D(N2AmIm)	 $C_8H_{10}N_4O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])NCc1ncc[nH]1
104	KTfa, K(Tfa), L-Lys(Tfa)	 $C_8H_{11}F_3N_2O_2R_2$	O=C([C@H](CCCCNC(C(F)(F)F)=O)N[R])[R]
105	E(OAll)	 $C_8H_{11}NO_3R_2$	C=CCOC(CC[C@@H](C([R])=O)N[R])=O
106	D(NPyr)	 $C_8H_{13}N_3O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])NC1CNCC1
107	Chg	 $C_8H_{13}NOR_2$	O=C([C@H](C1CCCCC1)N[R])[R]






108	R5Me, aMeR5H	 $C_8H_{13}NOR_2$	C[C@@](CCCC=C)(C([R])=O)N[R]
109	R6H, (R,E)-2-amino-8-hydroxyoct-7-enoic acid	 $C_8H_{13}NOR_2$	C=CCCCC[C@H](C([R])=O)N[R] C=CCCCC[C@H](C=O)N
110	S5Me aMeS5H	 $C_8H_{13}NOR_2$	C[C@](CCCC=C)(C([R])=O)N[R]
111	S6H	 $C_8H_{13}NOR_2$	C=CCCCC[C@@H](C([R])=O)N[R]
112	KAc, K(Ac), K(COMe), K-Ac, N6-acetyl-L-Lysine	 $C_8H_{14}N_2O_2R_2$	CC(NCCCC[C@@H](C([R])=O)N[R])=O






113	Pip(NMe2)	 $C_8H_{15}N_2OR_2^+$	C[N+](C)(CC1)CCC1(C([R])=O)N[R]
114	K(Gly)	 $C_8H_{15}N_3O_2R_2$	NCC(NCCCC[C@@H](C([R])=O)N[R])=O
115	8Aoc, 8Aoc(2)	 $C_8H_{15}NOR_2$	O=C(CCCCCCCN[R])[R]
116	2Benzyl	 $C_8H_6OR_2$	O=C(c1c(C[R])cccc1)[R]
117	6OH3Pya	 $C_8H_8N_2O_2R_2$	Oc1ncc(C[C@@H](C([R])=O)N[R])cc1
118	3Pya, 3Pal, 3-(2-pyridyl)-alanine	 $C_8H_8N_2OR_2$	O=C([C@H](Cc1cnccc1)N[R])[R]







119	4Pya, 4Pya, 4Pal, (S)-2-amino-3-(pyridin-4-yl)propanoic acid 4PyridinAla	 $C_8H_8N_2OR_2$	O=C([C@H](Cc1ccncc1)N[R])[R]
120	dPal, dpal, d3Pya, 3pya, 3-pyridylalanine, (R)-2-amino-3-(pyridin-3-yl)propanoic acid	 $C_8H_8N_2OR_2$	O=C([C@@H](Cc1cnccc1)N[R])[R]
121	6MePyridazAla	 $C_8H_9N_3OR_2$	Cc1cc(C[C@@H](C([R])=O)N[R])cnn1
122	5MePyridinAla	 $C_9H_{10}N_2OR_2$	Cc1cc(C[C@@H](C([R])=O)N[R])cnc1
123	J, Aph, 4-aminophenylalanine	 $C_9H_{10}N_2OR_2$	Nc1ccc(C[C@@H](C([R])=O)N[R])cc1
124	NMe3Pya	 $C_9H_{10}N_2OR_2$	CN([C@@H](Cc1cnccc1)C([R])=O)[R] CN[C@@H](Cc1cnccc1)C=O








125	SMSBCO	 $C_9H_{10}NO_3SR$	CS(NCc(cc1)ccc1C([R])=O)(=O)=O
126	Me3Pya	 $C_9H_{11}N_2OR_2^+$	C[n+]1cccc(C[C@@H](C([R])=O)N[R])c1
127	D(Pip), (S)-2-amino-4-oxo-4-(piperidin-1-yl)butanoic acid	 $C_9H_{14}N_2O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])N1CCCCC1
128	D(NPip)	 $C_9H_{15}N_3O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])NC1CCNCC1
129	N(Cyclohexyl)Gly	 $C_9H_{15}NOR_2$	O=C(CN(CC1CCCCC1)[R])[R]






130	R7H, (R,E)-2-amino-9-hydroxynon-8-enoic acid	 $C_9H_{15}NOR_2$	C=CCCCCC[C@H](C([R])=O)N[R] C=CCCCCC[C@H](C=O)N
131	K(COEt)	 $C_9H_{16}N_2O_2R_2$	CCC(NCCCC[C@@H](C([R])=O)N[R])=O
132	K(NMeAc), KNMeAc	 $C_9H_{16}N_2O_2R_2$	CC(N(C)CCCC[C@@H](C([R])=O)N[R])=O
133	Q(NHtBu)	 $C_9H_{16}N_2O_2R_2$	CC(C)(C)NC(CC[C@@H](C([R])=O)N[R])=O
134	K(Me)3	 $C_9H_{19}N_2OR_2^+$	C[N+](C)(C)CCCC[C@@H](C([R])=O)N[R]






135	dK(Me)3, k(Me)3	 $C_9H_{19}N_2OR_2^+$	C[N+](C)(C)CCCC[C@H](C([R])=O)N[R]
136	5cpaCO	 $C_9H_{19}NOR^+$	C[N+](C)(C)CCCCCC([R])=O
137	tetraFPhe	 $C_9H_5F_4NOR_2$	O=C([C@H](Cc(c(F)c(cc1F)F)c1F)N[R])[R]
138	5CF33Pya	 $C_9H_7F_3N_2OR_2$	O=C([C@H](Cc1cncc(C(F)(F)F)c1)N[R])[R] N[C@@H](Cc1cc(C(F)(F)F)cnc1)C=O
139	3,4diFPhe, 4diFPhe	 $C_9H_7F_2NOR_2$	O=C([C@H](Cc(cc1)cc(F)c1F)N[R])[R]






140	F(4N3)	 $C_9H_8N_4OR_2$	[N-]=[N+]=Nc1ccc(C[C@@H](C([R])=O)N[R])cc1
141	3FTyr	 $C_9H_8FNO_2R_2$	Oc(ccc(C[C@@H](C([R])=O)N[R])c1)c1F
142	2BrPhe, 2BrF	 $C_9H_8BrNOR_2$	O=C([C@H](Cc(ccc1)c1Br)N[R])[R]
143	2FPHE, 2FPhe	 $C_9H_8FNOR_2$	O=C([C@H](Cc(ccc1)c1F)N[R])[R]
144	3FPHE, 3FPhe	 $C_9H_8FNOR_2$	O=C([C@H](Cc1cc(F)ccc1)N[R])[R]







145	BHCO	 $C_9H_8IO_2R$	Oc(ccc(CCC([R])=O)c1)c1I
146	5AmPyridinAla	 $C_9H_9N_3O_2R_2$	NC(c1cc(C[C@@H](C([R])=O)N[R])cnc1)=O
147	mTYR, mY, mTyr	 $C_9H_9NO_2R_2$	Oc1cccc(C[C@@H](C([R])=O)N[R])c1
148	6OHQuin	 $C_{12}H_{10}N_2O_2R_2$	Oc1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2n1
149	4AmF, 4AmPhe	 $C_{10}H_{10}N_2O_2R_2$	NC(c1ccc(C[C@@H](C([R])=O)N[R])cc1)=O N[C@@H](Cc(cc1)ccc1C(N)=O)C=O
150	AEF(NMe(2))	 $C_{12}H_{15}N_2O_2R_3$	CN(CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)[R]






151	aMeY01	 $C_{11}H_{13}NO_2R_2$	C[C@](Cc(cc1)ccc1OC)(C([R])=O)N[R]
152	BiF	 $C_{16}H_{15}NOR_2$	C[C@](Cc(cc1)ccc1-c1ccccc1)(C([R])=O)N[R]
153	hdKMe3, hk(Me)3	 $C_{10}H_{23}N_2O^+$	C[N+](C)(C)CCCCC[C@H](C=O)N
154	Y(OTzl)	 $C_{12}H_{12}N_4O_2R_2$	O=C([C@H](Cc(cc1)ccc1OCc1c[nH]nn1)N[R])[R]
155	3CONH2F	 $C_{10}H_{10}N_2O_2R_2$	NC(c1cccc(C[C@@H](C([R])=O)N[R])c1)=O
156	4AmDF, 4AmDPhe	 $C_{10}H_{10}N_2O_2R_2$	NC(c1ccc(C[C@H](C([R])=O)N[R])cc1)=O
157	4AmF, 4AmPhe	 $C_{10}H_{10}N_2O_2R_2$	NC(c1ccc(C[C@@H](C([R])=O)N[R])cc1)=O N[C@@H](Cc(cc1)ccc1C(N)=O)C=O






158	D(NPh)	 $C_{10}H_{10}N_2O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])Nc1ccccc1
159	N(3AmBenzyl)Gly	 $C_{10}H_{10}N_2O_2R_2$	NC(c1cccc(CN(CC([R])=O)[R])c1)=O
160	N(4AmBenzyl)Gly	 $C_{10}H_{10}N_2O_2R_2$	NC(c1ccc(CN(CC([R])=O)[R])cc1)=O
161	2AmTyr	 $C_{10}H_{10}N_2O_3R_2$	NC(c(cc(C[C@@H](C([R])=O)N[R])cc1)c1O)=O
162	aMeFPhe	 $C_{10}H_{10}FNOR_2$	C[C@](Cc(cc1)ccc1F)(C([R])=O)N[R]





163	D(NmAn)	 $C_{10}H_{11}N_3O_2R_2$	Nc1cccc(NC(C[C@@H](C([R])=O)N[R])=O)c1
164	D(NoAn)	 $C_{10}H_{11}N_3O_2R_2$	Nc(cccc1)c1NC(C[C@@H](C([R])=O)N[R])=O
165	D(NpAn)	 $C_{10}H_{11}N_3O_2R_2$	Nc(cc1)ccc1NC(C[C@@H](C([R])=O)N[R])=O
166	4MeOF	 $C_{10}H_{11}NO_2R_2$	COc1ccc(C[C@@H](C([R])=O)N[R])cc1 COc1ccc(C[C@@H](C=O)N)cc1
167	NMeDTyr, NMeDY, NMedTyr, NMedY, N-Methyl-D-tyrosine, dNMeTyr dNMeY	 $C_{10}H_{11}NO_2R_2$	CN([C@H](Cc(cc1)ccc1O)C([R])=O)[R]





168	aMe3OHPhe	 $C_{10}H_{11}NO_2R_2$	C[C@](Cc1cc(O)ccc1)(C([R])=O)N[R]
169	aMeY, aMeTyr	 $C_{10}H_{11}NO_2R_2$	C[C@](Cc(cc1)ccc1O)(C([R])=O)N[R]
170	bMeDTyr(2R3S) bMeDTyr(2R,3S)	 $C_{10}H_{11}NO_2R_2$	C[C@H]([C@H](C([R])=O)N[R])c(cc1)ccc1O
171	4MeF	 $C_{10}H_{11}NOR_2$	Cc1ccc(C[C@@H](C([R])=O)N[R])cc1
172	aMeF, aMeF alpha-methyl phenylalanine	 $C_{10}H_{11}NOR_2$	C[C@](Cc1ccccc1)(C([R])=O)N[R] C[C@](Cc1ccccc1)(C=O)N






173	bMePhe	 $C_{10}H_{11}NOR_2$	CC([C@@H](C([R])=O)N[R])c1ccccc1
174	bMePhe(2S3S) bMePhe(2S,3S)	 $C_{10}H_{11}NOR_2$	C[C@H]([C@@H](C([R])=O)N[R])c1ccccc1
175	hF, hPhe, homoF, homoPhe	 $C_{10}H_{11}NOR_2$	O=C([C@H](CCc1ccccc1)N[R])[R]
176	F4CONH2, 4-carbamoyl-L-phenylalanine	 $C_{10}H_{12}N_2O_2$	N[C@@H](Cc(cc1)ccc1C(N)=O)C=O
177	Maf	 $C_{10}H_{12}N_2OR_2$	NCc1cccc(C[C@@H](C([R])=O)N[R])c1
178	Paf	 $C_{10}H_{12}N_2OR_2$	NCc1ccc(C[C@@H](C([R])=O)N[R])cc1 NCc1ccc(C[C@@H](C=O)N)cc1






179	dMaf, maf	 $C_{10}H_{12}N_2OR_2$	NCc1cccc(C[C@H](C([R])=O)N[R])c1
180	dPaf	 $C_{10}H_{12}N_2OR_2$	NCc1ccc(C[C@H](C([R])=O)N[R])cc1
181	oAMPhe	 $C_{10}H_{12}N_2OR_2$	NCc1c(C[C@@H](C([R])=O)N[R])cccc1
	F(G)		OC([C@@H](N[H])CC1=CC=C(C=C1)NC(N)=N)=O
182	F(4G)	 $C_{10}H_{12}N_4OR_2$	NC(N)=Nc1ccc(C[C@@H](C([R])=O)N[R])cc1
183	NMeDTyr	 $C_{10}H_{13}NO$	CN[C@H](Cc1ccccc1)C=O






184	dNMeTyr dNMeY, D-N-methyl tyrosine N-Methyl-D-tyrosine	 $C_{10}H_{13}NO_2$	CN[C@H](Cc(cc1)ccc1O)C=O
185	biotin	 $C_{10}H_{15}N_2O_2SR$	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)[R]
186	K(CO2allyl)	 $C_{10}H_{16}N_2O_2R_2$	C=CCC(NCCCC[C@@H](C([R])=O)N[R])=O C=CCOC(NCCCC[C@@H](C([R])=O)N[R])=O
187	K(COcPr)	 $C_{10}H_{16}N_2O_2R_2$	O=C([C@H](CCCCNC(C1CC1)=O)N[R])[R]
188	DAGSuc	 $C_{10}H_{16}NO_7R$	OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1NC(CCC([R])=O)=O





189	K(COPr)	 $C_{10}H_{18}N_2O_2R_2$	CCCC(NCCCC[C@@H](C([R])=O)N[R])=O
190	K(COiPr)	 $C_{10}H_{18}N_2O_2R_2$	CC(C)C(NCCCC[C@@H](C([R])=O)N[R])=O
191	Tzl(Ch)	 $C_{10}H_{18}N_5OR_2^+$	C[N+](C)(C)CCc1cn(C[C@@H](C([R])=O)N[R])nn1
192	hK(Me)3, hKMe3	 $C_{10}H_{21}N_2OR_2^+$	C[N+](C)(C)CCCCC[C@@H](C([R])=O)N[R]





193	hdK(Me)3, hk(Me)3, hdKMe3	 $C_{10}H_{21}N_2OR_2^+$	C[N+](C)(C)CCCCC[C@H](C([R])=O)N[R]
194	Dap(pF(6))	 $C_{10}H_7F_4N_2OR_3$	O=C([C@H](CCNc(c(F)c(c([R])c1F)F)c1F)N[R])[R]
195	4OCF3DPhe	 $C_{10}H_8F_3NO_2R_2$	O=C([C@@H](Cc(cc1)ccc1OC(F)(F)F)N[R])[R]
196	CF3F	 $C_{10}H_8F_3NOR_2$	O=C([C@H](Cc1ccc(C(F)(F)F)cc1)N[R])[R]





197	7AzaW	 $C_{10}H_9N_3OR_2$	O=C([C@H](Cc1c[nH]c2c1cccn2)N[R])[R]
198	Y(CHF2)	 $C_{10}H_9F_2NO_2R_2$	O=C([C@H](Cc(cc1)ccc1OC(F)F)N[R])[R]
199	CXF	 $C_{10}H_9NO_3R_2$	OC(c1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
200	CHF2Phe	 $C_{10}H_9F_2NOR_2$	O=C([C@H](Cc1ccc(C(F)F)cc1)N[R])[R]
201	TetraFAEF	 $C_{11}H_{10}F_4N_2O_2R_2$	NCCOc(c(F)c(c(C[C@@H](C([R])=O)N[R])c1F)F)c1F





202	5OHW	 $C_{11}H_{10}N_2O_2R_2$	Oc(cc1)cc2c1[nH]cc2C[C@@H](C([R])=O)N[R]
203	4AcDPhe	 $C_{11}H_{11}NO_2R_2$	CC(c1ccc(C[C@H](C([R])=O)N[R])cc1)=O
204	D(NBzl)	 $C_{11}H_{12}N_2O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])NCc1ccccc1
205	aMe2AmTyr	 $C_{11}H_{12}N_2O_3R_2$	C[C@](Cc(cc1)cc(C(N)=O)c1O)(C([R])=O)N[R]
206	psiW	 $C_{11}H_{12}N_2R_2$	[R]C[C@H](Cc1c[nH]c2c1cccc2)N[R]







207	aMeY01	 $C_{11}H_{13}NO_2R_2$	C[C@](Cc(cc1)ccc1OC)(C([R])=O)N[R]
208	3OMeY01	 $C_{11}H_{13}NO_3R_2$	COc(ccc(C[C@@H](C([R])=O)N[R])c1)c1OC
209			
210	dAEF	 $C_{11}H_{14}N_2O_2R_2$	NCCOc1ccc(C[C@H](C([R])=O)N[R])cc1
211	K(COBu)	 $C_{11}H_{20}N_2O_2R_2$	CCCCC(NCCCC[C@@H](C([R])=O)N[R])=O
212	K(COiBu)	 $C_{11}H_{20}N_2O_2R_2$	CCC(C)C(NCCCC[C@@H](C([R])=O)N[R])=O CC(C)CC(NCCCC[C@@H](C([R])=O)N[R])=O




213	K(COtBu)	 $C_{11}H_{20}N_2O_2R_2$	CC(C)(C)C(NCCCC[C@@H](C([R])=O)N[R])=O
214	succiniccarn	 $C_{11}H_{20}N_2O_4R^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCC([R])=O)=O
215	Aun	 $C_{11}H_{21}NOR_2$	O=C(CCCCCCCCCCN[R])[R]
216	5BrW, 5BrTrp	 $C_{11}H_9BrN_2OR_2$	O=C([C@H](Cc1c[nH]c(cc2)c1cc2Br)N[R])[R]







217	7BrTrp, 7BrW	 $C_{11}H_9BrN_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2Br)N[R])[R]
218	7ClW, 7ClTrp	 $C_{11}H_9ClN_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2Cl)N[R])[R]
219	5FW, 5FTrp	 $C_{11}H_9FN_2OR_2$	O=C([C@H](Cc1c[nH]c(cc2)c1cc2F)N[R])[R]
220	7FW, 7FTrp	 $C_{11}H_9FN_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2F)N[R])[R]






221	BT, L-3-Benzothienylalanine	 $C_{11}H_9NOSR_2$	O=C([C@H](Cc1csc2c1cccc2)N[R])[R]
222	2Quin 6OHQui	 $C_{12}H_{10}N_2O_2R_2$	Oc1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2n1
223	7CF2H	 $C_{12}H_{10}F_2N_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2C(F)F)N[R])[R]
224	3QuinolAla	 $C_{12}H_{10}N_2OR_2$	O=C([C@H](Cc1cc2ccccc2nc1)N[R])[R]




225	2MeTrp, 2MeW	 $C_{12}H_{12}N_2OR_2$	Cc1c(C[C@@H](C([R])=O)N[R])c(cccc2)c2[nH]1
226	5MeW, 5MeTrp	 $C_{12}H_{12}N_2OR_2$	Cc(cc1)cc2c1[nH]cc2C[C@@H](C([R])=O)N[R]
227	7MeW, 7(MeW), 7MeTrp	 $C_{12}H_{12}N_2OR_2$	Cc1cccc2c1[nH]cc2C[C@@H](C([R])=O)N[R] Cc1cccc2c1[nH]cc2C[C@@H](C=O)N
228	aMeW	 $C_{12}H_{12}N_2OR_2$	C[C@](Cc1c[nH]c2c1cccc2)(C([R])=O)N[R]





229	dW7Me, 7Mew, 7MedW	 $C_{12}H_{12}N_2OR_2$	Cc1cccc2c1[nH]cc2C[C@H](C([R])=O)N[R]
230	Y(OTzl)	 $C_{12}H_{12}N_4O_2R_2$	O=C([C@H](Cc(cc1)ccc1OCc1c[nH]nn1)N[R])[R]
231	4AllylY	 $C_{12}H_{13}NO_2R_2$	C=CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
232	4AllylF	 $C_{12}H_{13}NOR_2$	C=CCc1ccc(C[C@@H](C([R])=O)N[R])cc1
233	meW, NMeW, NMeTrp, N-Methyl-Tryptophan	 $C_{12}H_{14}N_2O_2$	CN[C@@H](Cc1c[nH]c2c1cccc2)C(O)=O
	AEF(G)		[R]C([C@H](CC1=CC=C(OCCNC(N)=N)C=C1)N[R])=O
234	AAMPhe	 $C_{12}H_{14}N_2O_2R_2$	CC(NCc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O CC(NCc1ccc(C[C@@H](C=O)N)cc1)=O






235	hC(pXyl)	 $C_{12}H_{14}NOSR_3$	O=C([C@H](CCS Cc1ccc(C[R])cc1) N[R])[R]
236	AEF(NMe(2))	 $C_{12}H_{15}N_2O_2R_3$	CN(CCOc1ccc(C[C@@H](C([R])= O)N[R])cc1)[R]
237	DY02	 $C_{12}H_{15}NO_3R_2$	C[C@@](Cc(cc1) cc(OC)c1OC)(C([R])=O)N[R]






238	Y02	 $C_{12}H_{15}NO_3R_2$	C[C@](Cc(cc1)cc(OC)c1OC)(C([R])=O)N[R]
239	AEF(NMe)	 $C_{12}H_{16}N_2O_2R_2$	CNCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
240	NMeAEF	 $C_{12}H_{16}N_2O_2R_2$	CN([C@@H](Cc(cc1)ccc1OCCN)C([R])=O)[R] CN[C@@H](Cc(cc1)ccc1OCCN)C=O
241	aMeAEF	 $C_{12}H_{16}N_2O_2R_2$	C[C@](Cc(cc1)ccc1OCCN)(C([R])=O)N[R] CC(C)(C)OC(NCCOc1ccc(C[C@@](C)(C([R])=O)N[R])cc1)=O
242	bMeAEF	 $C_{12}H_{16}N_2O_2R_2$	CC([C@@H](C([R])=O)N[R])c(cc1)ccc1OCCN
243	bMeAEF(2S,3R*), bMeAEF(2S3R*) (*pure but configuration unknown)	 $C_{12}H_{16}N_2O_2R_2$	C[C@@H]([C@@H](C([R])=O)N[R])c(cc1)ccc1OCCN







244	bMeAEF(2S3S*), bMeAEF(2S,3S*) (*pure but configuration unknown)	 $C_{12}H_{16}N_2O_2R_2$	C[C@H]([C@@H](C([R])=O)N[R])c(cc1)ccc1OCCN
245	K(Morph)	 $C_{12}H_{21}N_3O_3R_2$	O=C(CN1CCOCC1)NCCCC[C@@H](C([R])=O)N[R]
246	K(COPent)	 $C_{12}H_{22}N_2O_2R_2$	CCCCCC(NCCCC[C@@H](C([R])=O)N[R])=O
247	aMeK(Boc)	 $C_{12}H_{22}N_2O_3R_2$	CC(C)(C)OC(NCCCC[C@@](C)(C([R])=O)N[R])=O
248	E(C)	 $C_{12}H_{22}N_3O_4R_2^+$	C[N+](C)(C)C[C@H](CC(O)=O)NC(CC[C@@H](C([R])=O)N[R])=O







249	E(c) (R)-2-((R)-4-amino-4-carboxybutanamido)-3-carboxy-N,N,N-trimethylpropan-1-aminium, E(c)	 $C_{12}H_{22}N_3O_4R_2^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CC[C@@H](C([R])=O)N[R])=O
250	e(C), dE(C)	 $C_{12}H_{22}N_3O_4R_2^+$	C[N+](C)(C)C[C@H](CC(O)=O)NC(CC[C@H](C([R])=O)N[R])=O
251	e(c), dE(c)	 $C_{12}H_{22}N_3O_4R_2^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CC[C@H](C([R])=O)N[R])=O








252	dK(SP6), k(SP6)	 $C_{12}H_{25}N_4O_2R_2^+$	C[N+](C)(CCN)CC(NCCCC[C@H](C([R])=O)N[R])=O
253	7CF3W, (S)-2-amino-3-(7-(trifluoromethyl)-1H-indol-3-yl)propanoic acid	 $C_{12}H_9F_3N_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2C(F)(F)F)N[R])[R] N[C@@H](Cc1c[nH]c2c(C(F)(F)F)cccc12)C=O N[C@@H](Cc1c[nH]c2c(C(F)(F)F)cccc12)C=O
254	5Br2Nal	 $C_{13}H_{10}BrNOR_2$	O=C([C@H](Cc1cc2cccc(Br)c2cc1)N[R])[R]
255	6Br2Nal	 $C_{13}H_{10}BrNOR_2$	O=C([C@H](Cc(ccc1c2)cc1ccc2Br)N[R])[R]





256	7Br2Nal	 $C_{13}H_{10}BrNOR_2$	O=C([C@H](Cc1cc2cc(Br)ccc2cc1)N[R])[R]
257	6F2Nal	 $C_{13}H_{10}FNOR_2$	O=C([C@H](Cc(ccc1c2)cc1ccc2F)N[R])[R] N[C@@H](Cc1ccc(cc(cc2)F)c2c1)C=O
258	7OH2Nal	 $C_{13}H_{11}NO_2R_2$	Oc1ccc(ccc(C[C@@H](C([R])=O)N[R1])c2)c2c1
259	1Nal, Nal,	 $C_{13}H_{11}NOR_2$	O=C([C@H](Cc1cccc2ccccc12)N[R])[R]
260	2Nal	 $C_{13}H_{11}NOR_2$	O=C([C@H](Cc1cc2ccccc2cc1)N[R])[R]






261	dNal, d2Nal	 $C_{13}H_{11}NOR_2$	O=C([C@@H](Cc1cc2ccccc2cc1)N[R])[R]
262	6MeQui	 $C_{13}H_{12}N_2O_2R_2$	COc1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2n1
263	D(N5In)	 $C_{13}H_{13}N_3O_2R_2$	O=C(C[C@@H](C([R])=O)N[R])NCc(cc1)cc2c1[nH]cc2
264	psi2Nal	 $C_{13}H_{13}NR_2$	[R]C[C@H](Cc1cc2ccccc2cc1)N[R]
265	7EtW	 $C_{13}H_{14}N_2OR_2$	CCc1cccc2c1[nH]cc2C[C@@H](C([R])=O)N[R]






266	F(4TzlMME)	 $C_{13}H_{14}N_4O_2R_2$	COCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1
267	AcAEF	 $C_{13}H_{16}N_2O_3R_2$	CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
268	tButY, Y(tBu)	 $C_{13}H_{17}NO_2R_2$	CC(C)(C)Oc1ccc(C[C@H](C([R])=O)N[R])cc1
269	AEF(Me)2	 $C_{13}H_{18}N_2O_2R_2$	CN(C)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
270	Z, Amp	 $C_{13}H_{18}N_2OR_2$	CC(C)c1ccc(C[C@@H](C([R])=O)NCN[R])cc1
271	5amido2Nal	 $C_{14}H_{12}N_2O_2R_2$	NC(c1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1)=O






272	6amido2Nal	 $C_{14}H_{12}N_2O_2R_2$	NC(c1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2c1)=O
273	5OMe2Nal	 $C_{14}H_{13}NO_2R_2$	COc1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
274	6OMe2Nal	 $C_{14}H_{13}NO_2R_2$	COc1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2c1
275	5Me2Nal	 $C_{14}H_{13}NOR_2$	Cc1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
276	NMe2NAL	 $C_{14}H_{13}NOR_2$	CN([C@@H](Cc1cc2ccccc2cc1)C([R])=O)[R] CN[C@@H](Cc1cc2ccccc2cc1)C=O
277	aMe2Nal	 $C_{14}H_{13}NOR_2$	C[C@](Cc1cc2ccccc2cc1)(C([R])=O)N[R]





278	bMe2Nal(2S,3R), bMe2Nal(2S3R)	 $C_{14}H_{13}NOR_2$	C[C@@H]([C@@H](C([R])=O)N[R])c1cc2ccccc2cc1
279	bMe2Nal(2S3S), bMe2Nal(2S3R)	 $C_{14}H_{13}NOR_2$	C[C@H]([C@@H](C([R])=O)N[R])c1cc2ccccc2cc1
280	AEF(EtCO)	 $C_{14}H_{18}N_2O_3R_2$	CCC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
281	NMeY(tBu)	 $C_{14}H_{19}NO_2R_2$	CC(C)(C)Oc1ccc(C[C@H](C([R])=O)N(C)[R])cc1
282	AEF(NMe3)	 $C_{14}H_{21}N_2O_2R_2^+$	C[N+](C)(C)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
283	6O(COCF3)2Nal	 $C_{15}H_{10}F_3NO_3R_2$	O=C([C@H](Cc(ccc1c2)cc1ccc2OC(C(F)(F)F)=O)N[R])[R]
284	BIF	 $C_{15}H_{13}NOR_2$	O=C([C@H](Cc(cc1)ccc1-c1ccccc1)N[R])[R]





285	DiPhAla	 $C_{15}H_{13}NOR_2$	O=C([C@H](C(c1ccccc1)c1ccccc1)N[R])[R]
286	5Et2Nal	 $C_{15}H_{15}NOR_2$	CCc1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
287	CMF	 $C_{15}H_{19}NO_4R_2$	CC(C)(C)OC(COc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
288	F(4TzlTMA1)	 $C_{15}H_{20}N_5OR_2^+$	C[N+](C)(C)Cc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1





289	PiperazinequatF	 $C_{15}H_{22}N_3OR_2^+$	C[N+](C)(CC1)CCN1c1ccc(C[C@@H](C([R])=O)N[R])cc1
290	TMA3F	 $C_{15}H_{23}N_2O_2R_2^+$	C[N+](C)(C)CCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
291	TMA4F	 $C_{15}H_{23}N_2O_2R_2^+$	C[NH+](C)CCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
292	K5cpa, K(5cpa), K(5cpaCO)	 $C_{15}H_{30}N_3O_2R_2^+$	C[N+](C)(C)CCCCCC(NCCCC[C@@H](C([R])=O)N[R])=O
293	dK(5cpa), k(5cpa), k(5cpaCO)	 $C_{15}H_{30}N_3O_2R_2^+$	C[N+](C)(C)CCCCCC(NCCCC[C@H](C([R])=O)N[R])=O





294	2Nal6(3pyrazole)	 $C_{16}H_{13}N_3OR_2$	O=C([C@H](Cc(ccc1c2)cc1ccc2-c1c[nH]nc1)N[R])[R]
295	7PyrTrp	 $C_{16}H_{13}N_3OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c1ccncc1)N[R])[R]
296	4BzF	 $C_{16}H_{13}NO_2R_2$	O=C([C@H](Cc(cc1)ccc1C(c1ccccc1)=O)N[R])[R]
297	aMeBiF	 $C_{16}H_{15}NOR_2$	C[C@](Cc(cc1)ccc1-c1ccccc1)(C([R])=O)N[R]
298	NPyEF	 $C_{16}H_{17}N_2O_2R_2^+$	O=C([C@H](Cc(cc1)ccc1OCC[n+]1ccccc1)N[R])[R]





299	5iPr2Nal	 $C_{16}H_{17}NOR_2$	CC(C)c1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
300	TetraFAEF(Boc)	 $C_{16}H_{18}F_4N_2O_4R_2$	CC(C)(C)OC(NCCOc(c(F)c(c(C[C@@H](C([R])=O)N[R])c1F)F)c1F)=O
301	4TMABYF	 $C_{16}H_{21}N_2OR_2^+$	C[N+](C)(C)CCC#Cc1ccc(C[C@@H](C([R])=O)N[R])cc1
302	AEF(Boc)	 $C_{16}H_{22}N_2O_4R_2$	CC(C)(C)OC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
303	F(4TzlTMA2)	 $C_{16}H_{22}N_5OR_2^+$	C[N+](C)(C)CCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1




304	DMPMF	 $C_{16}H_{23}N_2O_3R_2^+$	C[N+]1(C)CC(COc2ccc(C[C@@H](C([R])=O)N[R])cc2)OCC1
305	KDde, K(Dde)	 $C_{16}H_{24}N_2O_3R_2$	CC(C)(CC(C1=C(C)NCCCC[C@@H](C([R])=O)N[R])=O)CC1=O
306	dKDde, k(Dde), dK(Dde)	 $C_{16}H_{24}N_2O_3R_2$	CC(C)(CC(C1=C(C)NCCCC[C@H](C([R])=O)N[R])=O)CC1=O
307	Y(OEOXIMECh)	 $C_{16}H_{24}N_3O_3R_2^+$	C[N+](C)(C)CCO/N=C/COc1ccc(C[C@@H](C([R])=O)N[R])cc1





308	Y(OZOXIMECh)	 $C_{16}H_{24}N_3O_3R_2^+$	C[N+](C)(C)CCO/N=C\COc1ccc(C[C@@H](C([R])=O)N[R])cc1
309	AEF(NHCh)	 $C_{16}H_{26}N_3O_2R_2^+$	C[N+](C)(C)CCNCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
310	K(Biotina), K(Biotin)	 $C_{16}H_{26}N_4O_3SR_2$	O=C(CCCC[C@H]([C@@H]1N2)SC[C@H]1NC2=O)NCCCC[C@@H](C([R])=O)N[R]
311	K(DAGSuc)	 $C_{16}H_{27}N_3O_8R_2$	OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1NC(CCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O







312	k(DAGSuc), dK(DAGSuc)	 $C_{16}H_{27}N_3O_8R_2$	OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1NC(CCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
313	DOTA	 $C_{16}H_{27}N_4O_7R$	OC(CN1CCN(CC(O)=O)CCN(CC([R])=O)CCN(CC(O)=O)CC1)=O
314	Dab(NMeCarn)	 $C_{16}H_{29}N_4O_5R_2^+$	CN(CC[C@@H](C([R])=O)N[R])C(CCC(N[C@@H](CC(O)=O)C[N+](C)(C)C)=O)=O
315	Dab(NMecarn)	 $C_{16}H_{29}N_4O_5R_2^+$	CN(CC[C@@H](C([R])=O)N[R])C(CCC(N[C@H](CC(O)=O)C[N+](C)(C)C)=O)=O





316	orn(d)	 $C_{16}H_{29}N_4O_5R_2^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCC(NCCC[C@H](C([R])=O)N[R])=O)=O
317	2Nal6((5CF3)3pyrazole)	 $C_{17}H_{12}F_3N_3OR_2$	O=C([C@H](Cc(ccc1c2)cc1ccc2-c1c[nH]nc1C(F)(F)F)N[R])[R]
318	7(2ClPh)W	 $C_{17}H_{13}ClN_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c(cccc1)c1Cl)N[R])[R]
319	TMAPF		C[N+](C)(CCCCCOc1ccc(C[C@H](N[R])C([R])=O)cc1)C
320	7(2OMe5Pyr)W	 $C_{17}H_{15}N_3O_2R_2$	COc(cc1)ncc1-c1cccc2c1[nH]cc2C[C@@H](C([R])=O)N[R]







321	W-7Ph, 7-phenyl-L-tryptophan	 $C_{17}H_{16}N_2O$	N[C@@H](Cc1c[nH]c2c1cccc2-c1ccccc1)C=O
322	5OH2Nal	 $C_{17}H_{19}NO_2R_2$	CC(C)(C)Oc1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
323	5tBu2Nal	$C_{17}H_{19}NOR_2$	CC(C)(C)c1c(ccc(C[C@@H](C([R])=O)N[R])c2)c2ccc1
324	hFTMAPF	 $C_{17}H_{21}F_6N_2O_2R_2^+$	C[N+](C)(C)CC(C(C(COc1ccc(C[C@@H](C([R])=O)N[R])cc1)(F)F)(F)F)(F)F
325	F(4TzlTMA3)	 $C_{17}H_{24}N_5OR_2^+$	C[N+](C)(C)CCCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1

326	DMMMF	 $C_{17}H_{25}N_2O_2R_2^+$	C[N+]1(C)CC(COc2ccc(C[C@@H](C([R])=O)N[R])cc2)CCC1
327	MMoEF	 $C_{17}H_{25}N_2O_2R_2^+$	C[N+]1(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)CCCCC1
328	MMoPF	 $C_{17}H_{25}N_2O_3R_2^+$	C[N+]1(CCCOc2ccc(C[C@H](C([R])=O)N[R])cc2)CCOCC1

329	AEF(MEP)	 $C_{17}H_{26}N_2O_4R_2$	COCCOCCCNCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
330	4DMPzEF	 $C_{17}H_{26}N_3O_2R_2^+$	C[N+]1(C)CCN(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)CC1 C[N+]1(C)CCN(CCOc2ccc(C[C@@H](C=O)N)cc2)CC1
331	TMAPF	 $C_{17}H_{27}N_2O_2R_2^+$	C[N+](C)(C)CCCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1 C[N+](C)(C)CCCCCOc1ccc(C[C@@H](C=O)N)cc1
332	K(D), KCar	 $C_{17}H_{31}N_4O_5R_2^+$	C[N+](C)(C)C[C@H](CC(O)=O)NC(CCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O

333	K(d), KdCar	 $C_{17}H_{31}N_4O_5R_2^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O
334	k(D), dKCar	 $C_{17}H_{31}N_4O_5R_2^+$	C[N+](C)(C)C[C@H](CC(O)=O)NC(CCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
335	k(d), dKdCar	 $C_{17}H_{31}N_4O_5R_2^+$	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
336	7(3CF3TAZP)W	 $C_{18}H_{12}F_3N_5OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c1cc2nnc(C(F)(F)F)n2cc1)N[R])[R]
337	7(4OCF3Ph)W	 $C_{18}H_{13}F_3N_2O_2R_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c(cc1)ccc1OC(F)(F)F)N[R])[R]
338	7(4CF3Ph)W	 $C_{18}H_{13}F_3N_2OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c1ccc(C(F)(F)F)cc1)N[R])[R]

339	7(7ImidPyr)W	 $C_{18}H_{14}N_4OR_2$	O=C([C@H](Cc1c[nH]c2c1cccc2-c1cc2nccn2cc1)N[R])[R]
340	Y(C9OH)	 $C_{18}H_{25}NO_4R_2$	OC(CCCCCCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
341	Y(OTzlCh)	 $C_{18}H_{26}N_5O_2R_2^+$	C[N+](C)(C)CCc1cn(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1
342	4DMPEF	 $C_{18}H_{27}N_2O_2R_2^+$	C[N+]1(C)CCC(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)CC1 C[N+]1(C)CCC(CCOc2ccc(C[C@@H](C=O)N)cc2)CC1

343	AEF(AcCh)	 $C_{18}H_{28}N_3O_3R_2^+$	CC(N(CC[N+](C)(C)C)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
344	TMA6F	 $C_{18}H_{29}N_2O_2R_2^+$	C[N+](C)(C)CCCCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
345	AEF(MePrpa)	 $C_{18}H_{30}N_3O_2R_2^+$	CN(CCC[N+](C)(C)C)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
346	2Nal6(Ph2OH)	 $C_{19}H_{15}NO_2R_2$	Oc(cccc1)c1-c1ccc(cc(C[C@@H](C([R])=O)N[R])cc2)c2c1
347	7(3NAcPh)W	 $C_{19}H_{17}N_3O_2R_2$	CC(Nc1cccc(-c2cccc3c2[nH]cc3C[C@@H](C([R])=O)N[R])c1)=O
348	7(4NAcPh)W	 $C_{19}H_{17}N_3O_2R_2$	CC(Nc(cc1)ccc1-c1cccc2c1[nH]cc2C[C@@H](C([R])=O)N[R])=O


















349	4PipPhe	$C_{19}H_{26}N_2O_3R_2$	CC(C)(C)OC(N(CC1)CCC1c1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
350	a	 $C_{19}H_{29}N_2O_2R_2^+$	C[N+](C)(C)[C@H]1CC[C@H](COc2ccc(C[C@@H](C([R])=O)N[R])cc2)CC1






Table 2D. Peg Moeties and Peg-modified Monomers






1	Structure	Names and Synonyms	Smiles Structure
2	C7H15NO3	CON(MePEG2)	CN(CCOCCOC)C=O
3	C7H14O4	mPEG3CO	COCCOCCOCC=O
4	C14H28O7	mPEG6CO	COCCOCCOCCOCCOCCOCCC=O
5	C21H36N3O5+	AEFNMePEG3a, AEF(NHcPEG3a)	C[N+](C)(C)CCOCCOCCC(NCCOc1ccc(C[C@@H](C=O)N)cc1)=O
6	C24H42N2O8	AEFNmPEG6, AEF(NmPEG6)	COCCOCCOCCOCCOCCOCCNCCOc1ccc(C[C@@H](C=O)N)cc1




7	 C22H37N4O8SR	BiotinPEG2PEG2, Biotin(PEG2PEG2)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCC(NCCOCCOCC([R])=O)=O
8	 C41H73N5O13R2	K(PEG2PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
9	 C36H62N6O13SR2	K(PEG6gEBiotin)	OC([C@H](CCC(NCCOCCOCCOCCOCCOCCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)NC(CCCC[C@H]([C@@H]1N2)SC[C@H]1NC2=O)=O)=O
10	 C57H98N4O14R2	K(PEG6gEVitE)	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O
11	 C21H34N3O4R2+	MPzPEG3F	CN1CC[N+](C)(CCOCCOCCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)CC1




12	 C27H47N2O4R2+	TBAPEG3F	CCCC[N+](CCCC)(CCCC)CCOCCOCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
13	 C23H36N5O5R2+	Y(OTzlPEG3a)	C[N+](C)(C)CCOCCOCCOCCOCc1cn(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1
14	 C25H40N5O6R2+	Y(OTzlPEG4a)	C[N+](C)(C)CCOCCOCCOCCOCCOCc1cn(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1
15	 C35H66BrN3O15R2	k(PEG6Biotin), dK(PEG6Biotin)	O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@@H](C([R])=O)N[R]
16	 C52H91N3O11R2	k(dPEG12Ac), dK(dPEG12Ac)	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
17	 C16H25N2O3R2+	mPEG2TMA2F	C[N+](C)(CCOC)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
18	 C20H33N2O4R2+	mPEG3TMA4F	C[N+](C)(CCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)CCOCCOC





19	 C16H25N2O3R2+	C[N+](C)(C)CCOCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
20	 C10H21N2O3R2+	C[N+](C)(C)CCOCCOC[C@@H](C([R])=O)N[R]
21	 C10H21N2O3R2+	C[N+](C)(C)CCOCCOCC(C([R])=O)N[R]
22	 C17H32NO8R	CC(NCCOCCOCCOCCOCCOCCOCCC([R])=O)=O





23	 C17H28N3O5SR	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCC([R])=O
24	 C17H31BrNO8R	O=C(CBr)NCCOCCOCCOCCOCCOCCOCCC([R])=O
25	 C17H36NO8R	COCCOCCOCCOCCOCCOCCOCCOCCOCCN[R]
26	 C14H28N3O4R2+	CN(CC[C@@H](C([R])=O)N[R])C(COCCOCC[N+](C)(C)C)=O
27	 C15H30N3O4R2+	CN(CC[C@@H](C([R])=O)N[R])C(CCOCCOCC[N+](C)(C)C)=O




28	 C14H28N3O4R2+	C[N+](C)(C)CCOCCOCCNC(CC[C@@H](C([R])=O)N[R])=O
29	 C17H34N3O4R2+	CN(CCCC[C@@H](C([R])=O)N[R])C(CCOCCOCC[N+](C)(C)C)=O
30	 C13H27N2O3R2+	C[N+](C)(CCCC[C@@H](C([R])=O)N[R])CCOCCOC
31	 C11H18N4O4R2	OCCOCCOCCn1nnc(C[C@@H](C([R])=O)N[R])c1
32	 C12H20N4O4R2	COCCOCCOCCn1nnc(C[C@@H](C([R])=O)N[R])c1




33	 C12H22N5O2R2+	C[N+](C)(CCc1cn(C[C@@H](C([R])=O)N[R])nn1)CCOC
34	 C16H30N5O4R2+	C[N+](C)(CCc1cn(C[C@@H](C([R])=O)N[R])nn1)CCOCCOCCOC
35	 C10H21NO3R+	C[N+](C)(C)CCOCCOCCC([R])=O



36	 C8H16N2O3R2	CNCCOCCOC[C@H](C([R])=O)N[R]	
37	 C37H49N3O10S2R+	(SulfoCy3dPEG2)	CC1(C)c(cc(cc2)S(O)(=O)=O)c2[N+](C)=C1/C=C/C=C(/C1(C)C)\N(CCCCCC(NCCOCCOCCC([R])=O)=O)c(cc2)c1cc2S(O)(=O)=O
38	 C39H53N3O11S2R+	(SulfoCy3dPEG3)	CC1(C)c(cc(cc2)S(O)(=O)=O)c2[N+](C)=C1/C=C/C=C(/C1(C)C)\N(CCCCCC(NCCOCCOCCOCCC([R])=O)=O)c(cc2)c1cc2S(O)(=O)=O





39	 C28H49N5O13R+	(d)gEPEG2PEG2	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O
40	 C29H57NO14	AcdPEG12CO	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC=O)=O
41	 C23H45NO11	AcdPEG9CO	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC=O)=O
42	 C42H75N4O15R	AEEP(PEG2PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCOCCOCCC([R])=O)=O)=O)=O)C(O)=O)=O)=O
43	 C47H86N7O14R2+	AEEPPEG2PEG2gEC18OH, k(PEG2Sp6PEG2gEC18OH), dK(PEG2Sp6PEG2gEC18OH)	C[N+](C)(CCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O





44	 C26H46N4O5R2+2	AEF((Ch)cPEG3a)	C[N+](C)(C)CCN(CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)C(CCOCCOCC[N+](C)(C)C)=O
45	 C25H46N4O4R2+2	AEF(BisPEG2a)(RS) AEF(BisPEG2a)(S*) (The RS and the S* indicates the stereochemistry)	C[N+](C)(C)CCOCCN(CCOCC[N+](C)(C)C)CCOc1ccc(CC(C([R])=O)N[R])cc1
46	 C21H34N3O5R2+	AEF(NMePEG3a), AEF(NMecPEG3aCO)	C[N+](C)(C)CCOCCOCCC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
47	 C20H33N2O5R2+	AEF(NMe2mPEG3)	C[N+](C)(CCOCCOCCOC)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1





48	 C26H45N2O8R2+	AEF(NMeBismPEG3)	C[N+](CCOCCOCCOC)(CCOCCOCCOC)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
49	 C19H32N3O3R2+	AEF(NMePEG2a)	CN(CCOCC[N+](C)(C)C)CCOc1ccc(C[C@H](C([R])=O)N[R])cc1
50	 C24H40N2O8R2	AEF(NmPEG6)	COCCOCCOCCOCCOCCOCCNCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
51	 C44H71N5O14R2	AEF(PEG2PEG2gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O)=O)=O)C(O)=O)=O)=O






52	 C46H75N5O14R2	AEF(PEG2PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O)=O)=O)C(O)=O)=O)=O
53	 C18H30N3O3R2+	AEF(Peg2a), AEF(PEG2a)	C[N+](C)(C)CCOCCNCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
54	 C67H119N6O22R2+	AEF(SP6PEG12gEC18OH)	C[N+](C)(CCNC(CCOCCOCCOCCOCCCOCCOCCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
55	 C69H123N6O22R2+	AEF(SP6PEG12gEC20OH)	C[N+](C)(CCNC(CCOCCOCCOCCOCCCOCCOCCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
56	 C52H88N7O15R2+	AEF(SP6PEG2PEG2gEC18OH)	C[N+](C)(CCNC(CCCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O






57	 C54H92N7O15R2+	AEF(SP6PEG2PEG2gEC20OH)	C[N+](C)(CCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
58	C55H95N6O16R2+	AEF(SP6PEG6gEC18OH)	C[N+](C)(CCNC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
59	C57H99N6O16R2+	AEF(SP6PEG6gEC20OH)	C[N+](C)(CCNC(COCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CC(NCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
60	 C20H35N3O3R2+2	AEF(aPEG2a)	C[N+](C)(C)CCOCC[N+](C)(C)CCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
61	 C35H62N4O10R2	k(PEG2gEC18OH), dK(PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O






62	 C44H80N4O14R2	k(PEG6gEC18OH), dK(PEG6gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
63	 C47H86N7O14R2+	, k(Sp6PEG2PEG2gEC18OH), dK(Sp6PEG2PEG2gEC18OH)	C[N+](C)(CCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CC(NCCCC[C@H](C([R])=O)N[R])=O
64	 C16H25N2O3R2+	APEG2F	C[N+](C)(C)CCOCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1
65	 C10H21N2O3R2+	APEG2ser	C[N+](C)(C)CCOCCOC[C@@H](C([R])=O)N[R]






66	 C10H21N2O3R2+	APEG2Ser(R*) APEG2Ser(S*)	C[N+](C)(C)CCOCCOCC(C([R])=O)N[R]
67	 C18H29N2O4R2+	APEG3F	C[N+](C)(C)CCOCCOCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1 C[N+](C)(C)CCOCCOCCOc1ccc(C[C@@H](C=O)N)cc1
68	 C17H32NO8R	AcdPEG6CO	CC(NCCOCCOCCOCCOCCOCCOCCC([R])=O)=O
69	 C21H36N3O7SR	BiotinPEG4CO, Biotin(PEG4CO), Biotin(PEG4)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCOCCOCCC([R])=O






70	 C17H28N3O5SR	Biotinyl(dPEG2), Biotin(dPEG2)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCC([R])=O
71	 C19H32N3O6SR	Biotinyl(dPEG3), Biotin(dPEG3)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCOCCC([R])=O
72	 C29H55BrNO14R	BrAcdPEG12CO	O=C(CBr)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC([R])=O
73	 C17H31BrNO8R	BrAcdPEG6CO	O=C(CBr)NCCOCCOCCOCCOCCOCCOCCC([R])=O





74	 C23H43BrNO11R	BrAcdPEG9CO	O=C(CBr)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC([R])=O
75	 C29H52N3O10R	C12gEPEG2PEG2, C12gEPEG2PEG2CO	CCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O
76	 C31H56N3O10R	C14gEPEG2PEG2, C14gEPEG2PEG2CO	CCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O
77	 C50H93N2O19R	C18OHgEPEG12, HOC18gEPEG12	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC([R])=O)=O)C(O)=O)=O)=O
78	 C35H62N3O12R	C18OHgEPEG2PEG2, HOC18gEPEG2PEG2PEG2PEG2gEC18OH	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC=O)=O)=O)C(O)=O)=O)=O
79	 C41H75N5O13R+	C18OHgEPEG2PEG2SP6, HOC18gEPEG2PEG2SP6	C[N+](C)(CCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)CC([R])=O





80	 C41H75N5O13R+	C18OHgEPEG2SP6PEG2, HOC18gEPEG2SP6PEG2	C[N+](C)(CCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCC(O)=O))=O)=O)=O)CC(NCCOCCOCC([R])=O)=O
81	 C38H69N2O13R	C18OHgEPEG6, HOC18gEPEG6	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCC([R])=O)=O)C(O)=O)=O)=O
82	 C37H66N3O12R	C20OHgEPEG2PEG2, HOC20gEPEG2PEG2	OC(CCCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O
83	 C37H68N3O10R	C20gEPEG2PEG2	CCCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O
84	 C10H22N2O3R+	CO(NHPEG3a) CON(PEG3a) CONHPEG3a	C[N+](C)(C)CCOCCOCCNC([R])=O
85	 C50H94N3O19R	CO(PEG12gEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC([R])=O)=O)C(O)=O)=O)=O
86	 C36H65N4O12R	CO(PEG2PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCCNC([R])=O)=O)=O)C(O)=O)=O)=O






87	 C17H36NO8R	CO(mPEG8)	COCCOCCOCCOCCOCCOCCOCCOCCN[R]
88	 C7H14NO3R	CON(MePEG2)	CN(CCOCCOC)C([R])=O
89	 C9H22N2O2R+	CONH(PEG3a)	C[N+](C)(C)CCOCCOCCN[R]
90	 C14H30N2O5R+	CONH(PEG5a)	C[N+](C)(C)CCOCCOCCOCCOCCNC([R])=O
91	 C6H12NO3R	CONH(mPEG2)	COCCOCCNC([R])=O





92	 C33H58N3O12R	PEG2PEG2gEC16OH	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC=O)=O)=O)C(O)=O)=O)=O
93	 C23H40N5O10R	DOTA(dPEG2)	OC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(NCCOCCOCCC([R])=O)=O)CC1)=O
94	 C25H44N5O11R	DOTA(dPEG3)	OC(CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(NCCOCCOCCOCCC([R])=O)=O)CC1)=O
95	 C19H36N2O8R2	Dab(NMeCOmPEG6)	CN(CC[C@@H](C([R])=O)N[R])C(CCOCCOCCOCCOCCOCCOC)=O
96	 C14H28N3O4R2+	Dab(NMecPEG2aCO), Dab(NMecPEG2a)	CN(CC[C@@H](C([R])=O)N[R])C(COCCOCC[N+](C)(C)C)=O






97	 C15H30N3O4R2+	Dab(NMecPEG3aCO), Dab(NMecPEG3a)	CN(CC[C@@H](C([R])=O)N[R])C(CCOCCOCC[N+](C)(C)C)=O
98	 C19H38N3O6R2+	Dab(NMecPEG5aCO), Dab(NMecPEG5a)	CN(CC[C@@H](C([R])=O)N[R])C(CCOCCOCCOCCOCC[N+](C)(C)C)=O
99	 C14H28N3O4R2+	E(COcPEG3a))	C[N+](C)(C)CCOCCOCCNC(CC[C@@H](C([R])=O)N[R])=O
100	 C20H30N5O2R2+	F(4TzlDMA4mPEG)	C[N+](C)(CCCCc1cn(-c2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1)CCOC
101	 C32H33N2O10SR	FITCPEG4CO	Oc1cc(Oc2c(C3(c(cc4)c5cc4NC(NCCOCCOCCOCCOCCC([R])=O)=S)OC5=O)ccc(O)c2)c3cc1






102	 C48H72N11O22R	FlagTag(dPEG2)	NCCCC[C@@H](C(NCCOCCOCCC([R])=O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](Cc(cc1)ccc1O)NC([C@H](CC(O)=O)N)=O)=O)=O)=O)=O)=O)=O
103	 C50H76N11O23R	FlagTag(dPEG3)	NCCCC[C@@H](C(NCCOCCOCCOCCC([R])=O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](Cc(cc1)ccc1O)NC([C@H](CC(O)=O)N)=O)=O)=O)=O)=O)=O)=O)=O
104	 C27H46N3O12R	HOC10gEPEG2PEG2, HOC10gEPEG2PEG2CO	OC(CCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC([R])=O)=O)=O)C(O)=O)=O)=O OC(CCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC=O)=O)=O)C(O)=O)=O)=O
105	 C38H67N5O13R2	HOC16gEPEG2PEG2orn, HOC16OHgEPEG2PEG2orn(2)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(N[C@H](CCCN[R])C([R])=O)=O)=O)=O)C(O)=O)=O)=O NCCC[C@H](C=O)NC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O






106	 C27H47N5O8SR2	K(BiotinPEG4)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O
107	 C38H44N4O11SR2	K(FITCPEG4)	Oc1cc(Oc2c(C3(c(cc4)c5cc4NC(NCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=S)OC5=O)ccc(O)c2)c3cc1
108	 C21H42N3O6R2+	K(NMeCOPEG4N+Me3)	CN(CCCC[C@@H](C([R])=O)N[R])C(CCOCCOCCOCCOCC[N+](C)(C)C)=O
109	 C21H40N2O8R2	K(NMeCOmPEG6)	CN(CCCC[C@@H](C([R])=O)N[R])C(CCOCCOCCOCCOCCOC)=O







110	 $C_{17}H_{34}N_3O_4R_2^+$	K(NMePEG3a), K(NMecPEG3a), K(NMecPEG3aCO)	CN(CCCC[C@@H](C([R])=O)N[R])C(CCOCCOCC[N+](C)(C)C)=O
111	 $C_{21}H_{40}N_2O_8R_2$	K(NmPEG6Ac)	CC(N(CCCC[C@@H](C([R])=O)N[R])CCOCCOCCOCCOCCOCCOC)=O
112	 $C_{58}H_{108}N_4O_{20}R_2$	K(PEG12NMegENMeC18OH)	CN(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)C(CC[C@@H](C(O)=O)N(C)C(CCCCCCCCCCCCCCCCC(O)=O)=O)=O
113	 $C_{59}H_{110}N_8O_{18}R_2$	K(PEG12NMegENMeC18Tetrazole)	CN(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)C(CC[C@@H](C(O)=O)N(C)C(CCCCCCCCCCCCCCCCCc1nnn[nH]1)=O)=O
114	 $C_{56}H_{104}N_4O_{20}R_2$	K(PEG12gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O






115	 C58H108N4O20R2	K(PEG12gEC20OH)	OC(CCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
116	 C75H145N3O29R2	K(PEG24C18OH)	OC(CCCCCCCCCCCCCCCCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O
117	 C78H148N4O32R2	K(PEG24gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
118	 C81H154N4O32R2	K(PEG24gEC18OH)	C[C@](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)(C([R])=O)N[R]
119	 C44H79N5O13R2	K(PEG2NMePEG2NMegENMeC18OH)	CN(CCOCCOCC(N(C)CCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(CC[C@@H](C(O)=O)N(C)C(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O






120	 C45H81N9O11R2	K(PEG2NMePEG2NMegENMeC18Tetrazole)	CN(CCOCCOCC(N(C)CCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(CC[C@@H](C(O)=O)N(C)C(CCCCCCCCCCCCCCCCc1nnn[nH]1)=O)=O
121	 C28H48N6O9SR2	K(PEG2PEG2Biotin)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O
122	 C34H62N4O10R2	K(PEG2PEG2C16OH)	OC(CCCCCCCCCCCCCCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O
123	 C36H66N4O10R2	K(PEG2PEG2C18OH)	OC(CCCCCCCCCCCCCCCCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O
124	 C41H73N5O13R2	K(PEG2PEG2DgEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O





125	 C41H73N5O11R2	K(PEG2PEG2PC18OH)	OC(CCCCCCCCCCCCCCCC(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O
126	 C51H87N7O13R2	K(PEG2PEG2PPPC18OH)	OC(CCCCCCCCCCCCCCCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)=O
127	 C56H94N8O16R2	K(PEG2PEG2PPPgEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)=O)C(O)=O)=O)=O
128	 C46H80N6O14R2	K(PEG2PEG2PgEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O)C(O)=O)=O)=O
129	 C47H86N7O14R2+	K(PEG2PEG2Sp6gEC18OH)	C[N+](C)(CCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)CC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O






130	 C49H86N6O14R2	K(PEG2PEG2TrxgEC18OH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NC[C@H](CC1)CC[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O
131	 C51H90N6O14R2	K(PEG2PEG2TrxgEC20OH)	OC(CCCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NC[C@H](CC1)CC[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O
132	 C59H103N7O15R2	K(PEG2PEG2TrxgETrxC20OH)	OC(CCCCCCCCCCCCCCCCCCCC(NC[C@H](CC1)CC[C@@H]1C(N[C@@H](CCC(NC[C@H](CC1)CC[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O)=O
133	 C33H57N5O13R2	K(PEG2PEG2gEC10OH)	OC(CCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
134	 C35H63N5O11R2	K(PEG2PEG2gEC12)	CCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O





135	 C37H67N5O11R2	K(PEG2PEG2gEC14) NMeK(PEG2PEG2gEC14)	CCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O
136	 C39H71N5O11R2	K(PEG2PEG2gEC16)	CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O
137	 C39H69N5O13R2	K(PEG2PEG2gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
138	 C40H71N9O11R2	K(PEG2PEG2gEC16tetrazole)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCCCCCCc1nnn[nH]1)=O)=O
139	 C41H75N5O11R2	K(PEG2PEG2gEC18)	CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O
140	 C42H75N9O11R2	K(PEG2PEG2gEC18tetrazole)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCCCCCCCc1nnn[nH]1)=O)=O






141	 C43H77N5O13R2	K(PEG2PEG2gEC20OH)	OC(CCCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
142	 C58H103N7O17R2	KPEG2PEG2gEDap(C16OH)2, K(PEG2PEG2gEDAP(C16OH)2)	OC(CCCCCCCCCCCCCCCC(NC[C@@H](C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O
143	 C60H91N7O19R2	K(PEG2PEG2gEDAP(mXOH)2) KPEG2PEG2gEDAP(mXOH)2	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC([C@H](CNC(CCCCCCCCCOc1cc(C(O)=O)ccc1)=O)NC(CCCCCCCCCOc1cc(C(O)=O)ccc1)=O)=O)=O
144	 C60H91N7O19R2	K(PEG2PEG2gEDAP(pXOH)2) KPEG2PEG2gEDAP(pXOH)2	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC([C@H](CNC(CCCCCCCCCOc(cc1)ccc1C(O)=O)=O)NC(CCCCCCCCCOc(cc1)ccc1C(O)=O)=O)=O)=O
145	 C47H86N7O14R2+	K(PEG2PEG2gESp6C18OH)	C[N+](C)(CCNC(CCCCCCCCCCCCCCCCCC(O)=O)=O)CC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O






146	 C49H86N6O14R2	K(PEG2PEG2gETrxC18OH)	OC(CCCCCCCCCCCCCCCCC(NC[C@H](CC1)CC[C@@H]1C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O)=O
147	 C51H90N6O14R2	K(PEG2PEG2gETrxC20OH)	OC(CCCCCCCCCCCCCCCCCCC(NC[C@H](CC1)CC[C@@H]1C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O)=O
148	 C40H63N5O14R2	K(PEG2PEG2gEmXOH)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCOc1cc(C(O)=O)ccc1)=O)=O
149	 C40H63N5O14R2	K(PEG2PEG2gEpXOH)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCOc(cc1)ccc1C(O)=O)=O)=O
150	 C41H73N5O11R2	K(PEG2PEG2pC18OH)	OC(CCCCCCCCCCCCCCCCC(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O






151	 C46H80N6O14R2	K(PEG2PEG2pgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O
152	 C51H87N7O13R2	K(PEG2PEG2pppC18OH)	OC(CCCCCCCCCCCCCCCCC(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)=O
153	 C56H94N8O16R2	K(PEG2PEG2ppppgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)C(O)=O)=O)=O
154	 C48H87N5O17R2	K(PEG2PEG6gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
155	 C50H91N5O17R2	K(PEG2PEG6gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O







156	 C47H86N7O14R2+	K(PEG2Sp6PEG2gEC18OH)	C[N+](C)(CCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)CC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O
157	 C33H58N4O10R2	K(PEG2gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
158	 C35H62N4O10R2	K(PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
159	 C49H85N11O17SR2	K(PEG2gEgEPEG24SBC16Tetrazole)	OC([C@H](CCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)NC(CC[C@@H](C(O)=O)NC(COCCOCCNC(CCCS(NC(CCCCCCCCCCCCCCCCCc1nnn[nH]1)=O)(=O)=O)=O)=O)=O)=O
160	 C16H30N2O6R2	K(PEG3OMe) K(mPEG4)	COCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O





161	 C27H47N5O8SR2	K(PEG4Biotina), K(PEG4Biotin)	O=C(CCCC[C@H]([C@@H]1N2)SC[C@H]1NC2=O)NCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O
162	 C31H55N5O10SR2	K(PEG6Biotin)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCOCCOCCCOCCCC(NCCCC[C@@H](C([R])=O)N[R])=O
163	 C57H105N5O21R2	K(PEG6PEG6gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCCC(NCCOCCOCCOCCOCCOCCOCCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
164	 C59H109N5O21R2	K(PEG6PEG6gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCCC(NCCOCCOCCOCCOCCOCCOCCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O





165	 C42H76N4O14R2	K(PEG6gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
166	 C44H80N4O14R2	K(PEG6gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
167	 C47H86N7O14R2+	K(Sp6PEG2PEG2gEC18OH)	C[N+](C)(CCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)CC(NCCCC[C@@H](C([R])=O)N[R])=O
168	 C16H32N3O4R2+	K(cPEG3a), K(cPEG3aCO)	C[N+](C)(C)CCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O
169	 C35H67N3O15R2	K(dPEG12Ac)	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O







170	 C35H66BrN3O15R2	K(dPEG12AcBr)	O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@@H](C([R])=O)N[R]
171	 C23H43N3O9R2	K(dPEG6Ac)	CC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O
172	 C23H42BrN3O9R2	K(dPEG6AcBr)	O=C(CCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@@H](C([R])=O)N[R]
173	 C29H55N3O12R2	K(dPEG9Ac)	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@H](C([R])=O)N[R])=O)=O
174	 C29H54BrN3O12R2	K(dPEG9AcBr)	O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@@H](C([R])=O)N[R]





175	 C32H62N2O14R2	K(mPEG12)	COCCOCCOCCO CCOCCOCCOCC OCCOCCOCCOC COCCC(NCCCC[C@@H](C([R])=O)N[R])=O
176	 C35H64N3O10R	PEG2PEG2gEC18	CCCCCCCCCCCC CCCCCC(N[C@@ H](CCC(NCCOCC OCC(NCCOCCOC C([R])=O)=O)=O) C(O)=O)=O CCCCCCCCCCCC CCCCCC(N[C@@ H](CCC(NCCOCC OCC(NCCOCCOC C=O)=O)=O)C(O) =O)=O
177	 C13H27N2O3R2+	Lys(N+Me2mPEG3)	C[N+](C)(CCCC[C @@H](C([R])=O) N[R])CCOCCOC
178	 C13H29N2O3+	LysQuatMe2mPEG3, Lys(N+(Me)2mPEG3)	C[N+](C)(CCCC[C @@H](C=O)N)CC OCCOC
180	 C37H66N4O12R2	N(PEG2PEG2gEC18OH)G ly	OC(CCCCCCCCC CCCCCCCC(N[C @@H](CCC(NCC OCCOCC(NCCOC COCCN(CC([R])= O)[R])=O)=O)C(O) =O)=O)=O




181	 $C_{52}H_{99}N_3O_{17}R_2$	NMeK(PEG12C18OH)	CN([C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)C([R])=O)[R]
182	 $C_{57}H_{106}N_4O_{20}R_2$	NMeK(PEG12gEC18OH)	CN([C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)C([R])=O)[R]
183	 $C_{45}H_{81}N_5O_{13}R_2$	NMeK(PEG2NMePEG2NMegENMeC18OH)	CN(CCOCCOCC(N(C)CCOCCOCC(NCCCC[C@@H](C([R])=O)N(C)[R])=O)=O)C(CC[C@@H](C(O)=O)N(C)C(CCCCCCCCCCCCCCCCC(O)=O)=O)=O
184	 $C_{31}H_{58}N_4O_8R_2$	NMeK(PEG2PEG2C12)	CCCCCCCCCCCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N(C)[R])=O)=O)=O
185	 $C_{36}H_{65}N_5O_{11}R_2$	NMeK(PEG2PEG2gEC12)	CCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C([R])=O)N(C)[R])=O)=O)=O)C(O)=O)=O
186	 $C_{40}H_{71}N_5O_{13}R_2$	NMeK(PEG2PEG2gEC16OH)	CN([C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C([R])=O)[R]







187	 C42H75N5O13R2	NMeK(PEG2PEG2gEC18OH)	CN([C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C([R])=O)[R]
188	 C44H79N5O13R2	NMeK(PEG2PEG2gEC20OH)	CN([C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C([R])=O)[R]
189	 C39H74N3O11R3	NMeK(PEG6C18OH)	CN([R])[R](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)C([R])=O
190	 C45H82N4O14R2	NMeK(PEG6gEC18OH)	CN([C@@H](CCCCNC(CCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)C([R])=O)[R]
191	 C42H77N6O11R2+	NMeK(SP6PEG2gEC18OH)	CN([C@@H](CCCCNC(C[N+](C)(C)CCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C([R])=O)[R]
192	 C50H94N3O19R	PEG12gEC18OH	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[R])=O)=O)C(O)=O)=O)=O





193	 $C_{52}H_{98}N_3O_{19}R$	PEG12gEC20OH	OC(CCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[R])=O)=O)C(O)=O)=O)=O
194	 $C_6H_{11}NO_3R_2$	PEG2, PEG2(2)	O=C(COCCOCCN[R])[R]
195	 $C_7H_{13}NO_3R_2$	PEG2(NMe(2)) PEG2NMe	CN(CCOCCOCC([R])=O)[R]
196	 $C_{34}H_{63}N_4O_{11}R$	PEG2PEG2eKC16OH	OC(CCCCCCCCCCCCCCC(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCN[R])=O)=O)C(O)=O)=O)=O NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC(O)=O)=O)=O)=O
197	 $C_{36}H_{67}N_4O_{11}R$	PEG2PEG2eKC18OH	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCN[R])=O)=O)C(O)=O)=O)=O NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O





198	 C34H63N4O11R	PEG2PEG2gDabC18OH	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCNC(COCCOCCNC(COCCOCCN[R])=O)=O)C(O)=O)=O)=O NCCOCCOCC(NCCOCCOCC(NCC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O
199	 C37H67N4O12R	PEG2PEG2gEC20OH	OC(CCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(N[R])=O)=O)=O)C(O)=O)=O)=O
200	 C15H29NO7R2	PEG6	O=C(CCOCCOCCOCCOCCOCCOCCN[R])[R]
201	 C26H52O13	Peg12-Ome Peg12OMe, Polyethylene12-O-Methyl Peg12-O methyl	COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC=O
202	 C23H48O11	Peg12OMe, Peg12-Omethyl	CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
203	 C54H100N4O18R2	Pip(PEG12gEC16), Spiral_Pip_PEG12_IsoGlu_Palm	CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(N(CC1)CCC1(C([R])=O)N[R])=O)=O)C(O)=O)=O
204	 C51H88N5O13R2+	TMAPF(PEG2PEG2gEC18OH)	C[N+](C)(CCCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)CCOCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O






205	 C11H18N4O4R2	Tzl(PEG3OH)	OCCOCCOCCn1nnc(C[C@@H](C([R])=O)N[R])c1
206	 C12H20N4O4R2	Tzl(mPEG3)	COCCOCCOCCn1nnc(C[C@@H](C([R])=O)N[R])c1
207	 C12H22N5O2R2+	TzlChmPEG	C[N+](C)(CCc1cn(C[C@@H](C([R])=O)N[R])nn1)CCOC
208	 C16H30N5O4R2+	TzlChmPEG3	C[N+](C)(CCc1cn(C[C@@H](C([R])=O)N[R])nn1)CCOCCOCCOC






209	 C19H26N4O5R2	Y(OTzl(mPEG3))	COCCOCCOCCn1nnc(COc2ccc(C[C@@H](C([R])=O)N[R])cc2)c1
210	 C20H30N5O3R2+	Y(OTzlChmPEG)	C[N+](C)(CCc1cn(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1)CCOC
211	 C24H38N5O5R2+	Y(OTzlChmPEG3)	C[N+](C)(CCc1cn(CCOc2ccc(C[C@@H](C([R])=O)N[R])cc2)nn1)CCOCCOCCOC







212	 C27H46N3O5R2+	YC8CO(NHPEG3a)	C[N+](C)(C)CCOCCOCCNC(CCCCCCCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)=O
213	 C55H104N4O18R2	aMeK(PEG12gEC16)	CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@@](C)(C([R])=O)N[R])=O)=O)C(O)=O)=O
214	 C62H116N6O22	aMeK(PEG12gEC18OH)	C[C@@H](C=O)NC([C@](C)(CCCCNC(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)NC(CN)=O)=O
215	 C40H71N5O13R2	aMeK(PEG2PEG2gEC16OH)	C[C@](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)(C([R])=O)N[R]
216	 C42H75N5O13R2	aMeK(PEG2PEG2gEC18OH)	C[C@](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)(C([R])=O)N[R]
217	 C10H21NO3R+	cPEG3aCO, cPEG3a	C[N+](C)(C)CCOCCOCCC([R])=O






218	 C14H29NO5R+	cPEG5aCO, cPEG5a	C[N+](C)(C)CCOCCOCCOCCOCCC([R])=O
219	 C21H31F2N2O4R2+	dFPPEG3F	C[N+](CCOCCOCCOc1ccc(C[C@@H](C([R])=O)N[R])cc1)(CC1)CCC1(F)F
220	 C16H32N3O4R2+	dK(cPEG3a), k(cPEG3a), dK(cPEG3aCO), k(cPEG3aCO)	C[N+](C)(C)CCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O
221	 C20H36N2O10R2	gEPEG6	OC([C@H](CCC(NCCOCCOCCOCCOCCOCCOCCC([R])=O)=O)N[R])=O
222	 C56H104N4O20R2	k(PEG12gEC18OH), dK(PEG12gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O






223	 C58H108N4O20R2	k(PEG12gEC20OH) dK(PEG12gEC20OH)	OC(CCCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)C(O)=O)=O)=O
224	 C28H48N6O9SR2	dK(PEG2PEG2Biotin), k(PEG2PEG2Biotin)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
225	 C40H75N5O11R2	k(PEG2PEG2C18GolB), dK(PEG2PEG2C18GolB)	CN(CCOCCOCC(NCCOCCOCC(NCCC[C@H](C([R])=O)N[R])=O)=O)C(CCCCCCCCCCCCCCCCC(NC(CO)CO)=O)=O
226	 C36H66N4O10R2	k(PEG2PEG2C18OH), dK(PEG2PEG2C18OH)	OC(CCCCCCCCCCCCCCCCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O





227	 C40H73N5O13R2	k(PEG2PEG2GolAC18OH), dK(PEG2PEG2GolAC18OH)	OCC(CO)(C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O
228	 C56H94N8O16R2	k(PEG2PEG2PPPgEC18OH) dK(PEG2PEG2PPPgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)C(O)=O)=O)=O
229	 C46H80N6O14R2	k(PEG2PEG2PgEC18OH), dK(PEG2PEG2PgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O
230	 C47H86N7O14R2+	k(PEG2PEG2Sp6gEC18OH), dK(PEG2PEG2Sp6gEC18OH)	C[N+](C)(CCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)CC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O
231	 C49H86N6O14R2	k(PEG2PEG2TrxgEC18OH), dK(PEG2PEG2TrxgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NC[C@H](CC1)CC[C@@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O






232	 C42H78N7O12R2+	k(PEG2PEG2gE(C)C12, dK(PEG2PEG2gE(C)C12	CCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(N[C@@H](CC(O)=O)C[N+](C)(C)C)=O)=O
233	 C48H88N7O14R2+	k(PEG2PEG2gE(C)C18OH, dK(PEG2PEG2gE(C)C18OH	C[N+](C)(C)C[C@H](CC(O)=O)NC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O
234	 C42H78N7O12R2+	k(PEG2PEG2gE(c)C12, dK(PEG2PEG2gE(c)C12	CCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(N[C@H](CC(O)=O)C[N+](C)(C)C)=O)=O
235	 C48H88N7O14R2+	k(PEG2PEG2gE(c)C18OH, dK(PEG2PEG2gE(c)C18OH	C[N+](C)(C)C[C@@H](CC(O)=O)NC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O
236	 C33H57N5O13R2	k(PEG2PEG2gEC10OH), dK(PEG2PEG2gEC10OH)	OC(CCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O





237	 C42H76N7O14R2+	k(PEG2PEG2gEC12OH(C), dK(PEG2PEG2gEC12OH(C)	C[N+](C)(C)C[C@H](CC(O)=O)NC(CCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
238	 C42H76N7O14R2+	k(PEG2PEG2gEC12OH(c), dK(PEG2PEG2gEC12OH(c)	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
239	 C39H71N5O11R2	k(PEG2PEG2gEC16), dK(PEG2PEG2gEC16)	CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O
240	 C39H69N5O13R2	k(PEG2PEG2gEC16OH), dK(PEG2PEG2gEC16OH)	OC(CCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
241	 C41H75N5O11R2	k(PEG2PEG2gEC18), dK(PEG2PEG2gEC18)	CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O
242	 C48H88N7O14R2+	k(PEG2PEG2gEC18OH(C), dK(PEG2PEG2gEC18OH(C)	C[N+](C)(C)C[C@H](CC(O)=O)NC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O

243	 C48H88N7O14R2+	k(PEG2PEG2gEC18OH(c), dK(PEG2PEG2gEC18OH(c)	C[N+](C)(C)C[C@@H](CC(O)=O)NC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
244	 C41H73N5O13R2	k(PEG2PEG2gEC18OH), dK(PEG2PEG2gEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
245	 C43H77N5O13R2	k(PEG2PEG2gEC20OH), dK(PEG2PEG2gEC20OH)	OC(CCCCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
246	 C58H103N7O17R2	k(PEG2PEG2gEDAP(C16OH)2), dK(PEG2PEG2gEDAP(C16OH)2)	OC(CCCCCCCCCCCCCCC(NC[C@@H](C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)NC(CCCCCCCCCCCCCCCC(O)=O)=O)=O)=O
247	 C47H86N7O14R2+	kPEG2PEG2gEDAP(C16OH)2;kPEG2PEG2gEDap(C16OH)2, k(PEG2PEG2gEDAP(C16OH)2), dKPEG2PEG2gEDAP(C16OH)2;dKPEG2PEG2gEDap(C16OH)2, dK(PEG2PEG2gEDAP(C16OH)2)	C[N+](C)(CCNC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)CC(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O

248	 C49H86N6O14R2	kPEG2PEG2gEDAP(C16OH)2, dKPEG2PEG2gEDAP(C16OH)2	OC(CCCCCCCCCCCCCCCCC(NC[C@H](CC1)CC[C@@H]1C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O)=O
249	 C51H90N6O14R2	k(PEG2PEG2gESp6C18OH), dK(PEG2PEG2gESp6C18OH)	OC(CCCCCCCCCCCCCCCCCCC(NC[C@H](CC1)CC[C@@H]1C(N[C@@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O)=O
250	 C40H63N5O14R2	k(PEG2PEG2gETrxC18OH), dK(PEG2PEG2gETrxC18OH)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCOc1cc(C(O)=O)ccc1)=O)=O
251	 C40H63N5O14R2	k(PEG2PEG2gETrxC20OH), dK(PEG2PEG2gETrxC20OH)	OC([C@H](CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)NC(CCCCCCCCCOc(cc1)ccc1C(O)=O)=O)=O
252	 C46H80N6O14R2	k(PEG2PEG2gEmXOH), dK(PEG2PEG2gEmXOH)	OC(CCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O)C(O)=O)=O)=O

253	 C56H94N8O16R2	k(PEG2PEG2gEpXOH), dK(PEG2PEG2gEpXOH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(N(CCC1)[C@H]1C(NCCOCCOCC(NCCOCCOCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)=O)=O)=O)C(O)=O)=O)=O
254	 C50H91N5O17R2	k(PEG2PEG2pgEC18OH), dK(PEG2PEG2pgEC18OH)	OC(CCCCCCCCCCCCCCCCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCCC(NCCOCCOC(NCCCC[C@H](C([R])=O)N[R])=O)=O)=O)C(O)=O)=O)=O
255	 C31H55N5O10SR2	k(PEG2PEG2pppgEC18OH), dK(PEG2PEG2pppgEC18OH)	O=C(CCCC[C@@H]([C@H]1N2)SC[C@@H]1NC2=O)NCCOCCOCCOCCOCCOCCCC(NCCCC[C@H](C([R])=O)N[R])=O
256	 C35H67N3O15R2	k(PEG2PEG6gEC18OH), dK(PEG2PEG6gEC18OH)	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCCOCCCC(NCCC[C@H](C([R])=O)N[R])=O)=O

257	 C23H43N3O9R2	k(dPEG12AcBr), dK(dPEG12AcBr)	CC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
258	 C23H42BrN3O9R2	k(dPEG12AcVitE), dK(dPEG12AcVitE)	O=C(CCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@H](C([R])=O)N[R]
259	 C29H55N3O12R2	k(dPEG6Ac), dK(dPEG6Ac)	CC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O
260	 C29H54BrN3O12R2	k(dPEG6AcBr), dK(dPEG6AcBr)	O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCNC(CBr)=O)NCCCC[C@H](C([R])=O)N[R]
261	 C57H98N4O14R2	k(dPEG9Ac), dK(dPEG9Ac)	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@](C)(CC1)Oc(c(C)c2C)c1c(C)c2OCC(N[C@@H](CCC(NCCOCCOCCOCCOCCOCCOCCC(NCCCC[C@H](C([R])=O)N[R])=O)=O)C(O)=O)=O


262	 C26H51O13R	mPEG12CO	COCCOCCOCCO CCOCCOCCOCC OCCOCCOCCOC COCCC([R])=O
263	 C18H29N2O3R2+	mPEG2TMA4F	C[N+](C)(CCCCO c1ccc(C[C@@H](C([R])=O)N[R])cc 1)CCOC
264	 C7H13O4R	mPEG3CO	COCCOCCOCC([R])=O
265	 C14H27O7R	mPEG6CO	COCCOCCOCCO CCOCCOCCC([R])=O

General Peptide Synthetic Procedure 1

[000130] IL-23R inhibitor compounds described herein were synthesized from amino acids monomers using Merrifield solid phase synthesis techniques on Protein Technology's Symphony multiple channel synthesizer. The peptides were assembled using HBTU (O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate), Diisopropylethylamine(DIEA) coupling conditions. For some amino acid couplings PyAOP(7-Azabenzotriazol-1-yloxy)tripyrrolidinophosponium hexafluorophosphate) and DIEA conditions were used. Rink Amide MBHA resin (100-200 mesh, 0.57 mmol/g) was used for peptide with C-terminal amides and pre-loaded Wang Resin with N-α-Fmoc protected amino acid was used for peptide with C-terminal acids. The coupling reagents (HBTU and DIEA premixed) were prepared at 100mmol concentration. Similarly, amino acids solutions were prepared at 100 mmol concentration. Peptide inhibitors of the present invention were identified based on medical chemistry optimization and/or phage display and screened to identify those having superior binding and/or inhibitory properties.

Preparation of Certain Modified Amino Acids

Synthesis of 7-(3-Nacetyl-phenyl)-tryptophan (7(3NAcPh)W) (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(7-(3-acetamidophenyl)-1H-indol-3-yl)propanoic acid



[000131] To a solution of 1 (30.0 g, 153 mmol), compound 2 (41.1 g, 230 mmol) and K3PO4 (97.4 g, 459 mmol) in H_2O/ethanol (500 mL) and, Pd(dppf)Cl2 (1.12 g, 1.53 mmol) was added under an N_2 atmosphere. The mixture was stirred at 80 ℃ for 16 h. The mixture was filtered. The mixture was concentrated, then extracted with ethyl acetate (500 mL x 2), dried with anhydrous Na_2SO_4. The organic layer was concentrated and purified by FCC (eluent:

petroleum ether/ ethyl acetate=1:0 to 55:45) to give 3 (25.0 g, yield: 62.5%) as yellow oil MS (ESI): mass calculated for C16H14N2O, 250.295, m/z found 251.0 [M+].

[000132] To a 1 L round-bottomed flask containing a solution of **3** (12.0 g, 47.9 mmol) in DMF (300 mL) bromine (Br_2, 2.422 mL, 47.0 mmol) was slowly added. The mixture was stirred at 25 °C for 16 hours. The solution was added to aqueous sodium sulfite (500 mL), the mixture was stirred at 25 °C for 2 hours. The mixture was filtered, the filter cake was mixed with H_2O (400 mL) and stirred at 25 °C for 1 h. The mixture was filtered, the solid was collected to give **4** as a crude product, which was purified by preparative high-performance liquid chromatography (Column: Phenomenex C18 250 x 50mm x 10 um, Condition: water (FA)-CAN (20 %- 60 %)). The mixture was concentrated, extracted with CH_2Cl_2 (1 L x 2), washed with brine, dried with anhydrous Na_2SO_4. The organic layers was filtered and concentrated to give **4** (9.70 g, yield: 60.8%) as a pale white. MS (ESI): mass calculated For $C_{16}H_{13}BrN_2O$, 329.191, m/z found 328.8 [M].


[000133] A 250 mL three neck round-bottomed flask was charged with activated Zn powder (5.84 g, 89.3 mmol), DMF (120 mL) and I_2 (382 mg, 1.50 mmol) was added under an N_2 atmosphere at room temperature. After stirring for 20 min, a solution of **5** (13.6 g, 30.1 mmol) in DMF (30 mL) was added to the mixture. The reaction mixture was stirred for 30 min at room temperature, after which **4** (9.70 g, 29.5 mmol), tris(dibenzylideneacetone)-palladium (826 mg, 0.902 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (617 mg, 1.50 mmol) were added under an N_2 atmosphere. The reaction mixture was stirred at 50 °C for 12 hours, after which solvent was removed under reduced pressure to give crude product **6**. The crude product was extracted with ethyl acetate (1500 mL). The extract was washed with H_2O (500 mL x 2), followed by brine (500 mL), after which it was dried over anhydrous Na_2SO_4, filtered, and concentrated to dryness in vacuo to give crude intermediate 6, which was purified by silica gel chromatography (0-100% ethyl acetate/petroleum ether (EtOAc/PE)) to afford **6** (11.0 g, yield: 63.8 %) as a brown-yellow oil. MS (ESI): mass calculated for $C_{35}H_{31}N_3O_5$, 573.638, m/z found 574.1 [M+1].

[000134] Intermediate **6** (11.0 g, 19.2 mmol), a stir bar, Me_3SnOH (3.64 g, 20.1 mmol) and DCE (150 mL) were added to a 250 mL round-bottomed flask and stirred at 50 °C for 12 hours. To the reaction mixture 2 N HCl was added to adjust the to pH to 6. A second reaction starting from intermediate **6** was conducted and the products were combined for further workup. The combined reaction mixture was concentrated under reduced pressure to give the crude, which was purified by preparative HPLC using a Xtimate C18 150 x 40mm x 5um (eluent: 38 % to 68

% (v/v) CH_3CN and H_2O with 0.05 % HCl) to afford product **7**. The product was suspended in water (100 mL), the mixture frozen using dry ice/ethanol, and then lyophilized to dryness to afford **7** (7(3NAcPh)W, 11.8 g, yield: 66.8 %) as a white solid. **MS (ESI):** mass calculated For $C_{34}H_{29}N_3O_5$, 559.611, m/z found 560.0 [M+1]. **^{1}H NMR** DMSO-d_6 (400 MHz) δ 10.73 (s, 1 H), 10.10 (s, 1 H), 7.52 - 8.02 (m, 7 H), 6.96 - 7.52 (m, 9 H), 4.03 - 4.44 (m, 3 H), 3.25 (d, J = 13.2 Hz, 2 H), 3.01 - 3.15 (m, 1 H), 2.08 (s, 3 H).

Synthesis of 5-methyl-pyridyl-alanine (5MePyridinAla)

(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-methylpyridin-3-yl)propanoic acid




[000135] Activated Zn powder (8.18 g, 125 mmol), DMF (150 mL) and I_2 (0.534 g, 2.11 mmol) were stirred under an N_2 atmosphere at room temperature for 20 min., after which (R)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate (19.0 g, 42.1 mmol) in DMF (25 mL) was added. The reaction mixture was stirred for 30 min at room temperature, after which a mixture of **1** (7.97 g, 46.3 mmol), tris(dibenzylideneacetone)-palladium (1.16 g, 1.26 mmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (0.864 g, 2.11 mmol) in DMF (25 mL) was added under an N_2 atmosphere. The resulting reaction mixture was stirred at 50 °C for 12 h. The solvent was removed under reduced pressure to give the crude, which was purified by FCC (eluent: petroleum ether: ethyl acetate = 1: 0 to 0: 1 and ethyl acetate: methanol = 1: 0 to 2: 1) to afford the product **2** (10.00 g, 57.0 % yield) as a pale yellow liquid. **MS (ESI):** mass calculated for $C_{25}H_{24}N_2O_4$, 416.469, m/z found 417.1 $[M+H]^+$.

[000136] To a mixture of **2** (9.50 g, 22.8 mmol) in THF (100 mL) was added $LiOH.H_2O$ (1.91 g, 45.6 mmol) in H_2O (10 mL). The mixture was stirred for 1 h at 0 °C. TLC showed most SM were consumed. To the reaction mixture was added HCl (1 N) dropwise at ice bath to pH=5. The reaction mixture was concentrated under reduced pressure, then poured into water (200 mL) the mixture was extracted with THF (200 mL x3). The organic layers were combined, washed with brine (100 mL), dried over anhydrous Na_2SO_4. After filtering the organic layers were concentrated under reduced pressure to afford crude product **3**, which was purified by FCC (eluent: ethyl acetate : methanol =1:0 to 2:1) to obtain **3** (**5MePyridinAla**, 6.716 g , yield: 72.3 %) as a white powder. MS (ESI): mass calculated For $C_{24}H_{22}N_2O_4$, 402.442, m/z found 403.1 $[M+H]^+$. ^{1}H NMR DMSO-d_6 (Bruker_400 MHz): δ 8.18 (s, 2H), 7.88 (d, *J*=7.6 Hz, 2H), 7.63

(d, *J*=7.2 Hz, 2H), 7.45 - 7.26 (m, 5H), 6.81 (s, 1H), 4.33 - 4.21 (m, 1H), 4.20 - 4.09 (m, 2H), 3.95 (s, 1H), 3.06 -3.05 (m, 1H), 2.92 - 2.89 (m, 1H), 2.18 (s, 3H).

Synthesis of AEF(G)

(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)ethoxy)phenyl)propanoic acid



[000137] Starting material **1** (9.9 g, 62.2 mmol), a stir bar, Et_3N (14 mL, 101 mmol), and dichloromethane (DCM, 250 mL) were added to a 500 mL round-bottomed flask. The resulting mixture was treated with **2** (10 g, 34.6 mmol) in portions under ice-water bath. Then the reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was diluted with H_2O (800 mL), extracted with DCM (400 mL x 2). The organic phase extracts were combined, washed with brine (800 mL), and concentrated to give the crude intermediate **3** as a yellow solid. The crude intermediate was triturated with ethyl acetate (50 mL) and the suspension isolated via filtration. The filter cake was washed with ethyl acetate (20 mL x 3) before drying under reduced pressure to give the **3** (7.12 g, 49%) as a white solid. **MS (ESI):** mass calculated for $C_{19}H_{29}N_3O_5S_6$, 411.5, m/z found 412.1 $[M+H]^+$.

[000138] Starting material **4** (50.0 g, 148 mmol), a stir bar, DMF (300 mL), and K_2CO_3 (102 g, 739 mmol) were added to a nitrogen-purged 1000 mL round-bottomed flask. The flask was subsequently evacuated and refilled with nitrogen (x 3), after which 1,2-dibromoethane (154 mL, 1.78 mol) was added, and the resulting mixture was stirred at 80 °C for 16 h under a N_2 atmosphere. The reaction mixture was filtered and concentrated to dryness under reduced

pressure to give the crude product, which was subjected to silica gel chromatography (eluent: EtOAc: pet ether = 0 - 60%) to give the **5** (64 g, 96%) as a light yellow oil. MS (ESI): mass calculated for $C_{20}H_{30}BrNO_5$, 444.36, m/z found 466.1 $[M+Na]^+$.

[000139] Intermediate **5** (6.1 g, 13.7 mmol), **3** (6.2 g, 15.1 mmol), K_2CO_3 (7.6 g, 55.0 mmol), a stir bar, and CH_3CN (100 mL) were charged into a 250 mL round-bottomed flask. The reaction mixture was stirred at 80 °C for 16 h under a N_2 atmosphere. The reaction mixture was cooled to room temperature, diluted with H_2O (200 mL), extracted with ethyl acetate (100 mL x 2). The organic phases were combined and washed with brine (300 mL) and concentrated to give the crude intermediate **6**. The crude intermediate was purified by flash column chromatography (FCC, eluent: ethyl acetate / petroleum ether =0:1 to 2:1) to give the **6** (6.62 g, 44.2%) as a white solid. MS (ESI): mass calculated for $C_{39}H_{58}N_4O_{10}S$, 774.9, m/z found 775.5 $[M+H]^+$.

[000140] Intermediate **6** (6.6 g, 8.52 mmol), HCl/1, 4-dioxane (90 mL, 4M), a stir bar, and 1, 4 - dixoane (30 mL) were charged into a 250 mL round bottomed flask. The resulting mixture was stirred at 25°C for 12hr. The solvent was removed under reduced pressure to give intermediate **7** (7.8 g, crude product) as a colourless oil, which was directly used to next step. **MS (ESI):** mass calculated for $C_{25}H_{34}N_4O_6S$, 518.6, m/z found 519.2 $[M+H]^+$.

[000141] Intermediate **7** (7.80 g, 15.0 mmol), a stir bar, Na_2CO_3 (3.19 g, 30.1 mmol), Fmoc-OSu (5.58 g, 16.5 mmol), 1, 4 - dioxane (50 mL), and H_2O (50 mL) were added into a 250 mL round-bottomed flask at 25 °C . The reaction mixture was stirred at 25 °C for 16 hours, after which it was adjusted to pH = 5-6 with HCl (2M) and the resulting reaction mixture was extracted with EtOAc (150 mL x 3). The organic phases from the extraction were combined and washed with brine (200 mL) and concentrated to give the crude intermediate **7**. The crude intermediate was purified by preparative HPLC with a Column: Phenomenex C18 150 x 40mm x 5um, (eluent: 42% to 72% (v/v) CH_3CN and H_2O with 0.1% HCl) to afford pure product. The product was suspended in water (100 mL), the mixture frozen using dry ice/ethanol, and then lyophilized to dryness to afford desired product **8** (**AEF(G),** 4 g, 36%) as a white solid. MS (ESI): mass calculated for $C_{40}H_{44}N_4O_8S$, 740.9, m/z found 741.3 $[M+H]^+$. ^1H NMR (400 MHz, DMSO-d_6): 7.87 (d, J = 7.2 Hz, 2H), 7.71 - 7.62 (m, 2H), 7.39 (td, J = 4.0, 7.2 Hz, 2H), 7.29 (td, J = 7.6, 12.0 Hz, 2H), 7.14 (br d, J = 8.0 Hz, 2H), 6.99 - 6.85 (m, 1H), 6.77 (br d, J = 8.4 Hz, 2H), 6.59 - 6.50 (m, 1H), 4.21 - 4.06 (m, 4H), 3.88 (br s, 2H), 3.42 - 3.36 (m, 4H), 2.99 (br dd, J = 4.4, 14.0 Hz, 1H), 2.92 (s, 2H), 2.78 (br dd, J = 10.8, 13.6 Hz, 1H), 2.47 (br s, 3H), 2.41 (s, 3H), 1.97 (s, 3H), 1.38 (s, 6H).

Assembly

[000142] The peptides may be assembled using standard Symphony protocols. The peptide sequences were assembled as follows: Resin (250 mg, 0.14 mmol) in each reaction vial was washed twice with 4ml of DMF followed by treatment with 2.5ml of 20% 4-methyl piperidine (Fmoc de-protection) for 10min. The resin was then filtered and washed two times with DMF (4ml) and re-treated with N-methyl piperidine for additional 30 minute. The resin was again washed three times with DMF (4 ml) followed by addition 2.5ml of amino acid and 2.5ml of HBTU-DIEA mixture. After 45min of frequent agitations, the resin was filtered and washed three timed with DMF (4 ml each). For a typical peptide of the present invention, double couplings were performed. After completing the coupling reaction, the resin was washed three times with DMF (4 ml each) before proceeding to the next amino acid coupling.

Ring Closing Metathesis to form Olefins

[000143] An an example of ring closing metathesis a the resin (100 μmol) was washed with 2 ml of DCM (3 × 1 min) and then with 2 ml of DCE (3 × 1 min) before being treated with a solution of 2 ml of a 6 mM solution of Grubbs' first-generation catalyst in DCE (4.94 mg ml−1; 20 mol% with regard to the resin substitution). The solution was refluxed overnight (12 h) under nitrogen before being drained. The resin was washed three times with DMF (4 ml each); DCM (4 ml) before being dried and cleaved.

Cleavage

[000144] Following completion of the peptide assembly, the peptide was cleaved from the resin by treatment with cleavage reagent, such as reagent K (82.5% trigluoroacetic acid, 5% water, 5% thioanisole, 5% phenol, 2.5% 1,2-ethanedithiol). The cleavage reagent was able to successfully cleave the peptide from the resin, as well as all remaining side chain protecting groups.

[000145] The cleaved peptides were precipitated in cold diethyl ether followed by two washings with ethyl ether. The filtrate was poured off and a second aliquot of cold ether was added, and the procedure repeated. The crude peptide was dissolved in a solution of acetonitrile:water (7:3 with 1% TFA) and filtered. The quality of linear peptide was then verified using electrospray ionization mass spectrometry (ESI-MS) (Micromass/Waters ZQ) before being purified.

Disulfide Bond Formation via Oxidation

[000146] The peptide containing the free thiol (for example diPen) was assembled on a Rink Amide-MBHA resin following general Fmoc-SPPS procedure. The peptide was cleaved from the resin by treatment with cleavage reagent 90% trifluoroacetic acid, 5% water, 2.5% 1,2-ethanedithiol, 2.5% tri-isopropylsilane). The cleaved peptides were precipitated in cold diethyl ether followed by two washings with ethyl ether. The filtrate was poured off and a second aliquot of cold ether was added, and the procedure repeated. The crude peptide was dissolved in a solution of acetonitrile:water (7:3 with 1% TFA) and filtered giving the wanted unoxidized peptide crude peptide.

[000147] The crude, cleaved peptide with positions X4 and X9, for example, possessing either Cys, Pen, hCys, (D)Pen, (D)Cys or (D)hCys, was dissolved in 20ml of water : acetonitrile. Saturated Iodine in acetic acid was then added drop wise with stirring until yellow color persisted. The solution was stirred for 15 minutes, and the reaction was monitored with analytic HPLC and LCMS. When the reaction was completed, solid ascorbic acid was added until the solution became clear. The solvent mixture was then purified by first being diluted with water and then loaded onto a reverse phase HPLC machine (Luna C18 support, 10u, 100A, Mobile phase A: water containing 0.1% TFA, mobile phase B: Acetonitrile (ACN) containing 0.1% TFA, gradient began with 5% B, and changed to 50% B over 60 minutes at a flow rate of 15ml/min). Fractions containing pure product were then freeze-dried on a lyophilyzer.

Thioether Bond Formation

[000148] The peptide containing the free thiol (e.g., Cys) and hSer(OTBDMS) was assembled on a Rink Amide-MBHA resin following general Fmoc-SPPS procedure. Chlorination was carried out by treating the resin with PPh_3 (10 equiv.) and Cl_3CCN (10 equiv.) in DCM for 2 h. The peptide was cleaved from the resin by treatment with cleavage reagent 90% trifluoroacetic acid, 5% water, 2.5% 1,2-ethanedithiol, 2.5% tri-isopropylsilane). The cleaved peptides were precipitated in cold diethyl ether followed by two washings with ethyl ether. The filtrate was poured off and a second aliquot of cold ether was added, and the procedure repeated. The crude peptide was dissolved in a solution of acetonitrile:water (7:3 with 1% TFA) and filtered giving the wanted uncyclized crude peptide

[000149] The crude peptide possessing a free thiol (e.g., Cys, Pen, aMeCys, hCys, (D)Pen, (D)Cys or (D)hCys and the alkyl halide (hSer(Cl)) at either the X4 and X9 position or X9 and X4 position was dissolved in 0.1 M TRIS buffer pH 8.5. Cyclization was allowed to take place overnight at RT. The solvent mixture was then purified by first being diluted two-fold with

water and then loaded onto a reverse phase HPLC machine (Luna C18 support, 10u, 100A, Mobile phase A: water containing 0.1% TFA, mobile phase B: Acetonitrile (ACN) containing 0.1% TFA, gradient began with 5% B, and changed to 50% B over 60 minutes at a flow rate of 15ml/min). Fractions containing pure product were then freeze-dried on a lyophilizer

Purification

[000150] Analytical reverse-phase, high performance liquid chromatography (HPLC) was performed on a Gemini C18 column (4.6 mm x 250 mm) (Phenomenex). Semi-Preparative reverse phase HPLC was performed on a Gemini 10 μm C18 column (22 mm x 250 mm) (Phenomenex) or Jupiter 10 μm, 300 angstrom (Å) C18 column (21.2 mm x 250 mm) (Phenomenex). Separations were achieved using linear gradients of buffer B in A (Mobile phase A: water containing 0.15% TFA, mobile phase B: Acetonitrile (ACN) containing 0.1% TFA), at a flow rate of 1 mL/min (analytical) and 15 mL/min (preparative). Separations were achieved using linear gradients of buffer B in A (Mobile phase A: water containing 0.15% TFA, mobile phase B: Acetonitrile (ACN) containing 0.1% TFA), at a flow rate of 1 mL/min (analytical) and 15mL/min (preparative).

General Procedure 1A:

[000151] IL-23R inhibitor compounds described herein were synthesized from amino acids monomers using standard Fmoc solid phase synthesis techniques on a CEM Liberty Blue™ microwave peptide synthesizer. The peptides were assembled using Oxyma/DIC (ethyl cyanohydroxyiminoacetate/diisopropyl-carbodiimide) with microwave heating. Rink Amide-MBHA resin (100-200 mesh, 0.66 mmol/g) was used for peptides with C-terminal amides and pre-loaded Wang Resin with N-α-Fmoc protected amino acid was used for peptide with C-terminal acids. Oxyma was prepared as a 1M solution in DMF with 0.1M DIEA. DIC was prepared as 0.5M solution in DMF. The Amino acids were prepared at 200mM. Peptide inhibitors of the present invention were identified based on medicinal chemistry optimization and/or phage display and screened to identify those having superior binding and/or inhibitory properties.

Assembly

[000152] The peptides may also be made using standard CEM Liberty Blue™ protocols. The peptide sequences were assembled as follows: Resin (400 mg, 0.25 mmol) was suspended in 10 ml of 50/50 DMF/DCM. The resin was then transferred to the reaction vessel in the microwave cavity. The peptide was assembled using repeated Fmoc deprotection and

Oxyma/DIC coupling cycles. For deprotection, 20% 4-methylpiperidine in DMF was added to the reaction vessel and heated to 90 °C for 65 seconds. The deprotection solution was drained and the resin washed three times with DMF. For most amino acids, 5 equivalents of amino acid, Oxyma and DIC were then added to the reaction vessel and microwave irradiation rapidly heated the mixing reaction to 90 °C for 4 min. For Arginine and Histidine residues, milder conditions using respective temperatures of 75 and 50 °C for 10 min were used to prevent racemization. Rare and expensive amino acids were often coupled manually overnight at room temperature using only 1.5-2 eq of reagents. Difficult couplings were often double coupled 2 x 4 min at 90 °C. After coupling the resin was washed with DMF and the whole cycle was repeated until the desired peptide assembly was completed.

Cleavage

[000153] Following completion of the peptide assembly, the peptide was then cleaved from the resin by treatment with a standard cleavage cocktail of 91:5:2:2 TFA/H_2O/TIPS/DODT for 2 hrs. If more than one Arg(pbf) residue was present the cleavage was allowed to go for an additional hour.

[000154] The cleaved peptides were precipitated in cold diethyl ether. The filtrate was decanted off and a second aliquot of cold ether was added, and the procedure was repeated. The quality of linear peptide was then verified using electrospray ionization mass spectrometry (ESI-MS) (Waters® Micromass® ZQ™) before being purified.

Disulfide Bond Formation via Oxidation

[000155] The peptide containing the free thiol (for example diPen) was assembled on a Rink Amide-MBHA resin following general Fmoc solid phase synthesis, cleavage and isolation as described above.

[000156] The crude cleaved peptide comprising two thiol containing amino acids selected independently from Cys, Pen, hCys, (D)Pen, (D)Cys and (D)hCys was dissolved ~2mg/ml in 50/50 acetonitrile/water. Saturated iodine in acetic acid was then added dropwise with stirring until yellow color persisted. The solution was stirred for a few minutes, and the reaction was monitored with analytic HPLC and LCMS. When the reaction was completed, solid ascorbic acid was added until the solution became clear. The solvent mixture was then purified by first being diluted with water and then loaded onto a reverse phase HPLC Column (Luna® C18 support, 10u, 100A, Mobile phase A: water containing 0.1% TFA, mobile phase B: acetonitrile (ACN) containing 0.1% TFA, gradient began with 15% B, and changed to 50% B over 60


minutes at a flow rate of 15ml/min). Fractions containing pure product were then freeze-dried on a lyophilizer.

Purification

[000157] Analytical reverse-phase, high performance liquid chromatography (HPLC) was performed on a Gemini® C18 column (4.6 mm x 250 mm) (Phenomenex). Semi-Preparative reverse phase HPLC was performed on a Gemini® 10 µm C18 column (22 mm x 250 mm) (Phenomenex) or Jupiter® 10 µm, 300 angstrom (Å) C18 column (21.2 mm x 250 mm) (Phenomenex). Separations were achieved using linear gradients of buffer B in A (Mobile phase A: water containing 0.15% TFA, mobile phase B: Acetonitrile (ACN) containing 0.1% TFA), at a flow rate of 1 mL/min (analytical) and 20 mL/min (preparative).

Example 1. Preparation of Peptide of SEQ ID NO.:1

Ac-[Pen]*-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]*-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[3-Pal]-Sarc-NH_2 (*Pen-Pen form disulfide bond) (SEQ ID NO.:1)



[000158] The synthesis of SEQ ID NO.:1 is prepared using FMOC solid phase peptide synthesis techniques.

[000159] The peptide is constructed on Rink Amide MBHA resin using standard FMOC protection synthesis conditions reported in the literature. The constructed peptide is isolated from the resin and protecting groups by cleavage with strong acid followed by precipitation.

Oxidation to form the disulfide bond is performed followed by purification by reverse phase HPLC (RP-HPLC) and counter ion exchange. Lyophilization of pure fractions gives the final product.

[000160] Swell Resin: 10 g of Rink Amide MBHA solid phase resin (0.66mmol/g loading) is transferred to a 250 ml peptide vessel with filter frit, ground glass joint and vacuum side arm. The resin is washed 3x with DMF.

[000161] Step 1: Coupling of FMOC-Sarc-OH: Deprotection of the resin bound FMOC group is realized by adding 2 resin-bed volumes of 20% 4-methyl-piperidine in DMF to the swollen resin and shaking for 3-5 min prior to draining and adding a second, 2-resin-bed volume of the 4-methyl piperidine solution and shaking for an additional 20-30 min. After deprotection the resin is washed 3x DMF with shaking. FMOC-Sarc-OH (3 eq, 6.2 g) is dissolved in 100 ml DMF along with Oxyma (4.5 eq, 4.22g). Preactivation of the acid is accomplished by addition of DIC (3.9 eq, 4 ml) with shaking for 15 min prior to addition to the deprotected resin. An additional aliquot of DIC (2.6 eq, 2.65 ml) is then added after ~ 15 min of coupling. The progress of the coupling reaction is monitored by the colorimetric Kaiser test. Once the reaction is judged complete the resin is washed 3 x DMF with shaking prior to starting the next deprotection/coupling cycle.

[000162] Step 2: Coupling of FMOC-3Pal-OH: FMOC deprotection is again accomplished by adding two sequential, 2-resin-bed volumes of 20% 4-methyl-piperidine in DMF, one times 3-5 minutes and one times 20-30 minutes, draining in between treatments. The resin is then washed 3 times prior to coupling with protected 3-pyridyl alanine (3Pal). FMOC-3Pal-OH (3 eq, 7.8g) is dissolved in DMF along with Oxyma (4.5eq, 4.22g). Preactivation with DIC (3.9 eq, 4 ml) for 15 minutes is done prior to addition to the Sarc-Amide resin. After 15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000163] Step 3: Coupling of FMOC-Asn(Trt)-OH: The FMOC is removed from the N-terminus of the resin bound 3Pal and washed as previously described. FMOC-Asn(Trt)-OH (2eq, 8g) is dissolved in 100ml of DMF along with Oxyma (3eq, 2.81g). DIC (2.6 eq, 2.65 ml) is added for preactivation of the acid for ~15 minutes prior to addition to the 3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (1.4 eq, 1.43 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000164] Step 4: Coupling of FMOC-Glu(OtBu)-OH: The FMOC is removed from the N-terminus of the resin bound Asparagine and the resin washed with DMF as previously described. FMOC-Glu(OtBu)-OH (2 eq, 5.91 g) is dissolved in 100ml of DMF along with Oxyma (3eq, 2.81g). DIC (2.6 eq, 2.65 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (1.4 eq, 1.43 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test the resin is washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000165] Step 5: Coupling of FMOC-THP-OH: The FMOC is removed from the N-terminus of the resin bound peptide and the resin is washed as previously described. FMOC-THP-OH (3 eq, 7.36 g) is dissolved in 100ml of DMF along with Oxyma (4.5 eq, 4.22g). DIC (3.9 eq, 4 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test the resin is washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000166] Step 6: Coupling of FMOC-L-Ala(2-Naphthyl)-OH (Nal): The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-L-Ala(2-Naphthyl)-OH (3 eq, 8.66 g) is dissolved in 100ml of DMF along with Oxyma (4.5 eq, 4.22g). DIC (3.9 eq, 4 ml) is added for preactivation of the acid ~15 minutes prior to addition to the THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added. Once the reaction is complete as determined by the Kaiser test the resin was again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000167] Step 7: Coupling of FMOC-4-[2-(Boc-amino-ethoxy)]-L-Phenylalanine (FMOC-AEF): The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-4-[2-(Boc-amino-ethoxy)]-L-Phenylalanine (3 eq, 10.8 g) is dissolved in 100ml of DMF along with Oxyma (4.5 eq, 4.22g). DIC (3.9 eq, 4 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Nal-THP- Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test the resin is washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000168] Step 8: Coupling of FMOC-Pen(Trt)-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-

Pen(Trt)-OH (3 eq, 12.14 g) is dissolved in 100ml of DMF along with Oxyma (4.5 eq, 4.22g). DIC (3.9 eq, 4 ml) is added for preactivation of the acid ~15 minutes prior to addition to the AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000169] Step 9: Coupling of FMOC-Lys(Ac)-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-Lys(Ac)-OH (2 eq, 5.4 g) is dissolved in 100 ml of DMF along with Oxyma (3 eq, 2.81 g). DIC (2.6 eq, 2.65 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (1.4 eq, 1.43 ml) is added to the reaction. Once the reaction was complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000170] Step 10: Coupling of FMOC-7-Me-Trp-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-7-Me-Trp-OH (2 eq, 5.81 g) is dissolved in 100 ml of DMF along with Oxyma (3 eq, 2.81 g). DIC (2.6 eq, 2.65 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Lys(Ac)-Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (1.4 eq, 1.43 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000171] Step 11: Coupling of FMOC-Thr(tBu)-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-Thr(tBu)-OH (4 eq, 10.5g) is dissolved in 100 ml of DMF along with Oxyma (6 eq, 5.62 g). DIC (5.2 eq, 5.3 ml) is added for preactivation of the acid ~15 minutes prior to addition to the 7MeTrp-Lys(Ac)-Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000172] Step 12: Coupling of FMOC-Asn(Trt)-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-Asn(Trt)-OH (4 eq, 15.8 g) is dissolved in 100 ml of DMF along with Oxyma (6 eq, 5.62 g).

DIC (5.2 eq, 5.3 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Thr(tBu)-7MeTrp-Lys(Ac)-Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to starting the next deprotection/coupling cycle.

[000173] Step 13: Coupling of FMOC-Pen(Trt)-OH : The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. FMOC-Pen(Trt)-OH (2 eq, 8.1 g) is dissolved in 100ml of DMF along with Oxyma (3 eq, 2.81 g). DIC (2.6 eq, 2.65 ml) is added for preactivation of the acid ~15 minutes prior to addition to the Asn(Trt)-Thr(tBu)-7MeTrp-Lys(Ac)-Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin. After ~15 minutes, an additional aliquot of DIC (2.6 eq, 2.65 ml) is added to the reaction. Once the reaction is complete as determined by the Kaiser test, the resin is again washed 3x with DMF prior to the final deprotection and acetic acid capping of the constructed peptide.

[000174] Step 14: Acetyl Capping: The FMOC is removed from the N-terminus of the resin bound peptide and the resin washed as previously described. 150 ml of Capping Reagent A (THF/Acetic anhydride/Pyridine, 80:10:10) is added to the constructed Pen(Trt)-Asn(Trt)-Thr(tBu)-7MeTrp-Lys(Ac)-Pen(Trt)-AEF-Nal-THP-Glu(OtBu)-Asn(Trt)-3Pal-Sarc-Amide resin and shaken for 30 min. The resin is washed 3 x with DMF followed by 5x with DCM. The resin is divided into 5 – 50 ml centrifuge tubes and placed under vacuum for 1.5 hrs prior to cleavage with TFA.

[000175] Step 15: TFA Cleavage and Ether precipitation: 200 ml of the TFA cleavage cocktail (90/5/2.5/2.5 TFA/water/TIPS/DODT) is prepared. 40 ml of the cleavage cocktail is added to each of the 5 tubes containing the protected resin bound peptide and shaken for two hours. The spent resin is filtered away and the filtrate divided evenly into 18 – 50 ml centrifuge tubes for precipitation. Cold diethyl ether is added to each forming a white precipitate that is then centrifuged. The ether is decanted to waste and 2 more ether washes of the precipitate are performed. The resulting white precipitate cake is dried overnight in the hood to give the crude reduced peptide.

[000176] Step 16: Disulfide Oxidation: The crude peptide is oxidized and purified in four 1L batches. ~ 2.5 g of crude peptide is dissolved in 1L 20% ACN/water. With stirring, a saturated solution of iodine in acetic acid/methanol is added dropwise to the 1L peptide solution


until the yellow/brown color of the I_2 remains and does not fade away. The light yellow solution is allowed to sit for 5 min prior to quenching the excess I_2 with a pinch of ascorbic acid.

[000177] Step 17: RP-HPLC purification: The RP-HPLC purification is performed s immediately following each I_2 oxidation. A preparative purification column (Phenomenex, Luna, C18(2), 100□, 250x50mm) is equilibrated at 70ml/min with 20% MPB in MPA (MPA = 0.1% TFA/water, MPB = 0.1% TFA in ACN). The 1 L of quenched oxidized peptide is loaded onto the equilibrated column at 70 ml/min. After the solvent front elutes, a gradient of 25-45% MPB at 70ml/min is run over 60 min. The desired material is isolated in fractions and each are analyzed by analytical RP-HPLC. Pure fractions are combined from all four purifications and lyophilized to give purified TFA salt ready for counterion exchange.

[000178] Step 18: Counterion Exchange to Acetate: The same preparative RP-HPLC column is equilibrated with 5% MPB in MPA at 70 ml/min (MPA = 0.3% AcOH in Water, MPB = 0.3% AcOH in ACN, MPC = 0.5M NH_4OAc in Water.) The purified peptide TFA salt is dissolved in 50/50 ACN/water and diluted to 15% ACN. The solution is loaded onto the equilibrated column at 70 ml/min and the solvent front is eluted. The captured peptide is washed with 5% MPB in MPA for 5 min. The captured peptide is then washed with 5% MPB in MPC for 40 min at 70 ml/min to exchange the counterions to Acetate. The captured peptide is washed with 5% MPB in MPA at 70ml/min for 10 min to clear all NH_4OAc from the system. Finally, the peptide is eluted with a gradient of 5-70% MPB in MPA over 60 minutes and collected in fractions.

[000179] Step 19: Final Lyophilization and Analysis: The collected fractions are analyzed by analytical RP-HPLC, and all fractions >95% purity are combined. Lyophilization of the combined fractions gives SEQ ID NO.:1 as a white powder with a purity >95 % as determined by RP-HPLC. Peptide identity is confirmed with LC/MS of the purified Peptide of SEQ ID NO.:1, giving 2 charged states of the peptide, $M^+2/2$ of 950 amu and the molecular ion of 1899 amu.

EXAMPLE 2. Synthesis of MeCO-r-Pen-N-T-7MeW-K(Ac)-Pen-AEF-2Nal-THP-E-N-5MePyridinAla-Sar-CONH2 (Compound 345, SEQ ID NO:345)



Solid-Phase Peptide Synthesis:

[000180] The peptide was chemically synthesized using optimized 9-fluorenylmethoxy carbonyl (Fmoc) solid phase peptide synthesis protocols. For C-terminal amides, Rink-amide MBHA resin was used. The side chain protecting groups were as follows: D-Arg: Pbf; Thr, Glu: O-tButyl; Asn, Pen: Trityl; AEF: Boc. For coupling, a two to three-fold excess of a solution containing Fmoc amino acid, HATU and DIEA (1:0.95:2) in DMF was added to swelled resin for 1 to 4 hours. Double coupling is employed when coupling 2Nal. Fmoc protecting group removal was achieved by treatment with a DMF, piperidine (4:1) solution for 30 min. The cycles are repeated until the full-length peptide is obtained.

Peptide Cleavage:


[000181] Peptied was cleaved from the rsin by addition of cleavage buffer (5.0% DTT /2.5% H2O /2.5% TIS /90%TFA) 75 mL to the flask containing the side chain protected peptide at room temperature and stir for 3 hrs. The resin was filtered and washed with 5 mL TFA. The combined filtrate was precipitated with cold methyl tertbutyl ether (MTBE). The mixture was centrifuged (3000 rpm, 3 min) and decanted. The pellet was washed with MTBE and centrifuged. The lyophilized residue gave crude compound 1 (1.8 g).

Peptide Cyclization and Purification:

[000182] Crude peptide Compound 1 (1.8 g, 0.86 mmol) was dissolved in 20% MeCN /H2O (1000 mL). To the stirred solution of the peptide was added the iodine solution in MeOH (0.1M, 5.0 mL) drop-wise until solution remains yellow. After ~2h LCMS showed the reaction was complete. Excess iodine was quenched by the addition of 1M Na2S2O3 in water (15 uL)

(turned colorless instantly). Added 10-20 mL of MeCN to decrease turbidity. Purified the solution by Prep-HPLC (A: 0.075% TFA in H2O, B: ACN) to give compound **345** (371 mg, 96.4% purity, 17.0% yield for this step; over all yield: 14.8%) obtained as white solid. Analysis was performed using a C18 column with a flow rate of 1 mL/min. LCMS calculated MW: 2068.38, observed MW: 1034.5 [(M+2H)/2].

EXAMPLE 3. SYNTHESIS OF MeCO-Pen-N-T-7MeW-K(Ac)-Pen-AEF(G)-2Nal-THP-E-N-3Pya-Sar-CONH2 (Compound 477 SEQ ID NO:477)



Solid-Phase Peptide Synthesis:

[000183] Peptide were chemically synthesized using optimized 9-fluorenylmethoxy carbonyl (Fmoc) solid phase peptide synthesis protocols. For C-terminal amides, Rink-amide MBHA resin was used. The side chain protecting groups were as follows: AEF(G): Pbf; Thr, Glu: O-tButyl; Asn, Pen: Trityl. For coupling, a two to three-fold excess of a solution containing Fmoc amino acid, HATU and DIEA (1:0.95:2) in DMF was added to swelled resin for 1 to 4 hours. Double coupling is employed when coupling 2Nal. Fmoc protecting group removal was achieved by treatment with a DMF, piperidine (4:1) solution for 30 min. The cycles are repeated until the full-length peptide is obtained.


Peptide Cleavage:

[000184] Peptide was cleaved from the resin by the addition of cleavage buffer (5.0% DTT /2.5% H2O /2.5% TIS /90%TFA) 75 mL to the flask containing the side chain protected peptide at room temperature and stir for 3 hrs. The resin was filtered washed with 5 mL TFA, and the combined filtrate was precipitated with cold methyl tertbutyl ether (MTBE). The mixture was centrifuged (3000 rpm, 3 min) and decanted. The pellet was washed with MTBE and centrifuged. Lyophilized residue gave crude compound **1** (1.6 g).

Peptide Cyclization and Purification:

[000185] Crude peptide compound 1 (1.6 g, 0.824 mmol) was dissolved in 20% MeCN /H2O (1000 mL). To a stirred solution of the peptide was added the iodine solution in MeOH (0.1M, 2.0 mL) drop-wise until solution remains yellow. After ~2h LCMS showed the reaction was complete. Excess iodine was quenched by the addition of 1M Na2S2O3 in water (15 uL) (turned colorless instantly). Added 10-20 mL of MeCN to decrease turbidity. Purified the solution by Prep-HPLC (A: 0.075% TFA in H2O, B: ACN) to give compound **477** (575 mg, 96.4% purity, 31.0% yield for this step; over all yield: 25.5%) obtained as white solid. Analysis was performed using a C18 column with a flow rate of 1 mL/min (Analysis LCMS Method). LCMS calculated MW: 1940.21, observed MW: 970.7 [(M+2H)/2].

Example 4. Synthesis of MeCO-r-Abu(1)-N-T-W-K(Ac)-aMeC(1)-AEF-2Nal-THP-E-N-3Pya-Sar-CONH2 (Compoud 478, SEQ ID NO:478)



Solid-Phase Peptide Synthesis:

[000186] Peptide were chemically synthesized using optimized 9-fluorenylmethoxy carbonyl (Fmoc) solid phase peptide synthesis protocols. For C-terminal amides, Rink-amide MBHA resin was used. The side chain protecting groups were as follows: D-Arg: Pbf; Thr, Glu: O-tButyl; Asn, aMeCys: Trityl; AEF, Trp: Boc. For coupling, a two to three-fold excess of a solution containing Fmoc amino acid, HATU and DIEA (1:0.95:2) in DMF or Fmoc amino acid, DIC and HOAT(1:1:1) was added to swelled resin for 1 to 32 hours. Double coupling is employed when coupling 2Nal, Lys(Ac) and Fmoc-4-Br-L-HomoAla-OH. Fmoc protecting group removal was achieved by treatment with a DMF, piperidine (4:1) solution for 30 min. Trityl ("Trt") protecting group on aMeCys removal was achieved by treatment with trifluoroacetic acid, tri-isopropylsilane and DCM (2.5:2.5: 95) solution for 3min*10 times. For thioether cyclization, a solution containing DIEA (5eq) in DMF was added to swelled resin for 1h* 2 times. The cycles are repeated until the full-length peptide is obtained.

Synthetic method for thioether cyclization:

[000187] Coupling of Fmoc-4-Br-L-HomoAla-OH. After de-protection, the resin was washed with 30 mL of DMF (5x0.1 min) and followed by addition of 2.5 mL of Fmoc-4-Br-L-HomoAla-OH in DMF (400 mM) and 2.5 mL of coupling reagent HOAT in DMF (400 mM) and DIC(0.16 mL, 1.0 mmol). The coupling reaction was mixed for 16hrs. Then washed with 30 mL of DMF (5x0.1 min) and repeat coupling one more time for 16~32hrs. After completing the coupling reaction, the resin was washed with 30 mL of DMF (3x0.1 min) prior to starting the next step.

[000188] Trityl group removal on aMeCys was accomplished by washing with 30 mL of DMF (5x0.1 min) and DCM (5x0.1 min) followed by addition of 3% TFA and 2.5%TIS in DCM (30 mL) for 3min*10 times (the reaction solution changed from orange to colorless), washed with DCM, 5% DIEA in DMF and DMF for 3 times

[000189] Thioether cyclization on the resin was accomplished by washing the resin with 30 mL of DMF (5x0.1 min) followed by addition of DIEA (5 eq) in DMF (30 mL), the coupling reaction was mixed for 1h. Cleavage test and LCMS showed the reaction was finished. After completing the coupling reaction, the resin was washed with 30 mL of DMF (3x0.1 min) prior to starting the next step.

Peptide Cleavage:

[000190] Peptide was claved from the resin by addition of cleavage buffer (5.0% DTT /2.5% H2O /2.5% TIS /90%TFA) 75 mL to the flask containing the side chain protected peptide

at room temperature and stir for 3 hrs. The resin was filtered washed with 5 mL TFA. The combined filtrate was precipitated with cold methyl tertbutyl ether (MTBE). The mixture was centrifuged (3000 rpm, 3 min) and decanted. The pellet was washed with MTBE and centrifuged. Lyophilized the residue to give the compound **1** (750 mg, 75.7% yield, crude)

Peptide Purification:

[000191] Crude peptide was purified by Prep-HPLC (A: 0.075% TFA in H2O, B: ACN) to give compound **478** (82 mg, 95.2% purity, 6.72% yield) obtained as white solid. Analysis was performed using a C18 column with a flow rate of 1 mL/min. LCMS calculated MW: 1980.21, observed MW: 990.6 [(M+2H)/2].

Example 5. Biological Assays

IL23R Reporter Assay

[000192] Compounds were serially diluted in 100% (v/v) DMSO) and plated using an Echo acoustic dispenser (Labcyte) into 1536-well non-treated black assay plates (Corning # 9146). 3 µL of HEK293 cells containing IL-23R, IL-12Rβ1 and a firefly luciferase reporter gene driven by a STAT-inducible promoter (Promega) were added to the plates (4000 cells/well), followed by 3 µL of 10 ng/mL IL-23 (equivalent to EC_{90} concentration). After 5h at 37°C, 5% CO_2, 95% relative humidity, cells were placed at 20°C and treated with BioGlo reagent (Promega) according to the Manufacturer's instructions. Luminescence was measured on a Pherastar FSX (BMG LabTech). Data were normalized to IL-23 treatment (0% inhibition) and 30 µM of control inhibitor (100% inhibition), and IC_{50} values were determined using a 4-parameter Hill equation. Data for exemplary compounds are shown in Table 3b.

Table 3. IL-23 Binding Data for the Compound Numbers 158 to 478.

Number	IC_{50} (µM)	Number	IC_{50} (µM)	Number	IC_{50} (µM)	Number	IC_{50} (µM)
158	0.18	238	0.013	318		398	0.003
159	3.29	239	2.37	319	0.83	399	0.0046
160	1.45	240	0.23	320	0.079	400	0.0078
161	1.1	241	0.24	321	0.16	401	0.0042
162	0.3	242	0.19	322	0.45	402	0.0035
163	1.03	243	0.11	323	0.28	403	0.007
164	0.38	244	0.16	324	0.51	404	0.0057

Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)
165	0.37	245	0.18	325	0.33	405	0.0035
166	0.48	246	0.11	326	0.0037	406	0.0034
167	1.02	247	0.26	327	0.44	407	0.0035
168	0.63	248	0.13	328	0.097	408	0.0024
169	0.28	249	0.31	329	0.0024	409	0.0033
170	2.2	250	0.22	330	0.0037	410	0.0018
171	0.47	251	0.15	331	0.0049	411	0.0044
172	3.41	252	0.18	332	0.0053	412	0.0028
173	>16.61	253	0.055	333	0.0061	413	0.0068
174	0.21	254	0.037	334	4.1	414	0.01
175	0.26	255	0.05	335	0.03	415	0.015
176	0.43	256	2.06	336	0.013	416	0.013
177	0.35	257	1.25	337	0.0029	417	0.0035
178	0.39	258	1	338	>16.61	418	0.0036
179	0.63	259	0.87	339	0.0038	419	0.0032
180	0.74	260	0.48	340	0.0042	420	0.034
181	0.62	261	>16.61	341	0.0053	421	0.0033
182	1.02	262	5.72	342	0.0087	422	0.0077
183	1.31	263	0.0067	343	0.004	423	0.021
184	0.93	264	0.0095	344	0.0061	424	0.018
185	1.24	265	0.34	345	0.005	425	0.015
186	1.91	266	0.22	346	0.0062	426	0.046
187	1.07	267	6.28	347	0.029	427	0.0032
188	1.98	268	1.8	348	>16.61	428	0.0094
189	0.48	269	0.26	349	0.012	429	0.013
190	0.12	270	0.38	350	0.15	430	0.0051
191	>16.61	271	0.17	351	1.06	431	0.0034
192	0.35	272	0.03	352	0.0084	432	0.0034
193	0.27	273	0.032	353	0.0055	433	0.0093
194	0.22	274	0.034	354	0.015	434	0.0036
195	0.16	275	0.0024	355	0.014	435	0.0026
196	0.24	276	0.0031	356	0.0032	436	0.0037

Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)
197	0.24	277	0.0025	357	0.0085	437	0.0075
198	>16.61	278	0.0032	358	0.14	438	0.0084
199	1.9	279	0.33	359	>16.61	439	0.0048
200	0.72	280	0.61	360	2.19	440	0.0032
201	1.09	281	0.31	361	0.0051	441	0.0047
202	0.54	282	0.24	362	0.074	442	0.0058
203	0.42	283	0.054	363	0.13	443	3.22
204	0.66	284	0.39	364	0.004	444	0.04
205	>16.61	285	0.43	365	0.13	445	0.0036
206	~12.82	286	0.24	366	0.0041	446	0.0023
207	>16.61	287	0.43	367	0.096	447	0.0033
208	>16.61	288	0.056	368	0.018	448	0.0077
209	0.32	289	0.24	369	0.0044	449	0.014
210	0.49	290	0.2	370	0.0053	450	0.0022
211	0.047	291	2.24	371	0.007	451	0.026
212	0.49	292	2.08	372	0.0065	452	0.0069
213	0.085	293	0.17	373	0.0079	453	0.013
214	0.13	294	0.13	374	0.073	454	0.002
215	0.19	295	0.54	375	0.0054	455	0.001
216	0.35	296	0.0055	376	0.0068	456	0.0018
217	0.17	297	0.29	377	0.0052	457	0.00073
218	0.12	298	0.0069	378	0.0074	458	0.0021
219	0.066	299	3.34	379	0.0044	459	0.057
220	0.6	300	1.12	380	0.024	460	0.024
221	0.54	301	0.0023	381	0.0058	461	0.0076
222	0.065	302	0.0028	382	0.0055	462	0.0094
223	0.099	303	0.21	383	0.0071	463	0.0012
224	0.082	304	0.091	384	0.0036	464	0.024
225	0.066	305	0.045	385	0.0043	465	
226	0.19	306	0.068	386	0.0043	466	0.0014
227	6.13	307	0.004	387	0.055	467	0.0046
228	1.31	308	0.52	388	0.11	468	0.0014

Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)	Number	IC_{50} (μM)
229	3.54	309	0.6	389	0.006	469	0.002
230	2.58	310	0.13	390	0.0059	470	3.43
231	11.7	311	0.65	391	0.014	471	>16.61
232	4.48	312	0.64	392	0.036	472	0.0064
233	4.87	313	0.15	393	0.0059	473	0.017
234	3.65	314	0.0035	394	0.0066	474	>16.61
235	0.034	315	0.0038	395	0.0094	475	0.0069
236	0.17	316		396	0.0053	476	0.0086
237	0.019	317		397	0.092	477	0.091
						478	0.0013

DB Cells IL23R pSTAT3 Cell Assay

[000193] IL-23 is believed to play a central role in supporting and maintaining Th17 differentiation *in vivo*. This process is thought to be mediated primarily through the Signal Transducer and Activator of Transcription 3 (STAT3), with phosphorylation of STAT3 (to yield pSTAT3) leading to upregulation of RORC and pro-inflammatory IL-17. This cell assay examines the levels of pSTAT3 in IL-23R-expressing DB cells when stimulated with IL-23 in the presence of test compounds. Serial dilutions of test peptides and IL-23 (Humanzyme #HZ-1261) at a final concentration of 0.5 nM, were added to each well in a 96 well tissue culture plate (Corning #CLS3894). DB cells (ATCC #CRL-2289), cultured in RPMI-1640 medium (Thermo Scientific #11875093) supplemented with 10% FBS, were added at 5 X 10E5 cells/well and incubated for 30 minutes at 37°C in a 5% CO_2 humidified incubator. Changes in phospho-STAT3 levels in the cell lysates were detected using the Cisbio HTRF pSTAT3 (Tyr705) Cellular Assay Kit (Cisbio #62AT3PEH), according to manufacturer's Two Plate Assay protocol. IC_{50} values were determined from these data. IC_{50} data for exemplary compounds are shown in Table 4.

Table 4. IL-23 Data

Compound	IC_{50} (nM)
188	0.0507
190	0.064
191	0.042

Compound	IC_{50} (nM)
195	0.0709

PBMC pSTAT3 assay

[000194] Cryopreserved peripheral blood mononuclear cells (PBMCs) from healthy donors were thawed and washed twice in ImmunoCult-XF T cell expansion medium (XF-TCEM) supplemented with CTL anti-aggregate wash. The cells were counted, resuspended at 2x105 cells per mL XF-TCEM supplemented with penicillin/streptomycin and 100 ng/mL IL-1 (BioLegend, 579404), and cultured in tissue culture flasks coated with anti-CD3 (eBioscience, 16-0037-85 or BD Pharmingen, 555329) at 37oC in 5% CO2. On day 4 of culture, PBMCs were collected, washed twice in RPMI-1640 supplemented with 0.1% BSA (RPMI-BSA), and incubated in RPMI-BSA in upright tissue culture flasks for 4 hours at 37oC in 5% CO2. Following this 'starvation,' a total of 6x104 cells in 30 µL RPMI-BSA was transferred into each well of a 384-well plate pre-spotted with peptide or DMSO. The cells were incubated for 30 minutes prior to the addition of IL-23 at a final concentration of 5 ng/mL. The cells were stimulated with cytokine for 30 minutes at 37oC in 5% CO2, transferred onto ice for 10 minutes, and lysed. Cell lysates were stored at -80°C until phosphorylated STAT3 was measured using the phospho-STAT panel kit (Meso Scale Discovery, K15202D). Results are provided below.

Compound/ Example	SEQ ID NO:	PBMC pSTAT3 IC50 (nM)
345	345	0.0076
477	477	0.0055
478	478	0.015

[000195] Although the foregoing invention has been described in some detail by way of illustration and Example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced upon review of the specification and within the scope of the appended claims. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference. Where a conflict exists between the instant application and a

reference provided herein, the instant application shall dominate.

WHAT IS CLAIMED IS:

1. A peptide inhibitor of an interleukin-23 receptor of Formula (I), comprising an amino acid sequence:

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2

wherein:

R1 is hydrogen, $CH_3C(O)$-, EtC(O)-, MeSO2, AzCO, BHCO, FPrpTriazoleMeCO, SMSBCO, Biotin, BiotinPEG2PEG2CO, DAGSuc;

X3 is dR, dK, PEG6, gEPEG6, R, K, or absent;

X4 is Pen, aMeC, hC, or C;

X5 is A, N, Q, N-MeAsn, L, Asn(4C13_2N15), I, K(PEG2PEG2Biotin);

X6 is T, MeThr, V, K, Dbu, Dpr, A;

X7 is W7Me, W, W(4F7Me), 7MeW, 7PhW, 7EtW, 7FW, 7ClW, 5BrW, 7(3NAcPh)W'

X8 is KAc, Q, NMeGln, A, Cit, dK(Ac), dQ, dNMeGln, dA, or dCit;

X9 is Pen, aMeC, hC, or C;

X10 is F4OMe, AEF, F, F4Me, F4Ad, Nal, AEF(Boc), 4PipPhe, AEF(Ac), Y, 4OMeF, 4AmF, D(Pip), Tzl(mPEG3), 3FTyr, Y(OTzl), Y(OTzl(mPEG3)), Tzl, Tzl(PEG3OH);

X11 is Nal, Quin_3, Coumarin(7OMe), 2Nal, 3Quin;

X12 is aMeK, THP, Spiral_Pip_Ac, Spiral_Pip, MeK, aMeLeu, aMeL, aMeK(Boc)

X13 is KAc, K, dK(Ac), or dK ;

X14 is A, N, L, N-MeAsn, MeLeu, Asn(4C13_2N15), I;

X15 is 3Pya, bAla, Thiozolidine, H, dL, N, A, F, aMePhe, Aib, dK, h, 3MeH, 1MeH, tetraFPhe, bMePhe(SR), 5PyrimidAla, v, dR, homoF, Y, y, F(CF3), Y(CHF2), THP, or absent;

X16 is MeGly, dMeGly, dL, MeLeu, dMeLeu, N-MeNle, dN-MeNle, y, paf, maf, d3Pya, bAla, dbAla, P, dP, N(3AmBenzyl)Gly, N(4AmBenzyl)Gly, 4(R)HydroxyPro, 4(S)AminoPro, 5(R)diMePro, or absent

R2 is –OH, $-NH_2$, $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl$)_2$, MeNH, CONHMe; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

2. A peptide inhibitor of an interleukin-23 receptor of Formula (II), comprising an amino acid sequence:

R1- X3-Abu-X5-T-X7-X8-X9-AEF-X11-X12-X13-X14-X15-X16-X17-R2 (II)

wherein:

R1 is hydrogen, or $CH_3C(O)$-;

X3 is dR, R, or absent;

X4 is Abu;

X5 is Q, N, or T;

X6 is T;

X7 is W or 7MeW;

X8 is Q, K, KAc, dQ, dK, or dK(Ac);

X9 is Pen, C, hC, or aMeC;

X10 is AEF;

X11 is 2Nal, or Nal;

X12 is THP, Acvc, or Achx;

X13 is E, KAc, aMeE, Q, AIB, Achx, aMedE, dE, dK(Ac), or dQ;

X14 is N or S;

X15 is H, bAla, N, 3Pya, F, aMeF, aMeW, 1Nal, 4AmPhe, 2Nal, aMeFPhe, aMePhe, 3,4diFPhe, DY02, 5FW, or absent;

X16 is MeGly, AIB, or absent;

X17 is aMeK or absent;

R2 is –OH, $-NH_2$, $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl$)_2$; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9.

3. A peptide inhibitor of an interleukin-23 receptor of Formula (III), comprising an amino acid sequence:

R1- X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (III)

wherein:

R1 is hydrogen, $CH_3C(O)$-, FPrpTriazoleMeCO, NH2, EtCO, AzCO, or BHCO;

X3 is dR, R, K, or dK;

X4 is Pen, Abu, AIB, aMeC, C, hC, Ala, 4RAminoPro, or 4SAminoPro;

X5 is N, D, or E;

X6 is T, Hyp, or 3OHPro;

X7 is 7MeW, W, 3Pya, A, 7PyrW, or 7(3NAcPh)W;

X8 is KAc, or dKAc;

X9 is Pen, C, S5H, AIB, D, E, hC, aMeC;

X10 is AEF, AEF(EtCO), AEF(BH), AEF(Ac), bMeAEF(2S3R*), bMeAEF(2S3S*), Y, or A;

X11 is 2Nal, A, Nal, or W;

X12 is THP;

X13 is E, KAc, S5H, dE, dKAc, or R5H;

X14 is N, S, 3Pya;

X15 is 3Pya, H, bAla, v, dR, hF, PAF, F, THP, l, 4Pya, oAMPhe, 3MeH, D3Pya, N, 5MePyridinAla, 5AmPyridinAla, 3QuinolAla, 6OH3Pya, A

X16 is MeGly;

R2 is $-NH_2$ $-HN(C_1\text{-}C_4$ alkyl), $-N(C_1\text{-}C_4$ alkyl$)_2$ or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9; or

wherein when X4 is 4RAminoPro or 4SAminoPro and X9 is E or D, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X4 and X9;

or

wherein when X5 is D or E, and X10 comprises an AEF residue, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X5 and X10;

or

wherein when X9 and X13 comprise S5H residues the inhibitor of an interleukin-23 receptor is cyclized by an aliphatic linkage between X9 and X13.

4. A peptide inhibitor of an interleukin-23 receptor of Formula IV, comprising an amino acid sequence:

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (IV)

wherein:

R1 is hydrogen, $CH_3C(O)$-, Ac_Morph, or MorphCO;

X3 is K(AcMorp), Kmorp, dK(AcMorp), or absent;

X4 is Pen, C, hC, or aMeC;

X5 is L, N, or nLeu;

X6 is T or L;

X7 is W or 7MeW;

X8 is KAc, K(AcMorph), K(IsoButyl_Ac), K(Butyl_Ac), K(Benzyl_Ac), KMorph, K, dKAc, dK(AcMorph), dK(IsoButyl_Ac), dK(Butyl_Ac), dK(Benzyl_Ac), dKMorph, or dK;

X9 is Pen, C, hC, or aMeC;

X10 is F4OMe, F, AEF, F4Ad, L, F4CN, or 4OMeF;

X11 is 2Nal or Nal;

X12 is L, THP, Spiral_Pip, aMeK, or aMeL;

X13 is L, dL, or nL (i.e., norleucine);

X14 is N or L;

X15 is 3Pya or absent;

X16 is MeGly or absent;

R2 is NH(2-(pyridin3-l)ethyl), -NH_2, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, or –OH; and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.

5. A peptide inhibitor of an interleukin-23 receptor of Formula V, comprising an amino acid sequence:

R1-X3-X4-X5-X6-X7-X8-X9-X10-X11-THP-X13-X14-X15-R2 (V)

wherein:

R1 is hydrogen, or $CH_3C(O)$, Propionic_acid, EtCO, PentCO, AzCO, MeSO2, NH2, BHCO, FPrpTriazoleMeCO, (SulfoCy3), (SulfoCy3dPEG2), (SulfoCy3dPEG3), or SMSBCO;

X3 is dR, R, or absent;

X4 is Abu, Pen, C, hC, aMeC, aG,or Dpr;

X5 is Q or N;

X6 is T;

X7 is W, W7Me, 7MeW, bMeW(2S3R), bMeW(2S3S), 7FW, 7ClW, 5BrW, or 5MeW;

X8 is Q, K, KAc, Q, dK, or dKAc;

X9 is C, Pen, hC, aMeC, aG, E, or D;

X10 is AEF, F4OMe, F4Ad, Phe(4(2(Ac)aminoethoxy)), ac , LY02, AEF(Boc), 4PipPhe, AEF(BH), or AEF(SMSB);

X11 is 2Nal or Nal;

X12 is THP;

X13 is E, KAc, K, Q, aMeE, AIB, dE, dKAc, dK, dQ, aMedE, or Achx;

X14 is N;

X15 is H, bAla, , N, F, aMePhe, aMeF, aMeW, 1Nal, 4AmPhe, 2Nal, aMeFPhe, 3,4diFPhe, DY02, 5FW, D(NBzl), D(NPh), D(NoAn), D(NPip), D(NPyr), D(NpAn), D(NmAn), D(N4Pyz), D(N5In), D(NPrAm), dH, D(NEtNH2), 3MeH, 1MeH, tetraFPhe, bMePhe(SR), 5PyrimidAla, 3OHPhe, 4PyridinAla, 3Pya, 4TriazolAla, bMePhe(2S3S), 2AmTyr, bMeH(2S3S*), or 5MeH;

R2 is $–NH_2$, -OH, -HN(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, or CONHMe and

wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a cysteine, homocysteine, or alpha methylcysteine residue at X9; or

wherein when X4 is Dpr and X9 is E or D, the inhibitor of an interleukin-23 receptor is cyclized by an amide bond between X4 and X9; or

wherein when X4 and X9 are aG, the inhibitor of an interleukin-23 receptor is cyclized by an aliphatic bond (generated from a Ring Closing Metathesis "RCM" reaction) between X4 and X9.

6. A peptide inhibitor of an interleukin-23 receptor of Formula VI, comprising an amino acid sequence:

R1-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-R2 (VI)

wherein:

R1 is hydrogen, or CH3C(O);

X4 is Pen, Abu, C, hC, dPen, dC, or aMeC;

X5 is L, N, Q, T, dN or absent;

X6 is T, L, dT, or absent;

X7 is W7Me, W(4F7Me), 7PhW, 7MeW, 7EtW, W, 7BrW, 7(2ClPh)W, 7(4CF3Ph)W, 7(3CF3TAZP)W, 7(4NAcPh)W, 7(3NAcPh)W, 7(4OCF3Ph)W, 7(4OMePh)W, 7(4Paz)W, 7(7Imzpy)W, 7(6(1)7dMeNDAZ))W, 7(3UrPh)W, 7(5(Ina7Pyr))W, 7(4(CpCNPh))W, 7(6(2MeNDAZ))W, BT, D7MeW;

X8 is KAc, Q, K(Gly), dKAc, dQ, or dK(Gly);

X9 is Pen, C, hC, aMeC, or dPen;

X10 is AEF, F4Ad, F4OMe, F4Me, Nal, F, Spiral_Pip, L, 4AmF, AEF(G), dY, or Y;

X11 is Nal, 3Quin, 2Nal, 2Quin, d2Nal, or W;

X12 is THP, aMeLeu, Acvc, aMeK, or Acpx, A;

X13 is E or dE;

X14 is N, L, or dN;

X15 is 3Pya, THP, N, H, dK, dL, dPaf, PAF, 3MeH, 3pya, or F;


X16 is MeGly, dK, K, or absent; and

R2 is $–NH_2$, -OH, $-HN(C_1-C_4$ alkyl), $-N(C_1-C_4$ alkyl$)_2$, or CONHMe; and


wherein the inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between a Pen, C, hC, dPen, dC, or aMeC at X4 and a Pen, C, hC, aMeC, or dPen residue at X9; or

wherein the inhibitor of an interleukin-23 receptor is cyclized by a thioether bond between the Abu residue at X4 and a Pen, C, hC, or aMeC residue at X9.

7. A compound, or a pharmaceutically acceptable salt thereof, having a structure of a compound as set forth in Table 1A, Table 1B, Table 1C, Table 1D, Table 1E, Table 1F, Table 1G, Table 1H, Table 1I. An inhibitor of an interleukin-23 receptor which is selected from compound 345, 469, 477 or 478 as shown below:




Compound 345 SEQ ID NO:345




;

Compound 468, SEQ ID NO:468



Compound 477 SEQ ID NO:477



Compound 478, SEQ ID:NO:478

8. The peptide inhibitor of an interleukin-23 receptor of any of claims 1-8, wherein D amino acids are present or substituted for a corresponding L amino acid only at

(i) one or more of positions X3, X5, X6, X8 and X13, and optionally one of positions X1-X2, X4, X7, X9 to X12, X14-X18 present in the inhibitor; or

(ii) one or more of positions X3, X8 and X13, and optionally at one of positions X1-X2, X4-X7, X9 to X12, X14-X18 present in the inhibitor.

9. The peptide inhibitor of an interleukin-23 receptor of any of claims 1-8, wherein D amino acids are present or are substituted for a corresponding L amino acid only at

(i) X3, and optionally at one of positions X1-X2, X4 -X18 present in the inhibitor; or

(ii) one of positions X3, and X8, and optionally one of positions X1-X2, X4-X7, X9-X18 present in the inhibitor.

10. The peptide inhibitor of an interleukin-23 receptor of any of claims 1-8, wherein the inhibitor comprises amino acids of the D-isomeric form, or is substituted with a D amino acid in place of the corresponding L amino acid, at one to six of positions X1 to X18 appearing in the inhibitor.

11. The peptide inhibitor of an interleukin-23 receptor of claim 11, wherein the inhibitor comprises amino acids of the D-isomeric form, or is substituted with a D amino acid in place of the corresponding L amino acid at one or two of positions X1 to X18 appearing in the inhibitor.

12. The peptide inhibitor of an interleukin-23 receptor of claim 11, wherein the inhibitor comprises amino acids of the D-isomeric form, or is substituted with a D amino acid in place of the corresponding L amino acid at three or four of positions X1 to X18 appearing in the inhibitor.

13. The peptide inhibitor of an interleukin-23 receptor of claim 11, wherein the inhibitor comprises amino acids of the D-isomeric form, or is substituted with a D amino acid in place of the corresponding L amino acid at five or six of positions X1 to X18 appearing in the inhibitor.

14. A pharmaceutical composition comprising:

(i) a peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to any of claims 1 to 14, and

(ii) a pharmaceutically acceptable carrier, excipient, or diluent.

15. A pharmaceutical composition comprising:

(i) a peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to claim 7, and

(ii) a pharmaceutically acceptable carrier, excipient, or diluent.

16. A pharmaceutical composition comprising:

(i) a peptide inhibitor of an interleukin-23 receptor or pharmaceutically acceptable salt, solvate, or form thereof according to claim 8, and

(ii) a pharmaceutically acceptable carrier, excipient, or diluent.

17. The use of a peptide inhibitor of an interleukin-23 receptor according to any of claims 1 to 14, or a pharmaceutical composition according to any of claims 15 to 17, for the preparation of a medicament for the treatment of an inflammatory, autoimmune inflammation diseases and/or related disorders.

18. The use according to claim 18, for the preparation of a medicament for the treatment of associated with inflammatory, autoimmune inflammation diseases and/or related disorders is selected from multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, Celiac disease (nontropical Sprue), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, enteropathy associated with seronegative arthropathies, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

19. The use according to claim 18 for the preparation of a medicament for the treatment of a disease or disorder which is selected from Inflammatory Bowel Disease (IBD), Ulcerative colitis (UC), Crohn's Disease (CD), psoriasis (PsO) or psoriatic arthritis (PsA).

20. A method for **treating** a disease or disorder associated with Interleukin 23 (IL-23)/Interleukin 23 Receptor (IL-23R), which comprises administering:

(i) an effective amount of a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt, solvate, or form thereof according to any of claims 1 to 14; or

(ii) a pharmaceutical composition according to any of claims 15 to 17, respectively

to a patient in need thereof.

21. The method according to claim 21, wherein the disease or disorder is associated with inflammatory, autoimmune inflammation diseases and/or related disorders.

22. The method according to claim 22, wherein the disease or disorder associated with inflammatory, autoimmune inflammation diseases and/or related disorders is selected from multiple sclerosis, asthma, rheumatoid arthritis, inflammation of the gut, inflammatory bowel diseases (IBDs), juvenile IBD, adolescent IBD, Crohn's disease, ulcerative colitis, Celiac disease (nontropical Sprue), microscopic colitis, collagenous colitis, eosinophilic gastroenteritis/esophagitis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, sarcoidosis, Systemic Lupus Erythematosus, ankylosing spondylitis (axial spondyloarthritis), psoriatic arthritis, psoriasis (e.g., plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, Palmo-Plantar Pustulosis, psoriasis vulgaris, or erythrodermic psoriasis), atopic dermatitis, acne ectopica, enteropathy associated with seronegative arthropathies, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, Wiskott-Aldrich Syndrome, pouchitis, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, primary biliary cirrhosis, viral-associated enteropathy, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, uveitis, or graft versus host disease.

23. The method of claim 22, wherein the disease or disorder is associated with and automimmine disease is selected from Ulcerative colitis (UC), Crohn's Disease (CD), psoriasis (PsO), or psoriatic arthritis (PsA).